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ABSTRACT 
 
Role of dietary etiological factors involved in the molecular 
pathogenesis of liver cancer 
 
Şehriban Özge Gürsoy Yüzügüllü 
Ph.D. in Molecular Biology and Genetics 
Supervisor: Prof. Dr. Mehmet Öztürk 
February, 2011, 183 Pages 
 
 
Hepatocellular carcinoma is ranked third foremost cause of cancer deaths. Dietary factors 
play a crucial role in the molecular pathogenesis of liver cancer. Oxidative stress is 
usually coupled with the malignancy and progression of HCC since it is considered as a 
common factor during inflammation after chronic viral infection. Chemical stress caused 
by aflatoxin exposure, metabolic stress produced by alcohol abuse and selenium 
deficiency as a risk factor for HCC are associated with oxidative stress. It should be 
eliminated with an intact antioxidant defense mechanism. It is a major cause of 
genotoxicity endogenously through metabolic stress and exogenously produced by 
chemical and physical carcinogens. Even though the contribution of dietary factors in 
HCC progression has been established, the underlying molecular mechanism has not been 
fully understood.  
Cancer cells may respond to genotoxic stress with a cryptic development of survival 
advantage mechanisms. Therefore we wanted to investigate this idea with dietary factors 
involved in liver cancer. In this work, we studied the implication of Se-deficiency in 
tumorigenesis of hepatocytes and the mechanism underlying the selective selection of 
aflatoxins for p53-249 mutation in HCC. Aflatoxins are the most potent naturally 
occurring carcinogens and may play a causative role in 5-28% of hepatocellular 
carcinomas, worldwide. Aflatoxins are activated in liver cells and induce principally G-
>T mutations, including a codon 249 (G->T) hotspot mutation of TP53 gene that is 
specifically associated with aflatoxin-related hepatocellular carcinoma.  
However, our comparative analysis showed that R249S does not provide survival 
advantage at heterozygous state. Thus, the selection could be at the mutation induction 
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stage. The lack of p53 activation in Aflatoksin B1 exposed HCC cells led us to test DNA 
damage response after aflatoxin exposure. Unexpectedly, DNA damage checkpoint 
response to aflatoxins has not been studied thoroughly before. Although, DNA damage 
checkpoint response acts as an anti-tumor mechanism by protecting genome integrity 
against genotoxic agents, this highly critical aspect of aflatoxin carcinogenicity is poorly 
known.  
 
Our findings provide evidence for the contribution of ERK, p38MAPK and PI3K/Akt 
survival pathways under selenium supplementation in some HCC cell lines. Apart from 
the effect of selenium deficiency, our results enlighten the aflatoxin carcinogenicity in 
vitro. Our study pointed out for a negligent G1 and G2/M checkpoint response to 
aflatoxin B1-induced DNA damage. This defective response may account mostly for 
mutagenic and carcinogenic influences of aflatoxins. It may also associate with the 
frequent induction of TP53 hotspot mutation in aflatoxin-related human HCC. 
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ÖZET 
Karaciğer kanserinin moleküler patogenezinde diyet etiyolojik faktörlerin rolü 
Şehriban Özge Gürsoy Yüzügüllü 
Moleküler Biyoloji ve Genetik Doktorası 
Tez Yöneticisi: Prof. Dr. Mehmet Öztürk 
Şubat, 2011, 183 sayfa 
 
Hepatoselüler karsinoma, kansere bağlı ölüm oranlarında üçüncü sırada yer almaktadır. 
Diyete bağlı faktörler karaciğer kanserinin moleküler patogenezinde önemli rol 
oynamaktadır. Oksidatif stres kronik viral enfeksiyonuna bağlı enflamasyon sırasında 
HCC ilerleyişi ile beraber devam eden yaygın bir durumdur. Aflatoksine maruz kalmaya 
bağlı kimyasal stres, alkol alımıyla oluşan metabolik stres ve HCC için bir risk faktörü 
olan selenyum eksikliği oksidatif stres ile ilişkilidir. Oksidatif stresin fonksiyonel bir 
antioksidan savunma mekanizması ile uzaklaştırılması gerekmektedir. Oksidatif stres  
metabolik stres yoluyla oluşan endojen ve kimyasak ya da fiziksel karsinojenlerin 
oluşturduğu egzojen genotoksisitenin major nedenidir. Diyet faktörlerin HCC 
ilerleyişindeki katkısı yerleşmiş olduğu halde, bu katkının altında yatan moleküler 
mekanizma tam anlamıyla anlaşılmamıştır. 
 
Kanser hücreleri genotoksik strese karşı şifreli bir sağkalım avantajı gelişimi ile yanıt 
verebilir. Bu nedenle, bu fikri karaciğer kanserinde rol alan diyet faktörleri ile araştırmak 
istedik. Bu çalışmada, Se-eksikliğinin hepatositlerin tümörigenezindeki etkisi ve HCC 
p53-249 mutasyonu için aflatoksinin seçici seçiminin altında yatan mekanizma araştırıldı. 
Aflatoksinler en doğal yollarla oluşan, dünya çapında hepatosellüler karsinomların % 5-
28 olarak katkıda bulunabilen kanserojenlerdir. Aflatoksin karaciğer hücrelerinde aktive 
edilir ve TP53 genindeki özellikle aflatoksin ile ilgili hepatosellüler kanser ile ilişkili 249 
kodonu da dahil olmak üzere esas olarak G-> T mutasyonlarını tetikler. 
 
Ancak, bizim karşılaştırmalı sonuçlarımız R249S mutasyonunun heterozigot koşullar 
altında sağkalım avantajı sağlamadığını gösterdi. Böylece, bu seçicilik mutasyon 
indüksiyon aşamasında olabilir. Aflatoksine maruz kalan HCC hücrelerinde p53 
aktivasyon eksikliği, bizi aflatoksine maruz kalımdan sonra DNA hasarına verilen cevabı 
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test etmeye yöneltti. Aflatoksine karşı DNA hasarı kontrol noktası yanıtlarının en ince 
ayrıntısına kadar çalışılmamış olmasını beklemiyorduk. DNA hasarı kontrol noktası 
yanıtlarının genotoksik ajanlara karşı genom bütünlüğünü koruyarak anti-tümör 
mekanizması oluşturduğu halde, aflatoksin karsinojenezindeki bu kritik yön az 
bilinmektedir.  
 
Bulgularımız, bazı HCC hücre hatlarında selenyum desteğinin altında ERK, p38MAPK 
ve PI3K/Akt sağkalım yolaklarının katkısını ortaya koymuştur. Selenyum eksikliğinin 
etkisi dışında, sonuçlarımız in vitro koşullar altında aflatoksin kanserojenisitesini 
aydınlattı. Bizim çalışmamız, aflatoksin B1 ile oluşan DNA hasarına verilen cevabın 
ihmalkar bir G1 ve G2 / M kontrol noktası yanıtı olduğunu gösterdi. Bu yetersiz yanıt 
aflatoksinin çoğunlukla mutajen ve kanserojen olan etkileri için sorumlu tutulabilir. Aynı 
zamanda bu durum aflatoksin ile ilişkilendirilen HCC’de sık rastlanan spesifik TP53 
mutasyonu ile bağdaştırılabilinir.  
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CHAPTER 1. INTRODUCTION 
 
1.1 Hepatocellular malignancy 
 
Hepatocellular carcinoma (HCC) is considered as one of the most widespread 
malignancies worldwide. It is ranked as the fifth most common cancer [1].  Due to its 
resistance to therapy and the limitations of the existing chemotherapeutic drugs and 
lack of biomarkers for early detection and resection, the five year survival of HCC 
patients is less than 3% [2][[1]. HCC frequency fluctuates depending on the 
geographical area. Eastern and southeastern Asia, some part of Western Pacific 
Islands, and most parts of South Africa are the areas with high occurrence, [3], [4], its 
incidence in Europe and USA is low, but increasing [5], [6].  
 
More than 90 % HCC tumor development takes place in chronic hepatitis or a 
cirrhosis background [7]. Although under normal cellular conditions, adult 
hepatocytes do not divide, as a response to chronic exposure to Hepatitis B Virus 
(HBV), Hepatitis C Virus (HCV), alcohol, Aflatoxins [8] and cellular factors such as 
iron, copper and reactive oxygen species (ROS) accumulation in liver [9]  (Figure 
1.1.1), many hepatocytes are killed, [10], [3] and in order to compensate the liver 
necrosis hepatocyte proliferation increases. Rounds of destructive and regenerative 
proliferation process lead not only to chronic liver disease which ends up with liver 
cirrhosis but also this turnover causes the accumulation of irreversible genetic 
alterations [11]. Cirrhosis is a stage caused by excessive collagen deposition induced 
by fibrotic scarring of the liver. Cirrhosis is followed by hyperplastic nodules and 
subsequently with dysplastic nodules. The last stage of 10-30 years of this slow 
process is HCC [12], which is classified as well differentiated, moderately 
differentiated and poorly differentiated [13].   
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Figure 1.1.1 Multistages and contributing factors of hepatocellular carcinoma. Modified from [14]. 
 
1.2 Pathogenesis of hepatocellular carcinoma 
 
1.2.1 Viral factors 
 
Two billions and 170 million people are infected by HBV and HCV respectively 
worldwide [15]. Nearly, 30-50 % of the HBV-related deaths are due to HCC. HCV on 
the other hand contributes to 20% of liver cirrhosis and 2.5% of HCC [16], [17]. 
(Figure 1.2.1)  
HBV can lead to carcinogenesis by mainly 3 different ways. First, the viral DNA can 
be integrated into the host genome and cause chromosome instability [18]. Second, 
while integrating into the host genome, insertional mutations can be induced 
associated with activation of certain genes such as retinoic acid β-receptor [19], cyclin 
A [20], platelet-derived-growth-factor receptor-β (PDGFRβ), mitogen activated 
protein kinase 1 (MAPK1) and human telomerase reverse transcriptase (hTERT) [21] 
in which site specific HBV integrations were observed in independent tumors[22], 
[23], [24]. Third mechanism is based on HBV encoded X antigen (HBxAg), one of 
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the viral proteins expressed by HBV. Even though, the function of HBxAg is still not 
fully understood, it has been reported to be a modulator of cell proliferation and 
viability [25],[26, 27]. Along with HBxAg, PreS2 structural protein, encoded by viral 
S gene can serve as transactivator proteins [28] and activate AP-1 and NFκB 
transcription factors that, in turn, lead to the activation of signaling pathways. The 
most important function of HBx in terms of tumorigenesis consists in its ability to 
bind the tumor suppressor p53 in vitro. Thus, while inactivating p53 activities, it 
contributes to cell survival and proliferation [29, 30].   
 
 
Figure 1.2.1 Distribution of HCC incidences, aflatoxin exposure, Hepatitis B virus infection rate and 
occurrence of R249S mutation according to geographical area [31]. 
 
 
 
HCV, opposite of HBV is an RNA virus, and can not integrate into the host genome 
[32]. The molecular mechanisms of HCV-induced persistent infection in hepatocytes 
by Base Excision Repair (BER) [15]. AFB1-induced DNA le-
sions that escape DNA repair can result in mutations [14].
AFB1-N7-Gua, AFB1-FAPY and AP sites are all candidate pre-
cursors of mutations, predominantly induce G–T transver-
sions. Polymorphisms that affect the levels or activity of
AFB1 metabolizing and detoxifying enzymes, or of DNA
repair, influence the susceptibility to aflatoxin-induced car-
cinogenesis. For example, in a case-control study in The
Gambia, Kirk and colleagues [16] reported that the
GSTM1-null genotype and XRCC1 399 G variant were both
significantly associated with HCC. Furthermore, when
high-risk combinatio s of g notypes were compiled from
Fig. 1. Geographical distribution of incidence of HCC, exposure to aflatoxin, Hepatitis B Virus chronic carriage and prevalence of R249S mutation. HCC
incidence data are from GLOBOCAN 2002, IARC (http://www-dep.iarc.fr) and R249S prevalence data are from IARC TP53 Mutation Database, R12 [10]
(http://www-p53.iarc.fr). Data on chronic HBV carriage are fromWorld Health Organization and data on aflatoxin exposure are referenced in the text. Maps
drawn thanks to Servier Medical Art (http://www.servier.fr/smart/homesmart.asp).
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are not fully known. Recent studies indicated that viral proteins interact with a variety 
of important cellular proteins, such as apolipoprotein AII, 14-3-3 protein, tumor 
necrosis factor (TNF) receptor, DEAD domain of RNA helicase, lymphotoxin-ß 
receptor, double-stranded RNA protein kinase (PKR), nuclear ribonucleoprotein, p53, 
SNARE-like protein [33-35]. It causes the down-regulation of p21cip1 expression [36], 
the activation of Ras/Raf signaling pathway and has an anti-apoptotic activity [37]. 
The 5’ region of the HCV genome encoding the nonstructural protein 3 (NS5A) has 
an oncogenic potential and NS5A was shown to interact with p53 in vivo [38]. HCV 
core protein and NS3 or NS5A inactivate p53 by transcriptional repression [39, 40], 
or directly binding to p53 [41, 42], respectively.  
In addition to the functions of virus proteins in HCC, chronic infection by HBV and 
HCV contribute to HCC by activating cytokines and growth factors including insulin-
like growth factor-2 (IGF2) and transforming growth factor-α (TGF-α) in 
preneoplastic hepatocytes, leading to the enhancement of proliferation and 
accumulation of genomic alterations [10, 43].  
 
 
1.2.2 Genetic alterations 
 
1.2.2.1 Allelic imbalance and microsatellite instability  
 
Many chromosomal aberrations and genetic mutations in HCC have been detected by 
genome-wide allelotype studies. These conventional cytogenetic methods performed 
with hepatocellular cell lines and liver tumor tissues demonstrated that most HCCs 
are aneuploid and harbor multiple allelic imbalances (AI) on 1p, 1q, 4q, 6q, 8p, 8q, 
9p, 10q, 13q, 16p, 16q and 17p chromosomal arms [44-51].  
 
Further studies with comparative genomic hybridization (CGH) revealed that AI was 
associated with gene dose decrease on 1p, 4q, 6q, 8p, 9p, 10q, 13q, 16q and 17p and 
gene dose increase on 1q and 8q [52-59]. However, due to the technical limitations of 
the conventional methods, the frequency of AI with gene dose increase was 
underestimated and recent studies indicated additional gen dose increases on 6p, 17q, 
20q, 1q and 8q [51].  
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Alterations on chromosomes 3p, 5q and 6q can be related to the activation of ß-
catenin (CTNNB1) that is reported to be associated with 19% of HCC [60], the 
adenomatous polyposis coli (APC) gene that is involved in the Wnt signaling pathway 
and is responsible for the initiation of ß-catenin degradation, and the loss of mannose 
6-phosphate/insulin-like growth factor II receptor (M6P/IGF2R) that contributes to 
the dysplastic nodules and HCC [61]. Loss of heterozygosity occurs in 50-80% of 
dysplastic nodules [10]. Although the microsatellite instability is associated with the 
failure of DNA mismatch repair genes MSH2 and MLH1 on chromosomes 2 and 3 
[62], in HCC those chromosomal locations are not commonly disturbed by allelic 
deletions. However, about 30% of HCCs were reported to be linked to mutations in 
another DNA mismatch repair gene called Human Mut S homolog-2 [63].   
 
Aberrations on chromosome 9p are associated with two-tumor suppressor proteins 
p16 ink4A and p14ARF. p16ink4A inactivation was detected in 48% of HCC due to the 
hypermethylation of its promoter [64-66], while p14ARF  inactivation was found in 
15 % of HCC cases, caused by deletion or promoter methylation [67]. An allelic loss 
of 10q resulting in the loss of somatic phosphatase and tensin homolog (PTEN) gene, 
a negative regulator of the phosphoinositide 3-kinase/AKT signaling pathway [68, 
69], was observed in 27 % of HCC cases.  The amplification and overexpression of 
cyclin D1 on 11q has been stated [70]. The loss of 13q region attributes to the loss of 
Rb tumor suppressor gene in 16% of HCC [71] and BRCA2 in 3 out of 60 HCCs, 
[72]. Alterations in Axin1 gene, which is crucial for the degradation of cytoplasmic ß-
catenin on 16p, was reported to be involved in 5 % of HCC without ß-catenin 
mutation [73]. TP53 tumor suppressor gene located on 17p.13.1 was indicated to 
contain mutations in 32% of HCC.  
 
1.2.2.2 Cell cycle regulation 
 
Signaling pathways, connecting growth and metabolic signals to the control of the cell 
cycle checkpoints in hepatocytes, have drawn attention since their key players are 
frequently disrupted in HCC.  
 
The period between the late G1 and S phases is one of the most important phases of 
the cell cycle. During this period, G1 checkpoint barriers decide whether to proceed 
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with the S phase or to rest at G1. At this point the most important pathways are the 
cyclin D1-Rb-CDK4/6 pathway or the p53-p14ARF pathway [74, 75].  
Basically, during the G1/S transition, cyclin D1/cyclin dependent kinase 4 or 6 and 
cyclin E/cyclin dependent kinase 2 dimers sequentially phosphorylate the 
retinoblastoma (Rb) protein to allow the dissolution of the repressive complex thereby 
allowing the transcription of E2F target genes. Consequently, cells can enter the S 
phase for proliferation [76-78]. Several evidences have been provided indicating the 
link between HCC and cyclin D1-Rb-CDK4/6 pathway. In vivo studies revealed that 
in early stages of carcinogenesis, hepatocyte proliferation is associated with E2F-1 
overexpression [79, 80]. Cyclin D1 overexpression in the liver is sufficient to induce 
hepatocyte replication [81] and research on transgenic models using chemical 
inhibitors revealed the importance of cyclinD1 for the signaling of hepatocytes 
progression through the G1/S barrier [81-85]. The increased expression of the cyclin 
D1 in HCCs is considered to be due to gene amplification or chromosomal 
rearrangements, thus is probably a late event in HCC that causes tumor growth rather 
than tumor initiation [70].   
 
INK4a ARF locus on 9q21 encodes two proteins with different functions; p16 
(INK4a) which acts as an inhibitor of CDK4 and cyclin D association, thereby 
contributing to the maintenance of Rb protein in its anti-proliferative-active state [75] 
and the p14ARF tumor suppressor is a key regulator of p53 stabilization [86] by 
antagonizing the activity of MDM2, a negative regulator of p53 stability. It initiates a 
p53-dependent transcriptional response such as growth arrest or apoptosis in normal 
and cancer cells. As it is discussed in previous section, INK4a-ARF locus is disturbed 
in HCC; 50% of HCC presents de novo methylation and 20 % of HCC shows LOH in 
the same locus [11, 87]. 
 
1.2.2.3 Alterations of the TGF-β and PI3K pathway 
 
Transforming growth factor-β (TGF-β) mediates growth arrest through the 
transcriptional activation of p15 ink4B and p21cip1; the CDK inhibitors. TGF-β allows 
also the transcriptional suppression of c-myc, CDK4 and cdc25A expression in 
epithelial and other cell types[88]. TGF-β is considered as a double-edged sword, 
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because of the fact that it can act as an early tumor suppressor, but later contributes to 
tumor progression by its action on the tumor cells and their microenvironment 
inducing invasion and metastasis.  
Regarding to the role of TGF-β in hepatocarcinogenesis, current data is conflicting. 
While in normal cultured hepatocytes, the addition of TGF-β inhibits hepatocyte 
proliferation; studies in multiplicity of cell types that express TGF-β and its receptors 
in the liver indicated the role of TGF-β in the regulation of proliferation, apoptosis, 
angiogenesis, tumor invasiveness and immune surveillance in liver carcinogenesis. In 
clinical samples, TGF-β and TGF-βRII receptors have been found to be 
downregulated in early HCC compared to surrounding liver, while the expression of 
TGF-β receptors were inversely correlated with tumor size and proliferative index 
[89-92]. Recent studies performed by our group indicated that TGF-β induces p21Cip1 
and p15Ink4b and ROS-dependent senescence in well-differentiated HCC cells, along 
with a strong anti-tumor response in vivo, yet poorly differentiated HCC cells found 
to be resistant to TGF-β induced senescence [93]. All these findings are consistent 
with the concept of the function of TGF-β as a tumor suppressor in early stages, yet, 
in late tumors; this cytokine may contribute to tumor progression by activating 
pathways involved in tumor invasion and angiogenesis. 
 
The activation of phosphatidylinositol 3-kinase (PI3K)/Akt/mTOR signaling cascade 
has been identified in many cancer cells [94]. The function of PI3K is controlled by 
PTEN in a negative direction. Mutations [95] and the functional loss of PTEN [96] 
have been reported in about 0-11% and >55% of HCC cases respectively. Upon 
activation of PI3K cascade, various survival genes are transcribed [97]. An important 
survival target of PI3K is a serine/threonine kinase AKT. When activated, it 
inactivates many pro-apoptotic proteins as well as its important downstream effector 
mTOR by phosphorylating them [97]. Activation of this pathway is associated with 
poor prognosis in HCC [98].  
Inhibition of the PI3K/AKT/mTOR pathway as a chemotherapeutic treatment is 
possible at various levels. Research in HCC animal models and HCC cell lines 
demonstrated limited efficiency of PI3K inhibitors such as wortmannin, LY294002 
[99] and FTY720 [100]. The most promising inhibitors of PI3K pathway are mTOR 
and have been tested in pre-clinical and clinical studies of HCC [101-103]. The major 
  8 
concern for the use of kinase inhibitors as chemotherapeutic drugs in HCC is the 
potential limitations due to the cross-talk between different signal-transducing 
pathways as well as the complexity of HCC [104].  
 
 
1.2.3 TP53 
 
The TP53 gene, located on chromosome 17p13.1 is regarded as an important tumor 
suppressor protein and “the guardian of genome” and possesses a fundamental role as 
the major controller of cellular activities concerning the genomic integrity, 
transcription, cell cycle, development process and the control of apoptosis, senescence 
and DNA repair [105, 106]. It encodes a 53kD DNA-binding transcription factor and 
it is a haploinsufficient tumor suppressor [107, 108]. Accordingly, malfunction in the 
p53 pathway is a hallmark of human cancers [109]. Wild-type p53 protein functions 
as a tumor suppressor in vitro and in vivo. Around 50% of all human cancers contain 
p53 mutations [110]. Beside the incidence of such frequent somatic mutations in 
human cancers, there are germline mutations in the p53 gene in some cancer-prone 
families with Li-Fraumeni syndrome as well [111].  
 
p53 protein is structurally organized with several domains consisting of 
transactivation domain in its N-terminal region, a proline rich regulatory domain, a 
central DNA binding domain (DBD) and a C-terminal regulatory area including 
nuclear localization and oligimerization domains [112] (Figure 1.2.2).  
 
 
 
 
Figure 1.2.2 Structural depiction of TP53. Each cube represents p53 functional domains. Modified 
from [109]. 
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Control of regulation and activation of p53 is a crucial event for the cells. Under 
normal unstressed conditions, p53 is kept inactive with the activity of negative 
regulator MDM2. MDM2 can either directly bind to the N-terminal transactivation 
domain of p53 [113, 114]) or ubiquitylate the protein and lead to the export of p53 to 
the cytoplasm [114]. Under high levels of stress conditions, the interaction between 
MDM2 and p53 are disrupted by post transcriptional modifications allowing the 
active p53 to function as a transcription factor; depending on the response to be given, 
inducing or suppressing the target genes involved in apoptosis, senescence, cell cycle 
arrest, DNA repair, angiogenesis[115] (Figure 1.2.3).  
 
Figure 1.2.3 TP53 activation and its functional involvement in cellular process. Purple boxes and green 
boxes represent the various types of stress and cellular events, respectively.  
(Modified from [116]). 
 
 
TP53 is unique with an incidence of 74% of missense mutations (Figure 1.2.4), 
occurring in the DBD of p53, yet resulting in full-length, slightly altered, albeit stable 
proteins with varying residual activities [117, 118].  Such elevated occurrence of 
mutations proposes a powerful selective pressure for disturbance of normal p53 
function in the development of tumorigenesis [119]. Interestingly, mutant p53 
proteins have very unique features in terms of structure, biochemical and biological 
aspects. Mutations in DBD are classified into two groups based on their 
thermodynamic stability and DNA binding properties; contact mutations that affect 
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directly DNA binding such as Arg-248 and Arg-273 and structural mutations that 
affect structural integrity of DNA binding site such as Arg-175, Gly-245, Arg-249 
and Arg-282 [120].  
 
 
 
Figure 1.2.4 High prevalence of missense mutations involved in p53 compared to other tumor 
suppressors. (Modified from Weinberg RA. Biology of Cancer, Chapter 9:311-314, Garland Pub, 
2006)  
 
Mutant p53 proteins are considered to have oncogenic activities in tumor cells (Figure 
1.2.5) [121]. In addition, observed amounts of mutant p53 protein in tumor cells are 
elevated when compared to both wild-type p53 and mutant p53 amounts in normal 
cells [122-124]. However, how this selectivity is established and sustained is not fully 
evidenced yet. 
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Figure 1.2.5 p53: a two-faced cancer gene. Modified from [125]. 
 
1.2.3.1 p53 and HCC 
 
p53 alterations are generally linked to poorly differentiated tumors and low survival 
rate [126]. After the restoration of p53 expression in murine liver tumors, senescence 
is triggered and tumor development is diminished [127]. Functional inactivation of 
p53 by HBx has been described in HCC and discussed in detail in section 1.2.1. The 
loss of p53 almost certainly plays an important role in HCC progression by 
contributing to proliferation under cirrhotic conditions in which oxidative stress; 
regeneration and genomic instability are provoked. Recent in vivo data indicated that, 
defect in a DNA repair gene Ku70 accelerates liver carcinogenesis under the setting 
of loss of p53 through proteosomal degradation [128]. Heterozygosity in p53 in the 
course of germ line mutations may also facilitate HCC progression in vivo with 
telomere shortenening, thereby chromosome instability [129-131].  
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The alterations in p53 are concentrated between exon 4 and 9 of DBD. The most 
important alteration among these mutations is the transversion in codon 249 (G→T), 
which causes an arginine to serine (R→S) substitution and exists in 50% of HCCs. 
This mutation will be discussed in detail in following sections.  
 
1.2.4 Epigenetic regulations 
 
1.2.4.1 DNA methylation 
Cancer is closely associated with global hypomethylation and CpG island 
hypermethylation [132]. The shift in DNA methylation pattern commonly results in 
improper silencing of genes especially the tumor suppressors through hyper 
methylation or protooncogene activation including c-JUN, c-MYC, and c-Ha-Ras; 
and generates genomic instability through global DNA demethylation. Table 1.2.4.1 
depicts the DNA methylation alterations observed in different human cancer types.  
 
Table 1.2.4.1 DNA methylation alterations observed in some human cancer types. (Modified from 
[133].  
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1.2.4.2 Histone modifications 
 
Nucleosomes are the basic units of DNA packaging. They are made up of 147 base 
pairs of DNA wrapped around a histone protein core. The core histones (H3, H4, H2A 
and H2B) undergo posttranslational modifications including methylation, acetylation, 
phosphorylation, ubiquitination. Combinations of these modifications constitute a 
“histone code” which is important for the biological activities such as gene expression 
regulation and DNA repair.  
 
However, the modifications that occur on histones are extremely complex and diverse 
due to the fact that lysines or arginines can be methylated with one of three different 
forms: mono-, di-, or trimethyl and mono- or di- (asymmetric or symmetric) 
respectively [134].  
 
Lysine methylation takes part in gene regulation depending on which residue is 
modified. While methylation of histone H3 lysine 4 (H3K4) and histone H3 lysine 36 
(H3K36) is related with transcription, methylations of H3 lysine 9 (H3K9), H3 lysine 
27 (H3K27), and H4 lysine 20 (H4K20) are usually associated with deactivation. 
Lysine acetylation, is almost always linked to chromatin accessibility and 
transcriptional activity.  
 
1.2.4.3 Histone methylation and cancer 
 
Novel technologies provide global assays for the exploration of key epigenetic marks 
including histone modifications. Accumulating data suggested the relationship 
between cell or context-specific histone modification patterns and cell or context-
specific gene expression, and these modulations have been associated with many 
cancers.  Recent research demonstrated the association with H3K27 trimethylation 
patterns with prostate, lung, and breast cancers; and H3K9 and H3K79 modification 
patterns with leukemia [135-142].  Association of H4K20 with cancer is demonstrated 
in a study, which reports the selective loss of the trimethylation of H4K20 in tumor 
cells, thereby contributing to the sensitization of mice to tumorigenesis [143].   
The major clue, which demonstrates the direct link between histone methylation, 
marks and HCC comes from a study that was conducted in a methyl deficient rat 
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model. During hepatocarcinogenesis, in rats fed with a methyl-deficient diet, H4K20 
trimethylation levels were diminished along with an ongoing reduction in the 
expression of Suv4-20h2 histone methyltransferase and a major rise in H3K9 
trimethylation in preneoplastic nodules and liver tumors [144].  
 
Even though, all these current studies provide experimental evidence on the inevitable 
role of histone methylation in the course of tumor onset and/or progression in various 
cancer types including HCC, ongoing research will enlighten this relationship better.  
 
 
1.2.5 Dietary factors involved in HCC 
     
1.2.5.1 Alcohol abuse   
Alcohol consumption is related to an augmented risk of liver cancer in the absence of 
chronic hepatitis and is considered not to be safe at any level of consumption [145, 
146]. Alcohol intake contributes to liver cancer by facilitating the onset of liver 
cirrhosis [147]. During alcohol metabolism, the generation of acetaldehyde and free 
radicals is enhanced [148] and these reactive species can immediately bind to DNA 
and proteins [149-151] and decrease the DNA repair capacity and antioxidant defense 
mechanisms [150, 152]. Thus, consequences of alcohol metabolism on genomic 
integrity and DNA repair processes are expected to participate considerably to the 
development of transformation. Alcohol also affects hepatic metabolism and 
hepatocyte signal transduction pathways involved in the regulation of normal 
hepatocyte function and proliferation as well [153].  
 
 
1.2.5.2 Obesity 
 
Obesity has been established to be an important risk factor for the progression of 
various malignancies, including liver cancer by contributing to the onset of NAFLD 
(non alcholic fatty liver disease)[154];[155]. Obesity and hepatic steatosis also play 
role in the development of HCC in other liver diseases such as chronic HCV [155].  
Death from liver cancer among obese males demonstrated the highest relative risk of 
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all the cancers. In a population-based cohort study, only men had significantly 
increased risks for cancers of the small intestine, liver, and pancreas, and for 
Hodgkin's disease  [156, 157]. The higher risks observed for liver and pancreas 
cancers among men were correlated with higher plasma insulin concentrations and 
alcohol abuse [157].   
 
 
1.2.5.3 Selenium deficiency and liver diseases 
 
1.2.5.3.1 Selenium and its deficiency 
 
Selenium (Se) is an essential trace element, which is a major component of 
selenoproteins with essential biological functions (Table 1.2.5.1).  
 
Table 1.2.5.1 Mammalian selenoproteins and their biological functions  
([158] see copyright permissions). 
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Selenium’s antioxidant effects stem from its necessity for many enzyme families such 
as glutathione peroxidases (Gpxs) and thioredoxin reductases that function to protect 
cellular macromolecules from the oxidative stress damage.  
 
Se-deficiency is associated with diseases such as Keshan disease, heart diseases, liver 
necrosis, and some cancer types (Table 1.2.5.2). 
 
Table 1.2.5.2 Examples of selenoproteins and corresponding human diseases and 
cellular functions 
 ([159] see copyright permissions). 
 
Low Se intake from agricultural products leads to serious health consequences that 
result from the induction of oxidative stress, especially in low Se areas of China and 
Eastern Siberia. In the Keshan region of China, Se deficiency causes endemic Keshan 
disease with the pathology of juvenile cardiomyopathy with myocardial insufficiency 
that affects mostly children aged from 2 to 10 years old [160]. 
 
Furthermore, several studies indicated that Se contributes to the defense of animals 
against the toxicity of high exposure and/or intake of heavy metals like mercury, lead, 
cadmium and silver [161-165]. Previous studies also correlated Se-deficiency with the 
pathology and virulence of viral infections [166-168]. Additionally, Se 
supplementation inhibits TNFα (tumour necrosis factor α) -induced HIV replication 
[169].  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1.2.5.3.2 Selenium and oxidative stress 
 
Reactive oxygen species (ROS) are formed by sequential reduction of one electron 
from oxygen. They are very reactive due to the presence of the unpaired valence shell 
electrons. ROS are generated as natural byproducts during the normal oxygen 
metabolism by NAD(P)H oxidases, xanthine oxidase, myeloperoxidase, 
cyclooxygenase and lipoxygenase [170]. However, when the biological system is 
exposed to environmental stress, ROS levels can raise significantly resulting in a 
condition called oxidative stress accompanied with considerable damage to cell 
structures such as DNA, lipids and proteins. In this condition, cells cannot cope with 
the produced ROS and repair the resulting damage [171].  
 
Cells possess a defense mechanism for the detoxification of ROS and the repair of 
deleterious oxidative damage. Among these mechanisms antioxidant enzymes such as 
superoxide dismutases (SOD), catalase and glutathione peroxidases (GPx) are the 
most important in humans. All these GPx isoenzymes and thioredoxin reductases 
(TrxRs) share a catalytic selenoprotein in their active center, consisting of 
selenocysteine[172-174]. 
GPx isoenzymes reduce hydrogen peroxide, organic hydroperoxides, and 
phospholipid hydroperoxides [175]. In addition to glutathione peroxidases, TrxRs 
degrade hydroperoxides including hydrogen peroxide and lipid hydroperoxides, as 
well (Figure 1.2.6) [176].  
 
Apart from the degradation of hydroperoxides, TrxRs reduce thioredoxin which is an 
intracellular protein located in the cytoplasm and mitochondria and serve as an 
electron and hydrogen donor when reduced, thereby restoring the activities of 
antioxidant enzymes [177-179].  
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Figure 1.2.6   Anti-ROS Internal Protection Mechanisms. SOD is implicated in the removal of -O2·. 
Gpx and CAT are implicated in the removal of H2O2, and Gpx and GST are implicated in the removal 
of lipid peroxides (ROOH) evading a chain reaction (Halliwell and Gutteridge, 1999, J.M.C., Free 
Radicals in Biology and Medicine, 3rd edition). Vitamin E inhibits lipid peroxidation by scavenging 
OH·[180]. (Modified from Irmak MB, thesis subject: Acquired Tolerance of Hepatocellular Carcinoma 
Cells to Selenium-Deficiency: A Selective Survival Mechanism, 2003)  
 
 
 
1.2.5.3.3 Selenium and cancer 
 
The relationship between selenium and cancer has been well documented. Se is 
considered as an anticarcinogenic as suggested by several animal studies [181]and 
previous studies indicated that Se could decrease the risk of different cancer types 
[182].  Figure 1.2.7 depicts the proposed link between Se and cell metabolism.  
 
Many selenoprotein gene alterations that are responsible for the inhibition of 
oxidative stress have been associated to the risk of cancer. These gene polymorphisms 
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including GPX1, GPX2, GPX4 and Sep15 are implicated in breast, prostate, lung, 
head, neck and colorectal cancer [183-188]. Additionally, changes in the expression 
of GPX1, GPX2, Sep15, SelP and TRXR1 have been documented in different forms 
of cancer [189].  
 
 
 
 
 
Figure 1.2.7 A model of selenium and its association with cell metabolism.  
 
 
1.2.5.3.3.1 Selenium and liver cancer 
 
Analogous to chronic alcohol exposure, Se-deficiency has also been associated with 
hepatocyte damage and necrosis[158]. As previously discussed in section 1.2.4.1, 
pathological mechanism of liver injury associated with alcohol abuse lies beneath the 
production of ROS [148].  
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Aside from the capability of ROS to attack proteins, polysaccharides, nucleic acids 
and polyunsaturated fatty acids, these species also have the ability to activate the 
cytokine release from immune cells to trigger inflammatory pathways and induce the 
expression of adhesion molecules, leading to the accumulation of granulocytes in 
organs and further increase the generation of ROS thus augmenting the inflammatory 
response and tissue injury [190]. Knowing the fact that, continuous tissue injury and 
inflammation are the major driving force for the onset of cirrhosis and HCC, 
oxidative stress scavengers are essential for liver function.  
 
Since, GPxs, the most effective defense mechanism proteins that cope with ROS and 
oxidative stress require Se to be incorporated in their catalytic center to function 
[191], chronic Se deficiency is a major risk factor in liver cirrhosis.  
 
Several case studies conducted in individuals with different liver pathologies 
indicated that serum or plasma Se levels of these individuals were considerably less 
than those in healthy control group (Table 1.2.5.3) [158, 192]. In correlation with this, 
chronic alcoholics suffer from the limited food intake and malnourishment since too 
much alcohol consumption disturb their diet, preventing the Se supply from food 
[158].   
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Table 1.2.5.3 Selenium levels in serum, plasma, whole blood, tissue and erythrocytes 
in healthy control and patients with different pathology.  
 
([193] see copyright permissions). 
 
Selenium supplementation has a protective role against hepatitis B and C virus (HBV, 
HCV) infection [194]. Although the exact underlying mechanism is not determined, 
selenium has been shown to maintain the growth of some HCC cell lines, Hep3B, 
HepG2, Hep40 and Huh-7 under serum-free conditions [195-197]. A recent study 
performed by our group indicated that ten out of thirteen HCC cell lines are resistant 
to Se-deficiency, while in a couple of them oxidative stress and apoptosis are induced 
[197].  
 
 
1.2.5.3.3.2 Signaling pathways and selenium  
 
The role of Se in the activation of specific signaling cascades that contributes to 
carcinogenesis is not fully characterized. However, growing evidence from clinical 
trials suggest that Se supplementation and certain Se metabolites effectively diminish 
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the incidence of cancers such as lung, colorectal, prostate and liver cancer [194, 198, 
199].  
  
Several studies reported that selenium functions directly in the regulation of many 
important survival and apoptosis signaling pathways. Figure 1.2.8 demonstrates the 
major response pathways after ROS formation and their key targets.  
 
 
 
 
Figure 1.2.8 ROS signaling targets in various biological signaling pathways (Modified from [200]). 
 
The activities of NF-κB, AP-1 [201], JNK1 [202], and caspase-3 [203] are inhibited 
through the redox regulation of their reactive cysteine residues. In those studies 
selenite is indicated as a suppressor of the JNK, stress-activated protein kinase 
(SAPK) and the p38 mitogen-activated protein kinase (p38MAPK) pathway, which 
are extremely fundamental cascades upon ROS induced oxidative stress response 
[202]. Apoptotic response is a common response after strong oxidative damage, one 
of its key elements; caspase-3 activity is also inhibited by selenium in embryonic 
kidney cells [203]. Another study indicated the anti-apoptotic role of selenite after 
hydrogen peroxide treatment through the inhibition of the ASK1/JNK pathway and 
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the induction of the PI3K/Akt survival pathway [204], complementary with a follow-
up study performed on Huh-7 HCC cell line [205], demonstrating the involvement of 
selenium supplementation for the inhibition of apoptosis and the activation of the 
PI3K/Akt kinase pathway.  
 
 
1.2.5.4 Hepatotoxic chemicals 
 
Multiple chemical components such as benzo(a)pyrene, 4-aminobiphenyl, vinyl 
chloride [206, 207] constituents of tobacco, inorganic arsenic[208] and aflatoxins 
[209] are hepatic carcinogens in animals. Along with the data provided for the 
genotoxic effects of benzo(a)pyrene and vinly chloride on p53 gene in human and 
animal [210, 211], many epidemiological studies strengthen the notion of cigaratte 
smoking as a hepatic carcinogen in humans. The consumption of aflatoxin 
contaminated food and inorganic arsenic contamination in drinking water supplies 
have been allied with HCCs [208, 212-214]. 
      
1.2.5.4.1 Aflatoxins 
 
Aflatoxins are mycotoxins produced by some Aspergillus flavus, A. parasiticus and A. 
nominus strains and production of aflatoxins B1, B2, G1, G2, and M1 contaminates 
several agricultural products [215]. These mold species are common and widespread 
in nature and they can contaminate grain prior to harvest and during improper drying, 
storage and processing by infection and colonization of the fungus. Cereals, oilseeds, 
spices and nuts are commonly affected with the aflatoxin contamination. Aflatoxin 
can also be present in the milk of animals, which are fed with contaminated crops 
[216].  
 
1.2.5.4.2 Aflatoxin exposure in humans 
 
The US Food and Drug Administration (FDA) regards aflatoxins as unavoidable food 
contaminants, thus in order to minimize the level of contamination, implementing 
strict regulations is a necessary precaution to be taken. The FDA’s goal has been to 
minimize contamination; this goal was realized by implementing regulations that 
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required special attention to the management of the problem. In developed countries, 
aflatoxin contamination is diminished by the regulations in imported food and 
industrial food processing techniques. However, in developing countries due to the 
characteristics of the food systems and the technological infrastructure, these methods 
remain to be limited and no control is applicable, hence people in these countries 
remain at high risk of exposure to aflatoxins.  
 
Though rare, acute exposure to high levels of aflatoxins (>20 µg/kg/day) leads to a 
lethal syndrome called aflatoxicosis associated with the symptoms of hemorrhagic 
necrosis of the liver and bile duct proliferation [217]. However, more than 90 % of 
people at high risk for aflatoxin-caused HCC are chronically exposed to low doses of 
aflatoxin (0.01-0.3 µg/kg/day) [217, 218]. Chronic exposure to low or moderate doses 
of aflatoxin may lead to the development of HCC [217]. 
      
1.2.5.4.3 AFB1-induced DNA damage and HCC 
 
1.2.5.4.3.1 Aflatoxin and HCC 
 
Dietary exposure to aflatoxins and infections with hepatitis B virus (discussed in 
section 1.2.1) are the major risk factors for HCC in Southeast Asia, sub-Saharan 
Africa and China [219] where populations suffer from both high hepatitis B virus 
prevalence and largely uncontrolled aflatoxin exposure in food.  A recently published 
risk assessment study indicated that about 5-28 % of all global HCC cases might be 
caused by aflatoxin exposure [218]. 
 
1.2.5.4.3.2 Aflatoxin metabolism and DNA damage 
 
Aflatoxin B1 (AFB1) is the most prevalent and carcinogenic of aflatoxins. After the 
intake of AFB1, it is oxidized into AFB1-8,9-exo-epoxide and 8,9-endo-epoxide by 
mainly cytochrome P450-mediated enzyme metabolism in liver (Figure 1.2.9). The 
exo-epoxide form of AFB1 binds to DNA to form the predominant 8,9-dihydro-8-
(N7-guanyl)-9-hydroxy AFB1 (AFB1-N7-Gua) adduct  with an extremely short half-
life, so it immediately undergoes processing reactions to form a more stable imidazole 
ring-opened AFB1-formamidopyrimidine (AFB1-FAPY) [220] DNA adducts which 
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can accumulate for several days and remain detectable for several weeks [221, 222] 
(Figure 1.2.9). In addition to AFB1-DNA adduct formation, AFB1 exposure has been 
reported to cause DNA damage through oxidative stress leading to the formation of 8-
hydroxydeoxyguanosine (8-OHdG) lesions in rat and duck liver [223, 224].  
Mispairing of AFB1-DNA adducts induce mainly G:C to T:A transversions [225]. 
Earlier studies showed the prevalence of G:C to T:A transversions in E. coli and 
plasmid based experimental settings [210, 226, 227].  
 
 
 
 
Figure 1.2.9 Aflatoxin metabolism in liver and Aflatoxin-induced DNA damage 
(Modified from [228]). 
 
 
1.2.5.4.3.3 Correlation between aflatoxin exposure and p53 
 
Experimental data that have been conducted for almost two decades defined aflatoxin 
as a causative factor for p53 mutations. These studies have led to the identification of 
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a HCC specific G->T mutation at codon 249 of TP53 gene (encoding the mutant 
p53ser249 protein) in HCC tissues of patients exposed to aflatoxins [212, 213, 229].  
Later, this hot spot mutation was indicated to be detectable in non-tumor liver 
samples [230] as well as in the plasma of 6 % healthy individuals and 15% of  
cirrhotic patients, and 40% of HCC patients living in aflatoxin-contaminated area 
[231]. Therefore, AFB1-specific G->T mutation of TP53 is commonly present in 
people exposed to aflatoxins, regardless of any clinically detectable liver tumor. 
Overall, all these findings present strong support for the mutagenicity of low level 
AFB1 in people chronically exposed to this hepatocarcinogenic agent. However, HCC 
patients carrying R249S p53 mutation drops to around 2-5% in regions where 
aflatoxin exposure is low or moderate [31].  
 
1.2.5.4.3.3.1 Functional characteristics of R249S p53 
 
R249S mutation in p53 is a structural mutation which destabilizes the core domain of 
p53 and disrupts its DNA-binding capacity [232]. Like many other common p53 
mutants in cancer, R249S mutant lacks the wild-type p53-dependent tumor suppressor 
functions. Other than the loss of tumor suppression activity, an abundance of data 
suggests that mutant p53 proteins including R249S gain additional functions that 
enhance genetic instability, tumorigenesis and drug resistance [233-236]. 
Interestingly, HCCs in areas not exposed to AFB1 do not harbor R249S mutation, 
which is extremely specific to AFB1 exposure [14]. Presently, the nature of this 
selective pressure to induce and maintain the expression of this hot spot R249S 
mutation of p53 is not fully known. After the initial description of increased mitotic 
activity associated with p53-249ser expression in human HCC cells [237], mouse 
equivalent of this mutation (p53-246ser) was shown enhance hepatocarcinogenesis 
induced by other factors [238], but it was not sufficient for hepatocyte 
immortalization by itself [239]. P53-249ser was reported to stimulate G0 to G1 and/or 
M to G1 transition in hepatocytes [240]. Recently, p53-249ser was shown to protect 
HCC cells from cytotoxic effects [241] of PRIMA-1, which restores sequence-
specific DNA binding and the active conformation to mutant p53 proteins [242]. 
However, in vivo studies failed to recapitulate the R246S (mouse equivalent of 
R249S) after AFB1 treatment even in the Hupki mice, which carry the human p53 
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locus in germ line, indicating the yet-undiscovered mechanisms [238, 243, 244]. 
Moreover, a very recent study indicated that, p53-246ser has dominant negative 
activity over wild-type p53 both in differentiated and undifferentiated embryonic stem 
cells [245]. Despite all the efforts, a common and well-accepted mechanism for 
selection of p53-249ser in HCC has not emerged yet. The underlying mechanism of 
its contribution to hepatocarcinogenesis is not fully-known.  
 
 
1.2.5.4.4 Response to AFB1-induced DNA damage  
 
 
In order to protect the genomic stability, eukaryotic cells, from yeast to human have a 
sophisticated and powerful DNA damage response system. Upon DNA damage, 
several cellular responses are induced to enable the cell either to repair the damage or 
to activate senescence and apoptosis processes. DNA damage checkpoint proteins 
play a central role in the coordination of repair and cell cycle progression to prevent 
mutations. In response to DNA damage, cell cycle checkpoint proteins at G1/S, S or 
G2/M barriers are induced. Damage is recognized by sensors, kinases including ATM 
and ATR and mediated by adaptor proteins such as 53BP1 and γ-H2AX to the 
transducers; Chk1 and Chk2.  The final induction of the effectors like p53 and cdc25 
arrest the cells at either of these checkpoints and inhibit cell cycle transition 
depending on the amount of damage  (Figure 1.2.10). DNA damage response also 
triggers a DNA repair process. DNA repair mechanisms are classified as direct repair, 
base excision repair, nucleotide excision repair (NER), double-strand break repair, 
and cross-link repair[246] [247]. 
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Figure 1.2.10 DNA damage checkpoint mechanism and its key regulators in humans.  
(Modified from [246]).  
 
 
AFB1-DNA adducts are believed to be repaired primarily by NER in prokaryotes and 
eukaryotes [248, 249] [250, 251] [252]. As a consequence of the attempted repair of 
AFB1-DNA adducts by NER DNA double-strand breaks (DSB) and single-strand 
breaks may form. It is also believed that replication forks collapse while AFB1- DNA 
adducts are encountered. Accordingly, in yeast, lack of NER and recombinational 
repair is proposed to contribute to mutagenesis proceeding via the error prone 
translesion bypass synthesis (TLS) pathway [249, 250] that is evolved to allow 
replication bypassing the damage to minimize cell death from replication blockage 
[253]. In mammals, further understanding of damage recognition by DNA repair 
enzymes in response to AFB1-DNA adducts is required. In mouse liver, after AFB1 
treatment, NER induction was observed but the exact mechanism is ill-known [254]. 
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Apurinic sites induced by AFB1 instead are believed to be repaired by base excision 
repair [255]. The susceptibility to AFB-induced carcinogenesis also shows differences 
between species, which correlates with the difference in DNA repair activity [254]. 
All in all, in order to fully understand the mechanism of DNA damage recognition 
and repair mechanism after AFB1 exposure, more mechanistic studies and 
considering the contributions of other repair pathways are required.  
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CHAPTER 2: OBJECTIVES and RATIONALE 
 
Dietary factors play a crucial role in the molecular pathogenesis of liver cancer. In 
this study we aimed to decipher the role of dietary factors in the pathogenesis of liver 
cancer.  
Oxidative stress is associated with the malignancy and progression of HCC. It is 
considered as a common factor during inflammation as a result of chronic viral 
infection, chemical stress caused by aflatoxin exposure, metabolic stress produced by 
alcohol abuse and selenium deficiency. Oxidative stress causes genotoxicity when the 
antioxidant defense mechanism of the organism is malfunctioning. It is a major cause 
of endogenous mutation source through metabolic stress and implicated in many 
tumors as a cause of exogenous mutation source produced by chemical and physical 
carcinogens.  
Our first specific aim was to clarify the implication of Se-deficiency in the 
tumorigenesis of hepatocytes. A recent study performed in our group showed the 
selective survival advantage of some HCC cell lines under Se-deficiency while a 
couple of them go through apoptosis under oxidative stress induced by Se-deficiency. 
In order to understand the mechanism and the key regulators beneath this selective 
survival under oxidative stress, we selected two isogenic HCC cell lines one of which 
was reported to be resistant to oxidative stress whereas the other was sensitive to Se-
deficiency induced oxidative stress. In this experimental model, the only difference 
between the isogenic clones is the presence of HBV in the apoptosis tolerant HepG2-
2.2.15 cells. Using this isogenic model we tried to provide evidence for the selective 
survival capacity by performing a comparative study of the main stress activated and 
survival signaling pathways. 
Cancer cells may respond to genotoxic stress with a cryptic survival advantage 
development. Therefore we wanted to further investigate this idea with other dietary 
factors involved in liver carcinogenesis. Hence, in the second part of our study we 
tried to identify the mechanisms underlying the selective selection of AFB1 for p53-
249 mutation in HCC. Aflatoxins are the most potent naturally occurring carcinogens 
and may play a causative role in 5- 28% of liver cancers. Aflatoxins are activated in 
liver cells and induce G->T mutations, specifically codon 249 (G->T) hotspot 
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mutation of the TP53 gene associated with aflatoxin-related HCC. For this purpose 
we first performed a comparative study using HepG2 p53wt and p53 R249S 
transfected clones of this cell line in order to check the acquired survival advantage of 
R249S mutation. We showed that R249S does not provide survival advantage at 
heterozygous state. Thus, the selection could be at the mutation induction stage. The 
lack of p53 activation in AFB1 exposed HCC cells led us to test the following 
hypothesis: DNA damage response (DDR) to AFB1 may be deficient in hepatic cells 
allowing mutation accumulation.  Surprisingly, DNA damage checkpoint response to 
aflatoxins has not been studied previously. DNA damage checkpoint response acts as 
an anti-tumor mechanism by protecting genome integrity against genotoxic agents. 
However, this highly critical aspect of aflatoxin carcinogenicity is poorly known.  
Therefore, in the last part of our work, we have studied the DNA damage checkpoint 
response in human cells after exposure to AFB1, the most common and mutagenic 
form of aflatoxins. Hepatocyte-like HepG2 and HCT116 cells have been used as our 
working model for the convenience of p53 and p53 knock out studies. Treatment of 
those cells with mutation-inducing doses (3-5 µmol/L) of AFB1 induced DNA 
adducts, 8-hydroxyguanine lesions, as well as single and double strand DNA breaks 
that lasted several days. Persistent DNA damage in aflatoxin B1-treated cells, did not 
affect not only effect cell growth but also in wild-type p53 and p53-deficient HCT116 
cells exhibited an incomplete checkpoint response. AFB1-exposed failed to activate 
Chk1, Chk2 and p53. Consequently, AFB1-exposed cells did not show sustained p53-
dependent G1 arrest, or a p53-independent G2/M arrest. In conclusion, a fully 
functional DNA damage response was inapplicable to AFB1 exposed cells in contrast 
with the Adriamycin treated ones. Thus, genotoxic doses of AFB1 induce an 
incomplete and inefficient checkpoint response in human cells.   
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CHAPTER 3: MATERIALS and METHODS 
 
 
3.1 MATERIALS 
 
3.1.1 General Reagents  
  
All laboratory chemicals were analytical grade from either Sigma (St. Louis, MO, 
U.S.A), Carlo Erba (Milano, Italy), Merck (Schucdarf, Germany), VWR company, 
(International S.A.S.. Le Périgares, France). 
 
3.1.2 Enzymes 
 
Restriction endonucleases used for restriction digestion confirmation experiments 
were purchased from either MBI Fermentas GmbH (Germany) or from Gibco 
Invitrogen SARL –France. 
 
3.1.3 Nucleic Acids 
  
DNA molecular weight standard and ultrapure deoxyribonucleotides were from MBI 
Fermentas GmbH (Germany).  
PCMV-p53 R249S vector is gift from Bert Vogelstein. 
 
3.1.4 Oligonucleotides 
  
p53-primers for mutation confirmation polymerase chain reactions (PCR) were 
synthesized by either İONTEK (Istanbul, Turkey) or Eurofins MWG Operon 
(Roissy CDG, France).  
 
3.1.5 Electrophoresis, photography and spectrophotometer 
 
Electrophoresis grade agarose was obtained from Sigma Biosciences Chemical 
Company Ltd. (St. Louis, MO, USA) and from Agarose D5 DNA grade from 
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Euromedex (Souffelweyersheim-France). Horizontal electrophoresis apparatuses were 
from Stratagene (Heidelberg, Germany) and Bio Rad Laboratories (CA, USA). The 
power supply Power-PAC300 and Power-PAC200 was from Bio Rad Laboratories 
(CA, USA). GeneFlash SYNGENE Bioimaging is used to visualize DNA. The 
Molecular Analyst software used in agarose gel profile visualizing was from BioRad 
Laboratories (CA, USA). The spectrophotometer was from Beckman Coulter (CA, 
USA).  
 
3.1.6 Tissue Culture Reagents  
  
Dulbecco's Modified Eagle's Medium (DMEM), HAM’s medium (with 10 µM  
Copper and 3mM Zinc), McCoy’s medium, nonessential amino acids, 
penicillin/streptomycin, trypsin /EDTA, calcium, magnesium-free phosphate buffered 
saline (PBS), HBBS Hanks balanced salt solution and transfection reagent 
Lipofectamine were purchased from Gibco Invitrogen company (Invitrogen SARL –
France) and fetal bovine serum (FBS) was purchased from PAA, France. Tissue 
culture petri dishes, flasks, 15 and 50 ml polycarbonate centrifuge tubes with lids, 6-
well, 24-well plates and cryotubes were from Costar Corp. VWR company 
International S.A.S.. Le Périgares, France). 
 
Geneticin-G418 sulfate was purchased GIBCO Invitrogen company (Invitrogen 
SARL –France). AFB1 (aflatoxin B1), ADR (adriamycin), Hydroxyurea (HU), 
sodium selenite, isocitric acid and β -Nicotinamide adenine dinucleotide phosphate 
sodium salt hydrate (NADP) were purchased from Sigma (St. Louis, MO, USA).. 
Sprague-Dawley rat liver and Wortmannin were purchased from Xenotech (Kansas, 
USA) and Calbiochem (NJ, USA) respectively.  
 
3.1.7 Western immunoblotting, antibodies and chemiluminescence  
 
10% or 4-12% Bis-Tris NuPAGE Novex Mini gel systems and 7% or 3-8% Tris-
Acetate NuPAGE Novex Mini gel systems were purchased from Invitrogen, SARL –
France. The antibodies used in immunoblotting, immunoperoxidase and 
immunoflorescence experiments were obtained from different sources, and are given 
in Table 3.3.2. Enhanced ChemiLuminescence (ECL) plus detection kit was from 
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Amersham-Pharmacia, Buckinghamshire, England. Nitrocellulose membrane was 
from Roche, Mannheim, Germany and Immobilon-P PVDF membrane were from 
Millipore, USA. Negative X-ray film was from Blue Devil, France.  
 
3.2 SOLUTIONS AND MEDIA 
 
 
3.2.1 General Solutions 
 
 
50X Tris-acetic acid-EDTA (TAE):  2 M Tris-acetate, 50 mM EDTA pH 8.5 
Diluted to 1X for working solution      
purchased from Euromedex. 
 
Ethidium bromide:    Uptime Interchim company 
10 mg/ml in water (stock solution), 
       30 ng/ml (working solution) 
 
4X Gel loading buffer: Purchased from Invitrogen (SARL–
France).   
 
 
Bradford Stock Solution Purchased ready-use solution from Sigma 
company with catalog number B6916 
 
 
3.2.2 Tissue culture solutions 
 
Standard working medium 10% FBS, 1% penicillin/streptomycin, 
1% Non-Essential Amino Acid were 
added and stored at 4oC.  
 
McCoy’s working medium 10% FBS, 1% penicillin/streptomycin, 
were added and stored at 4oC.  
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Selenium adequate medium Standard medium with 0.01% FBS and 
0.1 µM Na2SeO3.  
 
Selenium deficient medium Standard medium with 0.01% FBS.  
 
10X Phosphate-buffered saline (PBS) Purchased from Invitrogen Company 
Invitrogen SARL –France 
 
Freeze medium  70% DMEM control medium, 20%  
FBS, and 10% DMSO in 1 ml per  
cell line.  
 
Wortmannin 500mM stock solution in DMSO was 
prepared, aliquots were stored at -20°C. 
Working solutions of 500nM were used. 
 
 
Aflatoxin B1 20mM stock solution in DMSO was 
prepared aliquots were stored at -20°C. 
Working solutions were prepared and 
used freshly. 
 
Adriamycin (ADR) 6.66mg/ml stock solution in sterile 
double-distilled water. Working solutions 
were prepared and used freshly. 
 
S9-activation solution 0.20 g/L S9 fraction, 10.5 mM isocitric 
acid in ddH2O, 1.8 mM β-Nicotinamide 
adenine dinucleotide phosphate sodium 
salt hydrate (NADP) in H2O. It was 
filtered and used at 1:10 dilution in the 
cell culture medium. 
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Geneticin-(G418 Sulfate) 500 mg/ml solution in double-distilled 
water. Sterilized by filtration and stored 
at -20°C (stock solution). 1500 µg/ml 
(working solution for stable cell line 
selection), and 750 µg/ml (working 
solution for maintenance of stable cell 
lines) were used. 
 
 
3.2.3 Immunoblotting solutions 
 
 
10X Tris-buffer saline (TBS) Per liter: 100 mM Tris-base, 1.5 M NaCl, 
pH 7.6 in double distilled water.  
 
TBS-Tween (TBS-T) 0.1-0.5% Tween-20 solution in TBS. 
(Prepared freshly) 
 
Blocking solution 5% (w/v) non-fat milk or BSA, 0.1% 
Tween-20 in TBS.  
 
3.2.4 RNA Study Solutions 
 
DEPC-treated water 0.1% Diethylpyrocarbonate (DEPC) (v/v) 
in double-distilled water was autoclaved 
and stored at room temperature.    
 
 
3.2.5    Immunofluorescence and Immunoperoxidase solutions 
 
H33258 fluorochrome dye 1 mg/ml solution in double-distilled water 
and stored at -20 °C. Working solution 
was 1 µg/ml. 
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DAPI (4', 6-diamidino-2-phenylindole)        0.1-1 µg/ml (working solution in PBS). 
 
4% paraformaldehyde 4 g paraformaldehyde, 5 mM NaOH in 
100 ml. PBS, pH 7.4. Stable at 4°C for a 
week. 
 
PBS-TritonX-100 (PBS-T) 0.1 TritonX-100 in PBS. 
 
Permeabilization Solution 0.5% Saponine (w/v) and 0.3% Triton-X-
100 in PBS 
 
Blocking Solution 10% FBS, 0.3% Triton-X-100 in PBS 
 
Antibody Dilution and Wash Solution 2%FBS, 0.3% Triton-X-100 in PBS 
  
3.2.6 Single cell gel electrophoresis (COMET ASSAY) solutions 
 
Membrane Lysis Solution (pH 10.0) 2.5 M NaCl, 0.1M Na2EDTA, 0.01M 
Tris, 0.25M NaOH and 0.77% Na-
Laurosylsarcosinate were dissolved  and 
working solution was prepared by adding 
1:10 DMSO and 1% Triton-X 
 
Alkalin Electrophoresis Solution (pH 12.8) 0.555 gr Na2EDTA, 10 gr NaOH were 
dissolved in 1500 ml  double distilled 
H2O.  
Neutral Electrophoresis Solution (5X) 54g Tris Base, 27.5g Boric Acid, 20 mL 
of 0.5 M EDTA (pH 8.0) in1 liter double 
distilled H2O.  
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Neutralization Buffer (pH 7.5) 48.44g Trisma Base in 1 liter double 
distilled H2O.  
 
 
 
3.3 METHODS 
 
3.3.1 Tissue culture techniques 
 
3.3.1.1 Cell Lines and stable clones 
 
Huh7, Hep3B, PLC/PRF/5, HepG2, HepG2-2.2.15 HCC cell lines and HCT116, 
HCT116 p53KO colon cancer cell lines used in this study, were cultured as described 
previously [256, 257].  
 
3.3.1.2 Thawing cell lines 
 
Frozen cell line vial taken from the liquid nitrogen tank was instantly put onto ice. 
The vial was placed into 37oC water bath until the external part of the cell solution 
was thawed. The cells were resuspended gently with 10 ml of standard medium 
and centrifuged at 1500 rpm at 4oC for 5 minutes. Supernatant was discarded and 
the pellet was resuspended in 10 ml 37oC culture medium and plated into T25 or 
T75 flask depending on the amount of cell pellet.  
 
3.3.1.3  Transient transfection and stable clone formation 
 
Transfection was performed with Lipofectamine 2000 reagent with the 
manufacturer’s protocols. p53-R249S PCMV and empty vector transfected HepG2 
cells were selected for 15 days with 1500 µg/ml Geneticin until the non-transfected 
control cells were all dead. Selected colonies were trypsinized and passaged into 24-
well plates and tested for p53-R249S expression after they reach to a certain number 
of cells.  
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3.3.1.4 Cell Culture treatments 
 
3.3.1.4.1 Treatment of cell lines with Se-adequate vs. Se-deficient medium and 
Wortmanninn 
 
HepG2 and HepG2-2.2.15 cell lines were cultured in either Se-adequate standard 
medium supplemented with 0.01% FBS and 0.1 µM Na2SeO3 for 24h, 48h or 72h or 
Se-deficient medium. Cells were treated with 500nM Wortmanninn or its vehicle 
control DMSO (<10-3 v/v dilution) in Se-adequate/Se-deficient medium. 
 
3.3.1.4.2 Treatment of cell lines with TGF-beta and Adriamycin  
 
Purified recombinant human TGF-β1 (R&D Systems, Minneapolis, USA) was 
reconstituted in sterile 4 mM HCl containing 1 mg/ml bovine serum albumin (BSA, 
Sigma, St. Louis, MO, USA) and cells were treated with 5ng/ml TGF-β1 for 72h. 
Adriamycin treatments were done in standard medium with a changing dose of 0.1-
1µM. 
 
3.3.1.4.3 Treatment of cell lines with Aflatoxin B1 
 
Aflatoxin B1 treatment was performed in the presence of S9-activation system for all 
HCT116, HCT116-p53-/- and some HepG2 experiments for enzymatic activation into 
AFB1-8,9-exo-epoxide form. S9 activation system was prepared as described 
previously [258, 259].   
 
3.3.1.5 Cryopreservation of cell lines 
 
Exponentially growing cells with 60-70% confluency were trypsinized and collected 
with growth medium. The cells were centrifuged at 1500 rpm for 5 min. The 
precipitated cell pellet was resuspended in a freezing solution (10% DMSO, 20% FCS 
and 70% DMEM at a concentration of 3-4x106cells/ml.  1 ml of this solution was 
placed into 1 ml screw capped-cryotubes.  The tubes were left at -80°C overnight in a 
isoproponal containing shuttle container. The next day, the tubes were transferred into 
the liquid nitrogen storage tank. 
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3.3.1.6 Colony-forming ability assay 
 
Cell survival was determined by assessing cell growth in 100 mm dishes after 
exposure to AFB1 (0-50µM) in the presence of S9-activation system for 4 hours and 
24 hours. Control cells were exposed to ADR (0-5µM) in parallel. Following 
exposure, 104 cells were seeded into 100 mm dishes and cultured for 10 days. After 
fixation of colonies in cold methanol, they were stained with Crystal Violet (Sigma), 
and counted in triplicates. Cell survival was calculated as the % ratio of cell numbers 
in treated versus untreated cells. Survival parameters were determined by plotting in 
excel data sheets. 
 
3.3.2 Analysis of nucleic acids 
 
3.3.2.1  Purification of plasmid DNA using Qiagen miniprep kit 
 
This method was employed for the isolation of p53 plasmids in order to use in 
transfection protocol. 5 ml of saturated culture medium was used for the isolation of 
plasmid DNA by using “QI Prep spin miniprep plasmid DNA purification kit” 
(Qiagen- Courtaboeuf, France) according to the manufacture’s instructions. 
 
3.3.2.2  Quantification and qualification of nucleic acids 
 
RNA, Plasmid and genomic DNA concentrations and purity were determined using 
the Nanodrop from Thermoscientific Company. 
 
 
3.3.2.3  Extraction of total RNA from tissue culture cells and tissue 
samples 
 
Total RNAs were isolated from cultured cells using the NucleoSpin RNA II Kit (MN 
Macherey-Nagel, Duren, Germany) according to the manufacturer’s instructions. 
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3.3.2.4 First strand cDNA synthesis 
 
First strand cDNA synthesis from total RNA was performed using RevertAid First 
Strand cDNA synthesis kit (MBI Fermantas, Germany). The first strand reactions 
were performed according to the instructions for priming with oligo(dT) primer and 
RT- controls were also synthesized to make sure that there is no DNA contamination. 
1.5 to 3 µg total RNA was used to synthesize the first stand cDNA.  
 
3.3.2.5 Primer design for expression analysis by semi-quantitative PCR 
 
The primer pairs that have been used for the selection of p53-R249S expressing 
colonies were designed carefully. Forward and reverse primer were positioned 
between exon4, exon6 and exon8 of the TP53 respectively, so that the primer pair 
was including the R249S codon and not able to amplify from the covered genomic 
DNA region during PCR. Primers used for the selection have been designed 
strictly considering these criteria, and listed in Table 3.3.1. 
 
Table 3.3.1 Primer Sequences used in this study Target Gene  Primer Sequence TP53  F 5’ AAA ACC TAC CAG GGC A 3’  R 5’ CTC GTG GTG AGG CTC  3’ TP53  F 5’ TAT TTG GAT GAC AGA 3’ R 5’ CTC GTG GTG AGG CTC  3’ GAPDH  F 5’ GGC TGA GAA CGG GAA GCT TGT CAT 3’ R 5’ CAG CCT TCT CCA TGG TGG TGA AGA 3’ 
 
 
3.3.2.6 Selection of R249S expressing clones with PCR followed by restriction 
enzyme digestion. 
 
10x Invitrogen PCR supermix was used to perform PCR according to manufacturer’s 
instructions.  
 
Restriction enzyme digestions were routinely performed in 20 µl total reaction 
volumes with 2-5 µg PCR product. Reactions were carried out with the appropriate 
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reaction buffers for BsuRI and HinfI enzymes separately under conditions according 
to the manufacturer’s recommendations. 
   
3.3.2.7  Gel electrophoresis of nucleic acids 
 
DNA fragments were fractionated by horizontal electrophoresis by using standard 
buffers and solutions. DNA fragments less than 1 kb were generally separated on 
1.0% or 2 % agarose gel prepared with 1X TAE buffer and 30 µg/ml ethidium 
bromide and the gel was run in 1XTAE at various time and voltage depending on the 
size of fragments. 
 
3.3.3 Computer analyses 
 
Primers were designed by using web software provided by Steve Rozen and 
Whitehead Institute for Biomedical Research at http://frodo.wi.mit.edu/cgi-
bin/primer3/primer3_www.cgi. Alignments of nucleic acids or protein sequence were 
performed by using web page; http://www.ncbi.nlm.nih.gov/BLAST/.  
Analyis of COMET assay results were performed by CASP (Comet Assay Software 
Project) which measures tail moment, using DNA content in the tail and head along 
with the distance between the means of the head and tail distributions 
(http://casplab.com). 
 
3.3.4 Quantification of Proteins using Bradford Assay 
  
The conventional Bradford protein assay was employed to quantify protein 
concentration in the total cell lysates. After protein quantification, protein lysate 
aliquots were stored at –80°C.  
 
3.3.5 Western blotting  
 
RIPA extracted proteins were subjected to electrophoresis using 10% or 4-12% Bis-
Tris NuPAGE Novex or 3-8% Tris-Acetate Nupage mini gel systems (Invitrogen), 
according to the manufacturer’s instructions. For the detection of phosphorylated 
proteins, cell lysates were prepared according to the protocol provided by the supplier 
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using the following lysis buffer: 20mmol/L Tris (pH 7.5), 150 mmol/L NaCl, 1 
mmol/L EDTA, 1 mmol/L EGTA, 1% Triton X-100, 1 mmol/L Na3VO4, 1ug/ml 
leupeptin, 1 mmol/L phenylmethylsulfonyl fluoride.  Following electrophoresis, 
proteins were transferred on to Immobilon-P PVDF membrane (Millipore, USA), and 
analyzed, using antibodies against target proteins listed in Table 3.3.2.  
 
3.3.6 Senescence-associated beta-galactosidase (SABG) assay 
 
SABG activity was detected as described previously [260], using senescent cell 
staining kit (Sigma). 
 
3.3.7 Immunoperoxidase Staining  
 
Cells were fixed with 4% formaldehyde, and permeabilized with permeabilization 
solution. After blocking for one hour, cells were incubated overnight at 4°C with 
primary antibodies and washed three times with washing solution. the signals were 
detected by the Dako EnVision + Dual method, according to the manufacturer's 
instructions. The specimens were counterstained with hematoxylin.  
 
 
3.3.8 Immunoperoxidase detection of AFB1-DNA adducts and 8-OHdG 
 
AFB1-DNA adducts and 8-OHdG lesions were detected by immunoperoxidase 
assays, as described previously [224], with minor changes. Briefly, cells were treated 
with AFB1 or DMSO on coverslips, washed with PBS, and then fixed in ice-cold 
methanol. AFB1-DNA adducts were detected using a monoclonal antibody 6A10 
(Santa Cruz, Trevigen, France) against imidazol ring-opened persistent form of the 
major N7-guanine adduct of AFB1 [261].  Prior to immunoperoxidase assay of AFB1 
adducts, cells were treated with a buffer containing 15mmol/L Na2CO3 and 30 
mmol/L NaHCO3 (pH 9.6) for 2 hours at room temperature. For both AFB1 adducts 
and 8-OHdG lesions, cells were treated with RNAse from MBI Fermantas, Germany, 
(100 µg/mL) in Tris Buffer (10 mmol/L Trizma Base, 1 mmol/L EDTA, and 0.4 
mol/L NaCl; pH 7.5) for 1 h at 37 °C. After washing with PBS, proteinase K from 
Sigma (10 µg/mL) treatment was done for 7 min at room temperature. After rinsing 
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with PBS, DNA was denatured with 2N HCl for 10 min and cells were neutralized by 
soaking coverslips in 50mM Tris Base for 5 min. After blocking for 1 hour, cells were 
incubated with mouse 6A10 or mouse anti-8-OHdG (Trevigen, MD, USA) 
monoclonal antibody overnight at 4°C. Anti-mouse HRP-conjugated secondary 
antibodies (Invitrogen) were used for 30 min for primary antibody detection. Cells 
were stained with DAB (diaminobenzidine) solution (Dako, Denmark), 
counterstained with hematoxlin (Sigma), mounted with 80% glycerol, and observed 
under Olympus light microscope.  
 
3.3.9 Indirect immunofluorescence  
 
Cells were fixed with 4% formaldehyde, and permeabilized with permeabilization 
solution. After blocking for one hour, cells were incubated overnight at 4°C, with 
primary antibodies and washed three times with washing solution. Secondary 
antibodies conjugated to Alexa 568 or Alexa 488 (Invitrogen, USA) incubation was 
performed for 1h at room temperature. After washing the unbound antibodies slides 
were counterstained with DAPI (Roche, IN, USA), and observed using Apotome 
(Zeiss) microscope. Images were captured with a Axiocam HRc color CCD camera 
(Zeiss) and digitally saved using Axio Imager software (Zeiss).  
 
3.3.10 Costaining with immunoflorescence 
 
Cells were fixed with 4% formaldehyde, and after permeabilization, blocking was 
performed for one hour. Cells were incubated 2h with the primary antibodies 
simultaneously, and then washed three times with washing solution. Secondary 
antibodies conjugated to Alexa 568 or Alexa 488 (Invitrogen, USA) incubation was 
performed for 1h at room temperature. After washing the unbound antibodies slides 
were counterstained with DAPI and observed using Apotome (Zeiss) microscope. 
Images were captured with a Axiocam HRc color CCD camera (Zeiss) and digitally 
saved using Axio Imager software (Zeiss).  
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3.3.11 Cell cycle analysis and bromodeoxyuridine (BrdU) incorporation assay 
 
Cells were washed twice in PBS and fixed in ice-cold ethanol for 10 min. After two 
PBS washes, cells were incubated with 20ug/mL of RNase A (MBI Fermentas, USA) 
at 37°C for 10 minutes and stained with propidium iodide (10 ug/mL in PBS; Sigma). 
Cell cycle distribution was determined by flow cytometry using FacScan and the 
CellQuest software (Becton Dickinson, NJ, USA). Cell cycle analysis combined with 
BrdU incorporation assay was done as described, except that cells were first labeled 
with 10 µmol/L BrdU (Sigma) for 2 hours prior to each testing time, and cells 
subjected to anti-BrdU staining after DNA denaturation with 4N HCl for 30 minutes 
using FITC-conjugated anti-BrdU antibody (BD Bioscience, NJ, USA) at room 
temperature for 30 minutes in the dark.  
 
3.3.12 Single-cell gel electrophoresis (comet) assay  
 
Single strand and double strand DNA breaks were detected using alkaline and neutral 
comet assays, respectively [262, 263]. Alkaline comet was performed as described 
[263]. Neutral comet assay was done as described [262], using the lysis protocol 
described in [264]. Following electrophoresis, slides were rinsed, stained with 5µg/ml 
DAPI and analyzed under Apotome (Zeiss) microscope. Images were captured with a 
Axiocam HRc color CCD camera (Zeiss) and digitally saved using Axio Vision 
software (Zeiss). Data was analyzed by CASP (Comet Assay Software Project) which 
measures tail moment, using DNA content in the tail and head along with the distance 
between the means of the head and tail distributions (http://casplab.com). At least 30 
nuclei were analyzed for each experimental condition.  
 
 
Table 3.3.2 Antibodies used for immunoblotting, immunoflorescence and 
immunoperoxidase assays. Sec: Secondary antibody; lab; Laboratories. 
 
Antibody Source 
53BP1 Abcam 
8-OHdG Trevigen 
Actin  Sigma 
AFB1-DNA Santa Cruz 
Alexa anti mouse in goat 488 sec.  Invitrogen 
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Alexa anti mouse in goat 568 sec.  Invitrogen 
Alexa anti rabbit in goat 488 sec.  Invitrogen 
Alexa anti rabbit in goat 568 sec.  Invitrogen 
ATM  Oncogene Research 
ATR Oncogene Research 
Calnexin (Rabbit PAb) Sigma 
Chk1 Santa Cruz 
Chk2 Santa Cruz 
ERK1/2 cell signaling  
H3 K27 Me1 Upstate 
H3 K27 Me3 Upstate 
H3 K36 Me3   Abcam 
H3 K9 Me3 Upstate 
H3K27Me2 Abcam 
H3K36Me1 Abcam 
H3K36Me2 Upstate 
H3K4Me3 Abcam   
H3R17Me2 Abcam  
H3R2Me2 Upstate 
H4K20Me1 Abcam 
H4K20Me2 Abcam 
H4K20Me3 Upstate 
H4R3Me2 Upstate 
MDM2 Santa Cruz 
Mouse in goat sec.   Invitrogen 
NFκB Santa Cruz 
p15 Santa Cruz 
p16 Santa Cruz 
p21Cip1 CalbioChem 
p27 Santa Cruz 
P38MAPK  Cell Signaling 
P53-ser15  cell signaling  
phopho-AKT thr308 cell signaling  
Phospho-AKT S473 Cell Signaling 
phospho-ATMser1981 Cell Signaling 
phospho-ATR Ser 428 Cell Signalling 
Phospho-cdc25A S124 Abcam 
phospho-chk1 ser345 Cell Signaling 
phospho-Chk2 thr49 Cell Signaling 
Phospho-ERK1/2 T202/Y204 cell signaling  
Phospho-IKB  Santa Cruz 
Phospho-p38MAPK T180/Y182 Cell Signaling 
 Phospho-p53 S15 Cell Signaling 
 Phospho-p53 S20 Cell Signaling 
Phospho-SAPK/JNK T183/Y185 cell signaling 
Phospho-Stat1 S727 cell signaling 
Rabbit in goat sec.  DAKO 
SAPK/JNK cell signaling 
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Stat1  Transduction Lab. 
Total AKT cell signaling 
Total p53 Santa Cruz 
Tubulin CalbioChem 
γ-H2AX Milipore 
Wee1 UpState 
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CHAPTER 4. RESULTS 
 
Reactive oxygen species can be produced from mitochondria, peroxisomes, and 
inflammatory cell activation [265] endogenously; and exogenously from 
environmental agents, pharmaceuticals, and industrial chemicals. When ROS are not 
eliminated by antioxidant defense mechanisms, oxidative stress accumulated in the 
cell may cause DNA, protein, and/or lipid damage, leading to chromosome instability, 
genetic mutation, and/or modulation of cell growth that may result in cancer.  
In this study, we explored the role of genotoxic stress in the pathogenesis of HCC. In 
accordance with this objective, we classified the major genotoxic stress causing 
factors as follows:  
1. Selenium deficiency induced oxidative stress 
2. Environmental agents: Aflatoxins 
3. Therapeutic agents: Adriamycin 
First part of the study is mainly focused on understanding the selective tolerance of 
hepatocellular cell lines to Se-deficiency induced oxidative stress. In the second and 
third parts of our study, we tried to explore the effects of aflatoxins, the major 
environmental toxin that is only associated with liver cancer; with a comparative 
study employing the commonly used chemotherapeutic drug; Adriamycin as a 
positive control.  
 
4.1 Tolerance to selenium-deficient conditions 
 
The exact molecular mechanism of the relation between Se-deficiency with hepatic 
disease conditions including HCC is poorly understood. Previously our group 
reported that, in vitro Se-deficiency in a subset of HCC cell lines caused oxidative 
stress along with apoptosis. However, most of HCC cell lines tolerated Se-deficient 
conditions. There was no oxidative stress and cells escaped apoptotic response [197].  
 
In order to understand the mechanism of this selective survival advantage which is 
prominent under Se-deficient and oxidative stress conditions, we selected a human 
hepatoblastoma-derived cell line HepG2 and its isogenic HBV (hepatitis B virus) 
transfected form HepG2-2.2.15 which are sensitive and resistant to the selenium 
deficient conditions respectively [197]. 
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4.1.1 Analysis of survival pathways 
 
Several studies reported Se as a suppressor of the JNK, SAPK and p38MAPK 
pathways after oxidative stress [202, 203]. Therefore, these findings encouraged us to 
explore the key elements of possible stress activated and survival pathways triggered 
upon oxidative stress.  
 
We checked the key downstream elements of 3 major pathways; the MAPK/Erk 
pathway, which is important for cell growth and differentiation, the SAPK/JNK 
pathway, and the p38MAPK pathway, which are both, activated through various types 
of environmental stresses.  We observed cytoplasmic positivity in total ERK1/2 with 
no change in HepG2 clones under Se-deficient conditions at 48h while the 
phosphorylated ERK1/2 was very weakly increased in HepG2-2.2.15 cells in Se-
deficient conditions by immunoperoxidase staining (Figure 4.1.1 A). Phosphorylated 
ERK1/2 levels were high in HepG2-2.2.15 cells when compared to the HepG2 cells, 
but surprisingly the levels were diminished in a time manner under Se-deficient 
conditions (Figure 4.1.1 B).  
 
 
The immunoperoxidase staining pattern with SAPK/JNK demonstrated a weak 
increase in total levels in HepG2-2.2.15 under Se-deficient conditions at 48h (Figure 
4.1.2 A), which was also confirmed by immunoblotting (Figure 4.1.2 B). The total 
SAPK levels were diminished in HepG2 cells as opposed to the time dependent 
increase in HepG2-2.2.15 under Se-deficiency (Figure 4.1.2 B). We obtained a very 
weak signal under the same conditions with p-SAPK/JNK antibody in both cells 
without any intensity change by immunostaining (Figure 4.1.2 A).  
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FIGURE 4.1.1 Analysis of MAPK/ERK signaling pathway under selenium-deficiency. (A) HepG2 
and HepG2-2.2.15 cells were grown in selenium adequate (Se+) or selenium-deficient (Se−) conditions 
for 48 hours and subjected to indirect immunoperoxidase staining with anti-ERK1/2 and anti-phospho 
ERK1/2. Counterstaining was done with hematoxylene. (B) HepG2 and HepG2-2.2.15 cells were 
grown in selenium adequate (Se+) or selenium-deficient (Se−) conditions and cells were collected at 24 
hours, 48 hours and 72 hours. Immunoblotting was performed with anti-phospho ERK1/2. Cells grown 
in (Se+) for 24 hours were used as control. Calnexin was used as equal loading control.  
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FIGURE 4.1.2 Analysis of SAPK/JNK signaling pathway under selenium-deficiency. (A) HepG2 and 
HepG2-2.2.15 cells were grown in selenium adequate (Se+) or selenium-deficient (Se−) conditions for 
48 hours and subjected to indirect immunoperoxidase staining with antibody against SAPK/JNK and 
phospho- SAPK/JNK. Counterstaining was performed with hematoxylene. (B) HepG2 and HepG2-
2.2.15 cells were grown in selenium adequate (Se+) or selenium-deficient (Se−) conditions and cells 
were collected at 24 hours, 48 hours and 72 hours. Immunoblotting was done with antibody against 
SAPK/JNK. Cells grown in (Se+) for 24 hours were used as control. Calnexin was used as equal 
loading control.  
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Phosphorylated p38MAPK levels were increased in HepG2 cells when compared to 
the HepG2-2.2.15 cells while the total p38MAPK levels remained the same under Se-
deficient conditions. This observation was consistent with the apoptosis in those cells 
at 48h (Figure 4.1.3). In order to demonstrate the differences observed in the 
downstream of the p38MAPK signaling pathway, we looked for the activation of a 
previously reported target of p38MAPK, Stat1 [266]; which has an essential role in 
oxidative stress induced apoptosis. Nevertheless, our results failed to detect an 
activation of Stat1 in HepG2 cells under oxidative stress (Figure 4.1.4 A and B).  
 
 
FIGURE 4.1.3 Analysis of p38MAPK stress signaling pathway under selenium-deficiency. HepG2 
and HepG2-2.2.15 cells were grown in selenium adequate (Se+) or selenium-deficient (Se−) conditions 
for 48 hours and subjected to indirect immunoperoxidase staining with antibody against p38MAPK and 
phospho-p38MAPK. Counterstaining was performed with hematoxylene.  
 
 
  53 
 
FIGURE 4.1.4 Analysis of p38MAPK stress signaling pathway downstream apoptosis targets. (A) 
HepG2 and HepG2-2.2.15 cells were grown in selenium adequate (Se+) or selenium-deficient (Se−) 
conditions for 48 hours and subjected to indirect immunoperoxidase staining with antibody against 
Stat1 and phospho-Stat1. Counterstaining was performed with hematoxylene. (B) HepG2 and HepG2-
2.2.15 cells grown in selenium adequate (Se+) or selenium-deficient (Se−) conditions for 48 hours and 
subjected to western blotting with antibody against Stat1. Calnexin was used as equal loading control.  
 
 
4.1.2 AKT, as a key for survival under selenium deficient conditions 
 
The PI3K/AKT signal transduction pathway is a crucial regulator of cell proliferation 
and survival. Activation of Akt1 was reported in HBV-induced HCC [267] and 
viruses favor the inhibition of apoptosis through the induction of the PI3K/AKT 
pathway [268]. In our experimental model the only difference that may contribute to 
the survival advantage under Se-deficiency could be the presence of HBV, therefore 
we hypothesized AKT could play a role in the process of acquired selective survival 
mechanism.  
 
In order to test this hypothesis, we incubated HepG2 and HepG2-2.2.15 cells in 
selenium deficient medium and assessed the AKT activation status by immunostainig 
and immunoblotting by antibodies against total AKT and phospho-AKT thr308 and 
phospho-AKT ser473. Both critical residues of AKT required for its full activation 
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were detected to be phosphorylated in HepG2-2.2.15 cells under Se-deficient 
conditions (Figure 4.1.4 A), and this data was confirmed by immunoblotting of the 
samples that were taken at 24, 48 and 72h after incubation with Se-deficient medium 
with a time-dependent manner (Figure 4.1.4 B). Yet we did not observe any variations 
in total AKT levels indicating its activation was through phosphorylations.   
 
 
 
FIGURE 4.1.5 Phosphorylation of Akt is increased under selenium deficient conditions. (A) HepG2 
and HepG2-2.2.15 cells were grown in selenium adequate (Se+) or selenium-deficient (Se−) conditions 
for 48 hours and subjected to indirect immunoperoxidase staining with antibody against AKT, 
phospho-AKT thr308 and phospho-AKT ser473. Counterstaining was performed with hematoxylene. 
(B) HepG2 and HepG2-2.2.15 cells were grown in selenium adequate (Se+) or selenium-deficient 
(Se−) conditions and cells were collected at 24 hours, 48 hours and 72 hours and subjected to western 
blotting with antibodies against AKT, phospho-AKT thr308 and phospho-AKT. Cells grown in (Se+) 
for 24 hours were used as control. Actin was used as equal loading control.  
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To identify the mechanism of PI3K/AKT mediated cell survival, we checked for one 
of the functional targets of AKT; NF-κB [269]. Both clones treated under Se- 
deficient conditions for 48h were subjected to immunostaining and immunoblotting. 
We detected a stronger staining pattern (Figure 4.1.6 A) against NF-κB in the 
apoptosis resistant clone, yet our antibody failed to determine this change in 
immunoblotting (Figure 4.1.6 B) for both p105 and p50 NF-κB’s proteolytic cleavage 
products. Phosphorylated IKB, which is required for the release of NF-κB, thereby 
accumulating NF-κB in the nucleus, were remained to be unchanged (Figure 4.1.6 A). 
 
 
 FIGURE 4.1.6 Analysis of downstream signals in AKT induced survival under selenium deficient 
conditions. (A) HepG2 and HepG2-2.2.15 cells were grown in selenium adequate (Se+) or selenium-
deficient (Se−) conditions for 48 hours and subjected to indirect immunoperoxidase staining with 
antibody against NFκB, phospho-IKB. Counterstaining was performed with hematoxylene. (B) HepG2 
and HepG2-2.2.15 cells grown in selenium adequate (Se+) or selenium-deficient (Se−) conditions for 
48 hours and subjected to western blotting with antibody against NFκB. Calnexin was used as equal 
loading control.  
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4.1.3 Inhibition of AKT reverts HepG2-2.2.15 phenotype under Se-deficient 
conditions.  
 
Our observation of AKT activation through phosphorylation, despite its higher levels 
in Se-72h samples, was not only due to Se-supplementation, since both phospho-AKT 
residues were detectable in control HepG2-2.2.15 samples under Se-adequate 
conditions. This phenomenon, which was reported previously as a consequence of 
HBV [267], prompted us to further investigate the activation of AKT in the acquired 
tolerance to the Se-deficient conditions. To rule out the possibility of the requirement 
of AKT for inhibition of apoptosis, we treated HepG2 and HepG2-2.2.15 cells with 
Wortmannin, which is a specific and commonly used inhibitor of PI3Ks, at the same 
time with Se-supplementation. Cells incubated with Se-deficient or Se-adequate 
medium along with 500nM Wortmannin or its vehicle control DMSO for 48 and 72h, 
were subjected to immunoblotting to detect the protein levels of phospho-AKT 
(Figure 4.1.7). We were able to inhibit the ser473 residue phosphorylation of AKT 
after Wortmannin treatment. Subsequently, we checked for the caspase 3 dependent 
apoptosis with a specific antibody that recognizes both caspase-3 and its cleaved 
form. Upon the inhibition of phosphorylation in HepG2-2.2.15 under both Se- and 
Se+ conditions, cleaved caspase-3 levels were increased (Figure 4.1.7). This data 
indicated that the inhibition of the PI3K/AKT pathway regardless of Se-
supplementation recapitulate apoptosis in HepG2-2.2.15 cells.  
 
4.1.4 Inhibition of constitutively active AKT did not recapitulate apoptosis in 
Mahlavu and Snu475. 
 
Our previous results indicated that tolerance to selenium deficiency was not only due 
to the presence of HBV integration but also chronic aflatoxin exposure. In fact, after 
screening the HCC cell lines with different etiologies, it is concluded that the 
tolerance to the oxidative stress conditions under selenium deficiency stem from 
genotoxic stress induced either with HBV infection and/or chronic aflatoxin exposure 
[197]. Therefore, we wanted to test two different HCC cell lines; Mahlavu (chronic 
aflatoxin exposure with p53 R249S mutation) and Snu475 (HBV infection) both of 
which lack PTEN protein expression and have constitutively active PI3K/AKT 
pathway. We treated Mahlavu and Snu475 with Wortmannin as employed before 
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along with selenium supplemented or deficient medium for 48 and 72h, and the cell 
lysates were subjected to immunoblotting to detect the protein levels of phospho-Akt 
(Figure 4.1.8). We were only able to inhibit the ser473 residue phosphorylation of Akt 
partially after Wortmannin treatment. Accordingly, we checked the caspase 3 
dependent apoptosis with a specific antibody that recognizes both caspase-3 and its 
cleaved form. Upon the partial inhibition of phosphorylation in Mahlavu (Figure 4.1.8 
A) and Snu475 (Figure 4.1.8 B) under both Se- and Se+ conditions, cleaved caspase-3 
levels were not detected. This data may suggest that the inhibition of the PI3K/AKT 
pathway with Wortmannin was not enough to recapitulate apoptosis regardless of Se-
supplementation rescue apoptosis in HepG2-2.2.15 cells.  
 
 
 
FIGURE 4.1.7 Inhibition of PI3K/Akt pathway induced apoptosis. HepG2 and HepG2-2.2.15 cells 
were grown in selenium adequate (Se+) or selenium-deficient (Se−) conditions in the absence/presence 
of Wortmannin (500nM) for 48 and 72 hours and subjected to indirect western blotting. Phospho-AKT 
and caspase3 and cleaved caspase3 levels were shown. Calnexin was used as equal loading control. 
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FIGURE 4.1.8 Inhibition of PI3K/Akt pathway did not induce apoptosis in Mahlavu and Snu475. 
Mahlavu (A) and Snu475 (B) cells were grown in selenium adequate (Se+) or selenium-deficient (Se−) 
conditions in the absence/presence of Wortmannin (500nM) for 48 and 72 hours and subjected to 
indirect western blotting. Phospho-AKT and caspase3 and cleaved caspase3 levels were shown. 
Calnexin was used as equal loading control. 
 
4.2  Exploration of oncogenecity of R249S p53 mutation in HCC 
 
4.2.1 Formation and validation of R249S p53 expressing HepG2 clones 
 
In order to investigate the molecular mechanism underlying the oncogenecity of 
mutant p53-249ser in HCC, HepG2 cells were used as a model. This cell line displays 
wild-type p53, and transfection with p53-249ser mimics the initial steps of p53-
249ser-related hepatocellular carcinogenesis with a heterozygous state for p53 
mutation. We transfected HepG2 cell line, with either pCMV-Neo-Bam p53 R249S 
vector or the empty pCMV-Neo-Bam vector to obtain stable clones bearing R249S 
mutant p53 in the p53 wild type background.  To eliminate the false results that would 
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stem from clonal selection, six p53-249ser-expressing and four control clones have 
been selected by mutant p53 expression analysis using RT-PCR followed by 
249AGG-<AGT-selective BsuRI and HinfI digestions (Figure 4.2.1A and Figure 
4.2.1B). BsuRI is a restriction enzyme with a 5’ GG↓CC 3’ restriction recognition site 
and cuts if p53 is wild type at codon 249. On the contrary, HinfI has a recognition site 
at 5’ GAN↓TC 3’ meaning that it cuts p53 when it has 249AGG-<AGT transversion. 
PLC/PRF/5 cell line with a R249S p53 mutation was used as a positive control.  
 
After this first genotypic validation, we checked the protein level of a cyclin-
dependent kinase inhibitor p21cip1which is a well-characterized p53 target [270] after 
the induction of DNA damage. It is a well-known fact that, in wild-type TP53 
expressing cell lines, genotoxic treatment induces p53 protein levels and a subsequent 
transcription of the p21cip1gene while in a mutant TP53 background p21cip1 
accumulation is minimum [270-272]. Adriamycin (ADR) is an anti-cancer drug 
commonly used in the treatment of several human solid cancers including 
unresectable HCC [273] and its therapeutic effects have been linked to DNA 
intercalation and topoisomerase inhibition [274]. Therefore, we treated the cell clones 
with 1µM ADR and checked the nuclear accumulation of p21cip1 with the clones 
bearing R249S p53 mutation after DNA damage and manually counted the positive 
and total number of cells from at least 10 different regions and positive cell 
percentage was calculated (p<0.01) (Figure 4.2.2).  
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FIGURE 4.2.1 Validation of transcription of R249S p53 mutation in stable clones. Selected HepG2 
R249S p53 clones were subjected to restriction digestions with HinfI (A) and BsuRI (B). HepG2 and 
PLC/PRF/5 were used as negative and positive control respectively. R249S mutant transcripts give 
136, 84, 30 and 30bp length and wild-type transcripts give 166, 84, 30 bp fragments subsequently after 
digestion with HinfI. R249S mutant transcripts give 280, 138, and 142bp length, since they include 
wild type p53 also and wild-type transcripts give 138 and142 bp fragments subsequently after digestion 
with BsuRI.  
 
 
 
FIGURE 4.2.2 Expression of p53 target p21cip1 after treatment with Adriamycin in stable clones. 
Selected p53 R249S and control clones along with the parental HepG2 cells were treated with 1µM 
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ADR for 24 hours and then subjected to immunoperoxidase staining with an antibody against p21cip1. 
150 cells from 10 different places were counted and percentage of positive cells was calculated for 
non-treated and treated conditions separately. Blue and red bars represent non-treated and ADR treated 
positivity respectively. Error bars represent standard deviation.  
 
  
4.2.2 Subcloning of the selected R249S p53 expressing HepG2 clones 
 
Due to some limitations after transfection, cells can lose the ectopic expression of the 
gene, thus working with a wild type p53 carrying cell line and restrictions of 
transfection efficiency prompted us to do further subcloning of the selected clones.  
Our major aim was to ensure the expression of R249S p53 and to obtain a more 
homogenous population. That’s why we selected 2 clones with R249S p53; 
HepG2_249.4 and HepG2_249.8 with the lowest p21cip1 expression after ADR 
treatment and 2 control clones HepG2_emp.4 and HepG2_emp.5 with the lowest 
p21cip1 expression without any treatment to subclone them. After subcloning we tested 
15 clones derived from HepG2_249.4 and HepG2_249.8 and 7 clones from 
HepG2_emp.4 and HepG2_emp.5. Opposite of what we expect, we could not obtain 
such a population that is purely negative or positive (Figure 4.2.3A and B) in terms of 
p21cip1 expression. This may be either due to the fact that p53-249ser in the presence 
of wtp53 cannot inhibit wt p53 activity or tumor heterogenicity and/or cell plasticity.  
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FIGURE 4.2.3 Validation of transcription of R249S p53 mutation and expression of p21cip1 after 
Adriamycin treatment in subclones. Selected p53 R249S and control subclones along with the parental 
HepG2 cells were treated with 1µM ADR for 24 hours and then subjected to immunoperoxidase 
staining with an antibody against p21cip1. 150 cells from 10 different places were counted and 
percentage of positive cells was calculated for non-treated and treated conditions separately. Error bars 
represent standard deviation. (A) Blue and red bars represent non-treated and ADR treated positivity 
respectively.  4 subclones selected from different parental clones were subjected to immunoperoxidase 
staining with an antibody against p21cip1 to ensure the expression of p53 target (B) and subjected to 
restriction digestions with BsuRI and HinfI (C). 150 cells from 10 different places were counted and 
percentage of positive cells was calculated for non-treated and treated conditions separately. Error bars 
represent standard deviation (B). GAPDH was used as loading control. RT- controls were subjected to 
the same protocol in order to ensure there is no DNA contamination. PLC/PRF/5 was used as 
restriction digestion control.  
 
As a result, we selected the lowest p21cip1 expressing subclones; HepG2_249.44 and 
HepG2_249.89 derived from 2 different parental clones and two control subclones; 
HepG2_emp.49 and HepG2_emp.52 with the lowest background p21cip1 expression 
for further analysis and these clones were verified with restriction enzyme digestion 
method (Figure 4.2.3 C).  
 
4.2.3 Survival advantage of R249S p53 
 
Although the frequent p53 mutations are predominantly involved in the loss of tumor 
suppressor activity of the protein, there is accumulating evidence that indicates the 
resulting mutant p53 can contribute to carcinogenesis either with dominant negative 
effects of the protein or with gain-of-function features. In order to ascertain the role of 
R249S in tumorigenesis and understand whether, p53-249ser mutation serves as a 
selective growth advantage thus contributing to the oncogenicity, we performed long 
term colony formation experiments. 
 
A comparative analysis of in vitro growth characteristics of p53-249ser and control 
subclones was performed in order to assess the duplication capacity of these clones.  
Control and R429S p53 clones were plated in low density and stained after 15 days of 
culturing to observe any phenotypic difference between these two different p53 
backgrounds.  Figure 4.2.4 indicated that the difference of colony number and size 
were not significant.   
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FIGURE 4.2.4 Long-term colony formation assay. Selected subclones for R249S p53 and wild-type 
p53 were plated on 6-well plates in low density (1000cells/well) in triplicates and after 15 days fixed 
and stained with Coomasie-Blue. Mediums were changed every 3-4 days.  
 
 
Therefore, as a next step we checked the colony formation after ADR treatment. Cells 
plated in 48-well plates were treated with 0-2 µM ADR for 24h and then cultured for 
an additional time of 15 days.  We observed that 0.25 µM ADR was a threshold for 
the clones to survive, after that dose cells were all dead regardless of their p53 status 
(Figure 4.2.5).  
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FIGURE 4.2.5 Long-term colony formation assay after DNA damage induction. Selected subclones 
for R249S p53 and wild-type p53 were plated on 48-well plates in low density (200cells/well) in 
triplicates and next day 0, 0.1, 0.25, 0.5, 1, 1.5, 2µM ADR were given for 24 hours and after 15 days 
fixed and stained with Coomasie-Blue. Mediums were changed every 3-4 days. 
 
Treatment with doses below 0.2 µM ADR indicated a slight survival advantage of 
control clones over R249S p53 ones. Since DNA damage has been identified as 
potential mediators of cellular senescence and ADR is able to trigger senescence 
through mitotic catastrophe ([275], Gursoy-Yuzugullu, unpublished data) we checked 
the senescence response difference after the treatment with two different agents; ADR 
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and TGFβ-1 by senescence-associated β-galactosidase (SABG) assays (Figure 4.2.6A 
and Figure 4.2.6B). We could not conclude a significant senescence response 
difference with either of those treatments. 
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FIGURE 4.2.6 Difference between senescence response induced by low-dose Adriamycin (A) and 
TGF-β1 (B). Selected subclones for R249S p53 and wild-type p53 were plated on 6-well plates and 
treated with either 0.1µM ADR or 5ng/ml TGF-β1 for 72 hours and then subjected to senescence 
(SABG) assay protocol. Nuclear fast red was used as counterstain. Representative pictures from each 
condition were taken and compared with each other. Scale bar 100µm. 
 
How a cell line that already has the p53-249ser mutation along with wild type p53 
would respond when it is exposed to AFB1 is not known. p53-249ser mutation has 
been detected in the liver of aflatoxin-exposed people prior to liver cancer 
development [276]. Thus, people that carry this mutation are being exposed to AFB1 
in their diet; therefore their hepatocytes primed with a p53-249 mutation would be 
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exposed to this toxin in most of the time. This is why we attempted to check the 
response of p53-249ser and control subclones after AFB1 treatment in vitro.  After 
the exposure of our clones to AFB1, we detected aflatoxin-DNA adducts using a 
specific antibody (6A10). We expected that p53-249ser transfected cells would 
behave differently upon exposure to AFB1, when compared to wt-p53-expressing 
cells. However, we did not observe a significant difference in AFB1-DNA adduct 
formation in the R249S clones and the controls (Figure 4.2.7).  
 
 
FIGURE 4.2.7 Aflatoxin induced AFB1-DNA adduct detection. Selected subclones for R249S p53 and 
wild-type p53 were plated on 24-well plates and treated with either 3µM AFB1 or DMSO (>1:1000) for 
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24 hours and then subjected to immunoperoxidase detection protocol with the specific antibody against 
imidazole ring opened form of AFB1-FAPY adducts. Counterstaining was performed with 
hematoxylene. Representative pictures from each condition were taken and compared with each other. 
Scale bar 50µm. 
 
Lastly, we treated the clones with 1µM ADR and AFB1 separately for 24h and then 
incubated with complete medium for 24h and checked for senescence markers such as 
p53, p21, p15, p16, p27 and also MDM2; an important negative regulator of p53 by 
immunoblotting (Figure 4.2.8 A and B). Although the protein levels of p53, p21, p15, 
p16, p27 and MDM2 did not vary much between the p53-249ser and control clones, 
the response of cells was very different with the ADR and AFB1 treatment. To our 
surprise, AFB1 treatment did not change the p53 and p21 accumulation; protein levels 
were significantly lower than the level observed with the ADR treatment (Figure 
4.2.8A). MDM2, p15, p16 and p27 protein expression also did not change upon AFB1 
treatment, even though we observed a high increase in p15, slight increase in p16, no 
change in p27 and a diminish in MDM2 protein levels with a correlation with the p53 
increase after ADR treatment (Figure 4.2.8 B).  
 
 
FIGURE 4.2.8 Comparison of response after AFB1 (A) and ADR (B) treatment in R249S p53 and wt 
p53 subclones. Cells treated with either 1µM AFB1 or DMSO and 1µM ADR for 24 hours and then 
additional 24 hours without treatment and subjected to immunoblotting with the antibodies against p53, 
p21, p15, p16, p27 and MDM2. α-tubulin was used as loading control. 
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4.2.4 Global histone methylation marker status check 
 
4.2.4.1 Histone methylation marker status in R249S p53 bearing clones 
 
Our results on the survival advantage of genetic modulation of R249S over wild type 
p53 were not very significant and promising. So we speculated if R249S might be 
selective due to epigenetic modulation-derived mechanisms. Based on our 
observation indicating the expression difference of epigenetic related gene groups 
between senescent and immortal Huh7 clones, epigenetic regulation can play an 
important role in cell fate determination (Bagislar et al, unpublished data). Hence, we 
hypothesized that R249S p53 might change the global histone modification markers 
by itself, thus contribute to carcinogenesis. Therefore we immunostained the p53-
249ser and control subclones with polyclonal antibodies against H3K4me3, 
H3K9me3, H3K27me3, H3K27me1, H3K36me3, H3K36me1, H3R17me2, 
H4K20me3, H4R3me2.  
 
We tested 6 p53-249ser and 4 control subclones. We obtained positive signal for all 
the residues tested for both p53 background. In 6 249ser subclones, H3K27me3, 
H3K36me3, H4K20me3, H3R17me2 and H3K9me3 were observed to be 
heterogeneously stained and staining was stronger compared to the 4 control 
subclones, yet the difference was slight in H3K9me3 (Figure 4.2.9 D, F, I, B and H). 
We did not observe a marked alteration in this comparative study on H3K4me3, 
H3K27me1, H3K36me1 and H4R3me2 residues, all showing strong heterogenous 
nuclear staining (Figure 4.2.9 A, C, E, and J).  
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FIGURE 4.2.9 Global histone methylation marker status check (A-J). Selected subclones for R249S 
p53 and wild-type p53 were plated on 24-well plates and subjected to immunostaining with the specific 
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antibodies against H3K4me3, H3K9me3, H3K27me3, H3K27me1, H3K36me3, H3K36me1, 
H3R17me2, H4K20me3 and H4R3me2. Counterstaining was performed with hematoxylene. 
Representative pictures from each condition were taken and compared with each other. Scale bar 
100µm.  
 
 
4.2.4.2 Histone methylation marker status check in HCC upon Adriamycin and AFB1 
treatment 
 
Our previous studies indicated the increase of H3K27me1, H3K36me3, and  
H4K20me3 in pre and late senescent Huh7 clones compared to the immortal Huh7 
clone and H3K27me3 and H3R2me2 residues indicated a gradual increase with late 
senescence (Bagislar et. al. unpublished data). Therefore, employing another 
senescence model based on adriamycin-induced mitotic catastrophe [275],  (Gursoy-
Yuzugullu et al, unpublished data)  we checked the H3K27me1, H3K27me3, 
H3K36me1, H3K36me2, H3K36me3, H4K20me1, H4K20me2, H4K20me3 residues 
by indirect immunoflourescence staining. Huh7 cells treated with 0.1µM low dose 
(LD) ADR and 3µM AFB1 for 72 hours were subjected to staining protocol.  
 
We included AFB1 treatment in the set of experiments for two reasons: the first one is 
to explore the effect of AFB1 exposure on histone methylation marker status, due to 
the fact that we previously observed a change in the level of these residues in 249ser 
p53 bearing clones (Figure 4.2.9), the second one is to find out which modulations in 
those histone methylation marks were due to DNA damage in common.  
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FIGURE 4.2.10 Global histone methylation marker status check upon DNA damage induction (A-B). 
Huh7 cells were treated with 3µM AFB1 or DMSO and 0.1µM ADR (low dose) for 72 hours and 
subjected to immunoflorescence staining with the specific antibodies against H3K27me1, H3K27me3, 
H3K36me1, H3K36me3, H4K20me1, H4K20me2, and H4K20me3. Representative pictures from each 
condition were taken and compared with each other (A). Huh7 cells treated with 0.1µM ADR (low 
dose) for 72 hours are subjected to westernblotting with the specific antibodies against H3K27me1, 
H3K27me3, H3K36me1, H3K36me3, H3K36me2, H4K20me1, H4K20me2, and H4K20me3 (B). H3 
and H4 were used as loading controls. 
  79 
As a result, we observed an increase in H3K27Me3, H3K36Me3 and H4K20Me3 
levels and a corresponding decrease in monomethyl forms of these histones, 
H3K27Me1, H3K36Me1 and H4K20Me1 and no change in dimethyl forms 
H3K36me2 and H4K20me2 after low dose ADR treatment in Huh7 cells also 
confirmed by western blotting data (Figure 4.2.10 B). AFB1 treatment also modulated 
the histone residues H3K27Me3, H3K36Me3, H4K20Me3, monomethyl forms 
H3K36Me1, H4K20Me1 and dimethyl forms H3K36me2 and H4K20me2 in a same 
manner as with ADR (Figure 4.2.10 A).  These results not only confirmed the 
alteration in histone methylation phenotype observed in Huh7 senescent and immortal 
clones, but also pointed out the association with DNA damage response and global 
changes in histone methylation.  
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4.3 Effects of AFB1-induced genotoxicity in HCC  
  
The predominant adduct Aflatoxin B1 (AFB1)-N7-guanine is formed after the 
reaction of AFB1-8,9-exo-epoxide with guanine residues in DNA and leads to the 
formation of more stable imidozole ring-opened AFB1-formamidopyrimidine (AFB1-
FAPY) DNA adduct [219]. Since the pseudo-half-life for the loss of AFB1–FAPY is 
longer, adducts are stable, they remain to be detectable for several weeks in rat liver 
[218, 222]. Additionally, AFB1 contributes to the oxidative DNA damage, leading to 
8-hydroxydeoxyguanosine (8-OHdG) lesions in rat hepatic DNA [223, 225]. 
Therefore, we first explored AFB1 induced genotoxic effects. Before selecting the 
dosage range of AFB1, we considered the estimated chronic aflatoxin exposure levels 
in humans (0.01-0.3 µg/kg/day) [218] and the hepatocarcinogenic doses (0.015-1ppm) 
in rats [277]. 30 min of exposure to 1.6 µM AFB1 was enough for the induction of 
p53 R249S mutations in HepG2 cells [278] and 0.2-5 µM doses were sufficient to 
induce mutations in mouse fibroblasts [279]. Careful consideration of these findings 
prompted us to use an AFB1 dose range of 3-5µM in our experiments. The dose range 
we used in this study was at the upper limits of in vitro mutagenic activity in 
mammalian cells.  
 
4.3.1 AFB1 induced DNA adducts and 8-OHdG lesions in hepatocyte-like cells 
 
Since we did not observe any difference between the p53-249ser and control clones 
after AFB1 treatment, we decided to conduct our experiments with hepatocyte-like 
wild-type p53-expressing parental HepG2 cell line and explore the effects of AFB1 
on HCC. Cells were treated with 3-5 µM of AFB1 in the absence or the presence of 
S9-activating system that allows the activation of AFB1 into AFB1-8,9 epoxide [258]. 
Following 24 hours of exposure, cells were subjected to immmunoperoxidase assays 
to detect AFB1-FAPY DNA adducts and 8-OHdG DNA lesions. Our results 
highlighted the presence of AFB1-FAPY adducts in the nuclei of most cells with 3 or 
5 µM AFB1 (Fig. 4.3.1A). Adduct detection levels were quite similar between these 
two doses, indicating that AFB1 was capable of inducing highly abundant DNA 
adducts when tested at micromolar levels. We observed also the detection of 8-
OHdG-positive nuclear foci (Fig. 4.3.1B). Essentially the same results were obtained 
in the presence or in the absence of S9-activating system in this cell line (Fig.4.3.1). 
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Figure 4.3.1 Induction of DNA adducts and 8-hydroxy-deoxyguanosine lesions following aflatoxin B1 
(AFB1) exposure. HepG2 cells were exposed to AFB1 or DMSO for 24 hours, in the presence (S9+) or 
in the absence of S9-activating system (S9-), and then subjected to indirect immunoperoxidase assays 
using anti AFB1-FAPY (A) and anti-8OH-dG (B) antibodies. Counterstain was performed by using 
hematoxylin. Scale bar = 20 µm.  
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4.3.2 AFB1 exposure induces single and double strand breaks 
 
Cells were exposed to AFB1 (5 µM) or ADR (0.5 µM) as a positive control for 24 
hours, and then cultivated in the absence of test chemicals up to 72 hours. Genotoxic 
effects of AFB1 were studied by alkaline and neutral comet assays that detect single 
and double strand DNA breaks, respectively [262, 263]. Both AFB1- and ADR-
exposed cells, tested by alkaline comet assay at 72 hours post-exposure time 
displayed statistically significant increase in comet tail moments (P<0.0001), 
indicating the presence of abundant single strand DNA breaks (Fig. 4.3.2A-left, B). 
Neutral comet assay also detected statistically significant (P<0.0001) increase in tail 
moments with both chemicals that lasted at least 48 hours after the removal of 
chemicals from the cell culture medium (Fig. 4.3.2A-right; C). Tail moments obtained 
with neutral comet were nearly ten-fold less than those obtained with alkaline comet. 
Thus, AFB1 induced much more single strand breaks than double strand breaks. 
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Figure 4.3.2 Induction of persistent single and double strand DNA breaks after AFB1 treatment.  (A) 
HepG2 cells were exposed to DMSO, 5µM AFB1 or 0.5µM ADR as a positive control, for 24 hours, 
followed by a culture in the absence of test chemicals for up to 72 hours, and subjected to alkaline 
comet (A-left) or neutral comet (A-right) assays to detect single and double strand breaks respectively. 
Black, white and gray columns indicate cells exposed to DMSO, AFB, and ADR, respectively. Error 
bars indicate SD. AFB1- and ADR-treated cells displayed significantly increased tail moments in all 
time-points tested (P<0.0001).  (B) Representative pictures showing comet figures after 5µM AFB1, as 
compared to ADR exposure. HepG2 cells were treated with chemicals for 24 hours, and then cultivated 
in the absence of chemical for additional times up to 72 hours. Cells were then subjected to single cell 
electrophoresis under alkaline (B) or neutral (C) pH to detect nuclei with single strand and double 
strand DNA breaks, respectively. 
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4.3.3 AFB1-induced genotoxicity did not affect cell growth and colony survival 
 
Next, we studied the cellular response to AFB1-induced genotoxicity by cell growth, 
senescence and apoptosis assays. Three days of exposure to AFB1 (3 µM) did not 
induce senescence and had no visible effect on cell growth (Fig. 4.3.3 A-B).  AFB1 (5 
µM) was also ineffective for apoptosis induction (Fig. 4.3.3 C). In contrast, a low 
dose of ADR (0.1 µmol/L), inhibited cell growth and induced a senescence-associated 
β-galactosidase (SABG)-positive senescence response (Fig. 4.3.3 B), whereas a high 
dose (1 µM) induced activated-procaspase-positive apoptosis response, as evidenced 
by western blot analysis (Fig. 4.3.3 A and C).  
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Figure 4.3.3 Aflatoxin treatment does not induce senescence or apoptosis. HepG2 cells were exposed 
to 1 µM AFB1, or 1µM ADR for 24h and incubated with complete medium for an additional 24 hour 
period and visualized under light microscope (A). HepG2 cells treated with 3µM AFB1 and 0.1µM 
ADR were subjected to SABG assay to detect senescent cells (blue). Fast red was used as a 
counterstain. Scale bar = 100 µm (B).  HepG2 cells were exposed to 5µM AFB1, or 1µM ADR and 
then were subjected to Western blot assay to detect apoptosis by active caspase 3. Calnexin was used as 
a loading control (C). 
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Thus, HepG2 cells were not responsive to AFB1 DNA damage by undergoing a 
permanent growth arrest such as senescence or apoptosis, but they were partially 
arrested in the G2/M phase of the cell cycle after 72h of AFB1 exposure (Figure 4.3.4 
and 4.3.5- Left) while with ADR exposure, cells respond with either a complete G2/M 
arrest or apoptosis (Figure 4.3.5-Right). Short term BrdU incorporation rate after 
AFB1 treatment was not diminished as well, correlating with an incomplete G2/M 
arrest since the DNA synthesis was continuous (Figure 4.3.4). This partial arrest was 
not cell context dependent; we observed the same phenomenon with Huh7 (Y220C 
p53 Mutation) (Figure 4.3.6) and Hep3B (Null p53) (Figure 4.3.7). Since p53 was not 
playing a key role in the response of cells to AFB1 induced DNA damage, we 
checked G2/M checkpoint key elements such as cdc25A, Wee1 kinase and 14-3-3 
[246] (Figure 4.3.8). We observed the nuclear localization of phospho-cdc25A 
(Figure 4.3.8-top), which is inactive when phosphorylated, and 14-3-3σ (Figure 4.3.8-
middle), in both AFB1 and ADR exposed cells with weak signal in Wee1 (Figure 
4.3.8-bottom), under AFB1 exposure.  
  
 
Figure 4.3.4 Lack of permanent cell cycle arrest in response to AFB1-induced DNA damage. HepG2 
cells were treated with AFB1 (5 µM) or DMSO (in the presence of S9-activating system) for 24 hours, 
followed by additional cell culture in the absence of this chemical for another 4h and 24 hours. Cell 
cycle analysis was performed by flow cytometry after labeling of cells with BrdU and propidium 
iodide at indicated post-exposure times.  On the left, representative flow cytometry plots of AFB-
treated (+) and DMSO-treated (-) cells and on the right distribution of cells at G1, S and G2/M phases 
at different time points after exposure to AFB1 (+) or DMSO (-) is shown. 
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Figure 4.3.5 Cell cycle analysis of HepG2 cells after Aflatoxin and Adriamycin treatment. HepG2 
cells were treated with 0-3µM doses of AFB1 and 0-1µM ADR for 24h, 48h and 72h and cell cycle 
analysis were performed with Propidium Iodide. Graphs represent the cell cycle distribution of each 
corresponding condition above the graph. Blue, red, yellow and green bars represent cells in G1, S, 
G2/M and subG1 phase. 
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Figure 4.3.6 Cell cycle analysis of Huh7 cells after Aflatoxin and Adriamycin treatment. Huh7 cells 
were treated with 0-3µM doses of AFB1 and 0-1µM ADR for 24h, 48h and 72h and cell cycle analysis 
were performed with Propidium Iodide. Graphs represent the cell cycle distribution of each 
corresponding condition above the graph. Blue, red, yellow, green and purple bars represent cells in 
G1, S, G2/M, subG1 and polyploidy phase. 
 
 
Figure 4.3.7 Cell cycle analysis of Hep3B cells after Aflatoxin treatment. Hep3B cells were treated 
with 0-3µM doses of AFB1 for 24h, 48h and 72h and cell cycle analysis were performed with 
Propidium Iodide. Graphs represent the cell cycle distribution of each corresponding condition above 
the graph. Blue, red, yellow and green bars represent cells in G1, S, G2/M and subG1 phase 
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Figure 4.3.8 Cell cycle checkpoint key players localize into nucleus. HepG2 cells were treated with 
3µM of AFB1 and 0.1µM ADR for 72h and then subjected to immunoflorescence staining with the 
specific antibodies against phospho-cdc25A, 14-3-3σ and Wee1. DAPI is used for nuclear staining.  
Scale bar: 10µm. 
 
 
To verify that the effects of G2/M arrest were partial and not permanent, cell survival 
was determined by assessing colony growth in 100 mm dishes after exposure to AFB1 
or ADR. HepG2 cells were seeded in 6-well plates and semi-confluent cells were 
exposed to AFB1 (0, 1, 3, 5, 10, and 50 µM) in the presence of S9-activation system. 
Control cells were treated with ADR (0, 0.1, 0.3, 0,5, 1, and 5 µM). Following 4 
hours and 24 hours exposure, 104 cells were seeded into 100 mm dishes, and colonies 
were counted 10 days later. Cell survival was calculated as the % ratio of cell 
numbers in treated versus untreated cells. Survival parameters were determined by 
plotting survival data on a semilog plot. Aflatoxin B1 did not affect colony survival 
after 4 hours or 24 hours of treatment, when tested at doses ≤  5 µM. Under similar 
conditions, ADR displayed strong and time-dependent inhibition of colony survival 
being active with 50 times less concentrated molar doses (Fig. 4.3.9). Detectable 
effects of AFB1 were observed only when cells were exposed for 24 hours at very 
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high doses reaching 50 µM (Fig. 4.3.9, insets). Indeed, the AFB1 was more than 150-
fold less cytotoxic than ADR in HepG2 cells (Fig. 4.3.2A). 
 
Figure 4.3.9 The effects of AFB1 (closed circles), or ADR (open circles) treatment of HepG2 cells for 
4 hours (top) or 24 hours (bottom) on cell survival-colony forming ability. Cell survival was calculated 
as the % ratio of cell numbers in treated versus untreated cells (n=3). Survival parameters were 
determined by plotting survival data on a semilog plot. Insets: cell survival at higher AFB1 (up to 50 
µM) and ADR (up to 5 µM) doses. Error bars: SD. HepG2 cells were seeded in 6-well plates and semi-
confluent cells were exposed to aflatoxin (0, 1, 3, 5, 10, and 50 µM), or adriamycin (0, 0.1, 0.3, 0.5, 1, 
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and 5 µM) for 4 hours, or 24 hours. Following exposure, 104 cells were seeded into 100 mm dishes, 
and colonies were counted 10 days later.   
 
4.4 AFB1-induced DNA damage response in HCC 
 
DNA damage response to AFB1 is poorly known. AFB1-N7-Gua and AFB1–FAPY 
adducts appear to be removed primarily by NER in mammalian cells, but other repair 
systems have also been implicated in bacteria and yeast [228]. The mechanisms of 
DNA damage checkpoint response to AFB1 remain totally unknown. Here, we 
explored DNA damage checkpoint response of wild-type p53 human cells to AFB1 
exposure. Our findings indicate that the checkpoint response to genotoxic and 
mutagenic doses of AFB1 is incomplete, being unable to activate p53 and to induce 
cell cycle arrest or apoptosis. 
 
4.4.1 Increased DNA damage checkpoint foci in aflatoxin B1-exposed cells 
 
The lack of a significant effect of AFB1 on cell growth, despite the induction of 
persistent single and double strand breaks prompted us to test whether the AFB1 can 
induce a DNA damage response signaling activity. We used 53BP1 and phospho-
H2AX foci assays [246] by immunofluorescence following 3 days of exposure to 
either AFB1 (3 µM) or ADR (0.1 µM). Both agents induced 53BP1 and phospho-
H2AX foci that were detectable after three days of culture (Fig. 4.4.1), as an 
indication of double-strand DNA break response [246, 247]. The statistical 
significance of these observations was tested by counting percent number of cells 
with 53BP1- positive foci (>5 foci/cell). Cells exposed to AFB1 (3 µM) between 1 
hours and 72 hours showed progressive and statistically significant (P<0.0001) 
accumulation of 53BP1 foci, when tested at 72 hours of cell culture.  
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Figure 4.4.1 Induction of 53BP1 and phospho-H2AX foci following aflatoxin B1 exposure. HepG2 
cells were treated with AFB1 (3 µM) for three days and then subjected to 53BP1 and phoshpo-H2AX 
foci detection by indirect immunofluorescence. Control cells were exposed to DMSO only. ADR (0.1 
µM) was used as a positive control. Scale bar = 20 µm. 
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Figure 4.4.2 Time-dependent increase in 53BP1 foci-positive cells under aflatoxin B1 exposure. 
HepG2 cells were treated with AFB1 (3 µM) between 1 hour and 72 hours, and then cultivated in the 
absence of chemical for additional times up to 72 hours. Percent cells with 53BP1 foci (>5 foci) were 
calculated by manual counting following detection of 53BP1 foci by indirect immunoassay.  
(A) Representative examples of 53BP1 immunofluorescence data.  
(B). Comparative analysis of AFB1 -treated cells. Error bars indicate SD. The increase in 53BP1 foci 
positive cells was significant in all time points tested, when compared to DMSO-treated cells 
(P<0.0001). 
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Figure 4.4.3 The duration of 53BP1 foci after 24 hours of exposure to AFB1.  HepG2 cells were 
treated with AFB1 (5 µmol/L) for 24 hours, and then cultivated in the absence of chemical for 
additional times up to 120 hours. DMSO was used as a negative control. Percent cells with 53BP1 foci 
(>5 foci) were calculated by manual counting following detection of 53BP1 foci by indirect 
immunoassay. (A) Representative examples of 53BP1 immunofluorescence data. (B) Comparative 
analysis of AFB1- and DMSO-treated cells. Error bars indicate SD. The increase in 53BP1 foci 
positive cells was significant in all time points tested, when compared to DMSO-treated cells 
(P<0.0001). (C) The accumulation of total 53BP1 protein levels were tested by Western 
immunoblotting at indicated times. Calnexin was used as a loading control. 
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Figure 4.4.4 Activation of ATM, but not ATR after aflatoxin B1 exposure. HepG2 cells were exposed 
to AFB1 (3 µmol/L) or ADR (0.1 µmol/L), and tested for phosphorylated forms of ATM and ATR 
(red) three days later, by indirect immunofluorescence assay. DAPI (blue) was used for DNA 
visualization. p-ATM, phospho-ATM. Scale bar = 100 µm. 
 
 
Figure 4.4.5 Nuclear phospho-Chk1 expression was not affected after exposure AFB1 or ADR. HepG2 
cells were exposed to AFB1 (3 µM) or ADR (0.1 µM), and tested for phospho-Chk1 three days later, 
by indirect immunofluorescence assay (red). Counterstain was with DAPI (blue). Scale bar = 20 µm. 
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We observed a linear increase in the percent ratio of 53BP1 foci- positive cells from 
20% to more than 60% between 1 hour and 72 hours of exposure (Figure 4.4.2).  To 
test the duration of 53BP1 foci and phospho-H2AX foci following a fixed time of 
exposure to AFB1 (5 µM), cells were first treated with AFB1 for 24 hours, and then 
cultivated in the absence of chemical treatment up to 120 hours. Cells with positive 
53BP1 foci was detected by indirect immunofluorescence assay (Fig. 4.4.3 A and B), 
and then counted. The accumulation of foci peaked at 48 hours of post-treatment with 
40% positive cells. A residual foci activity with 15-20% positive cells was detectable 
for at least 120 hours in cells, which are no longer exposed to AFB1, confirmed by 
western blotting as well (Figure 4.4.3C). In contrast, cells exposed to DMSO only 
displayed low level foci activity (<5%) throughout the experiment indicating that 
increased foci formation was due to AFB1 exposure (Figure 4.4.3). Based on the 
induction of 53BP1 and phospho-H2AX foci by both AFB1 and ADR, we tested the 
activation states of ATM and ATR response pathways [15], using 
immunofluorescence analysis of phospho-ATM and phospho-ATR proteins, 
respectively. HepG2 cells were analyzed after three days of exposure to AFB1 (3 
µM), ADR (0.1 µM), or DMSO. As compared to cells treated with DMSO, both 
AFB1- and ADR-treated cells displayed increased nuclear signals for phospho-ATM, 
but there was no detectable change in the nuclear intensity of the phospho-ATR 
protein (Figure 4.4.4). We also tested phospho-Chk1 nuclear expression under the 
same experimental conditions. We observed punctuated nuclear staining by 
immunofluorescence assay with both control and treated cells, with no detectable 
difference between staining intensities (Figure 4.4.5). The other critical components 
of DNA damage signaling pathway were tested by immunoblotting using Adriamycin 
and hyrdoxyurea as positive controls in both HepG2 (Figure 4.4.6) and Huh7 (Figure 
4.4.7) cell lines. Although, Adriamycin treatment triggered a characteristic double 
strand break response in HepG2 and Huh7 cells by induced phosphorylation of H2AX 
(Figure 4.4.6 and Figure 4.4.7), HepG2 cells also displayed phosphorylation of Chk2, 
p53ser15 and p53ser20 weakly (Figure 4.4.6). Hydroxyurea treatment resulted in a 
phosphorylation of Chk1 in HepG2 and no phosphorylation of Chk1 was observed in 
Huh7. Inevitably, the response pattern was various in terms of time and cell line. 
However, after AFB1 exposure the only strong response we observed was with the 
phosphorylation of H2AX, as the major determinant of DNA damage.  
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Figure 4.4.6. Incomplete DNA damage checkpoint response of HepG2 cells to AFB1. HepG2 cells 
were treated with DMSO or AFB1 (5 µM) for four hours and 24 hours, and tested immediately (4h+0h 
and 24h+0h), or after 24 hours of incubation without treatment (24h+24h).  HepG2 cells treated with 
0.5 µmol/L Adriamycin (ADR) or 5 mM hydroxyurea (HU) were used as positive controls for 
experiments shown in A and B, respectively. Total cell lysates were subjected to Western blot analysis. 
Calnexin was used as a loading control. p-H2AX, phospho-H2AX; p- p53ser15, phospho-p53ser15; p-
p53ser20, phospho-p53ser20; p-Chk2, phospho-Chk2; p-Chk1, phospho-Chk1.  
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Figure 4.4.7. Incomplete DNA damage checkpoint response of Huh7 cells to AFB1.  
Huh7 cells were treated with DMSO or AFB1 (5 µM) for four hours and 24 hours, and tested 
immediately (4h+0h and 24h+0h), or after 24 hours of incubation without treatment (24h+24h).   
Huh7 cells treated with 0.5 µM Adriamycin (ADR) or 5 mM hydroxyurea (HU) were used as positive 
controls for experiments shown in A and B, respectively. Total cell lysates were subjected to Western 
blot analysis. Calnexin was used as a loading control. p-H2AX, phospho- H2AX; p-p53ser15, 
phospho-p53ser15; p-Chk2, phospho-Chk2; p-Chk1, phospho-Chk1.  
 
Derived from these findings, it was exciting to identify whether the DNA damage-
induced p53 response has been activated in AFB1 exposed cells. Although, HepG2 
cells express wild-type p53, but its p53-deficient isogenic clone is not available. 
Therefore, we expanded our studies to another cell line, HCT116 with wild-type p53 
expression and its p53-deleted isogenic clone [257]. 
 
4.5 Recapitulating the effects of AFB1 in isogenic wild-type and p53-/- HCT116 cells 
 
We first tested whether the response of HCT116 and HCT116-p53-/- cells to AFB1 
and ADR exposure induced changes that we have initially identified in HepG2 cells. 
We performed all AFB1 experiments in these cell lines in the presence of S9-
activating system to allow the transformation of AFB1 into epoxy-AFB1 [279]. First, 
we assessed the formation of DNA lesions following exposure to AFB1 (5µM) and 
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ADR (1 µM). The great majority of cells stained positive for 8-OHdG lesions 
following 24 hours of exposure to AFB1 or ADR (Figure 4.5.1A). The testing of 
AFB1-FAPY adducts was not possible, because HCT116 cells loosely attached to 
coverslips did not resist to the harsh treatment at pH 9.6, prior to antibody incubation. 
Next, DNA strand breaks were detected using neutral comet assay. Exposed cells 
were tested either immediately or following culture in the absence of chemical agents 
up to 48 hours. Both AFB1 and ADR caused comet formation with similar intensities 
and significant increases (P<0.0001) in tail moments at all tested time-points (Figure 
4.5.1B).  
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Figure 4.5.1 Induction of 8-hydroxy-deoxyguanosine lesions and double strand breaks following 
aflatoxin B1 (AFB1) exposure. HCT116 and HCT116-p53-/- cells were exposed to AFB1 (5 µM) or 
DMSO in the presence of S9-activating system. ADR (1 µM) treatment was performed in the absence 
of S9-activating system. Scale bar = 50 µm.  (A, B). 
(A) Cells exposed for 24 hours were subjected to indirect immunoperoxidase assays using anti-8OH-
dG antibody. Counterstain was by hematoxylin.  
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(B) Cells were tested immediately after 24 hours of exposure (24h+0h), or after 24 hours (24h+24h) 
and 48 hours (24h+48h) post-treatment. Neutral comet assay was used to detect double strand breaks. 
Black, white and gray columns indicate tail moments of cells exposed to DMSO, AFB, and ADR, 
respectively. Error bars indicate SD. AFB1- and ADR-treated cells displayed significantly increased 
tail moments in all time-points tested (P<0.0001). 
 
The responses observed with HCT116 and HCT116-p53-/- cells were similar to each 
other, although we observed less double strand breaks in HCT116-p53-/- cells. Taken 
together, these findings indicated that AFB1 and ADR induced genotoxic changes in 
these cell lines also, in addition to the initially tested HepG2 cell line. 
 
DNA damage foci induction in response to AFB1 exposure was assessed using anti-
53BP1 and anti-phospho-H2AX antibodies. Cells exposed to 5 µM AFB1 for 24h 
were examined for foci formation in the absence of AFB1 exposure up to 48 hours. 
Statistically significant (P<0.0001) increases of both 53BP1 and phospho-H2AX-
positive (>5 foci/nuclei) cells were in both HCT116 and HCT116 -p53-/- cells in all 
time-points tested (Figure 4.5.2). Percent number of 53BP1 foci-positive cells 
remained between 20 % and 50%. In addition, percentages of phospho-H2AX-
positive cells were between 30% and 60% for at least 48 hours, after the removal of 
AFB1 from the cell culture medium.  
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Figure 4.5.2 Increased DNA damage foci detection after exposure of HCT116 isogenic clones to 
aflatoxin B1. Cell lines were treated with AFB1 (5 µmol/L) for 24 hours, followed by further 
incubation for an additional 48 hours in the absence of the chemical. DNA damage foci-positive cells 
were detected by indirect immunofluorescence using anti-53BP1 and anti-phospho-H2AX antibodies 
and percent cells with positive foci (>5 foci per nucleus) were compared. Error bars indicate SD. The 
increase in aflatoxin B1-treated cells (red columns), compared to DMSO-treated cells (blue columns) 
was statistically significant (P<0.0001) in all time points tested with both HCT116 and HCT116-p53-/- 
cell lines. pH2AX, phospho-H2AX. 
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4.5.1 Dose-dependent and differential response of HCT116 and HCT116-p53-/- cells 
to adriamycin treatment 
 
Prior to testing of AFB1 effects on cell cycle checkpoint control, we first examined 
the responses of HCT116 and HCT116-p53-/- cells to ADR. Both p53 and p21Cip1 
responded to ADR treatment (0.0 to 0.5 µM) with a dose-dependent increase in 
HCT116 cells. The increase in p21Cip1 levels was p53-dependent, since we did not 
observe p21Cip1 response in HCT116-p53-/- cells  (Figure 4.5.3A). HCT116 cells 
displayed G1 and G2/M arrest in response to ADR, associated with low levels of 
apoptosis (subG1 peak) and polyploidy formation at higher doses. There was also a 
depletion of S phase cells, indicating an inhibition of DNA synthesis that lasted at 
least 48 hours following the removal of ADR from the cell culture medium. The 
response of HCT116-p53-/- cells to ADR was essentially similar with the noticeable 
absence of the G1 peak (Figure 4.5.3B). Comparative analysis of cell cycle changes in 
the two tested cell lines indicated that the loss of G1 peak in HCT116-p53-/- cell line 
was associated with a dose-dependent accumulation of nearly all cells at the G2/M 
phase. Both cell lines also displayed a drop in S phase cells, and an increase in 
apoptotic (subG1) and polyploidy cells (Figure 4.5.3C). Thus, the major effects of 
ADR-induced DNA damage in HCT116 cells were a p53-dependent G1 arrest and a 
p53-independent G2/M arrest. 
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Figure 4.5.3 p53-dependent and p53-independent cell cycle arrest after adriamycin treatment. 
(A) HCT116 and HCT116-p53-/- cells were treated with increasing doses of ADR (0-0.5 µM) for 24 
hours. Cell lysates were analyzed for p53 and p21Cip1 by Western blot. Calnexin was used as loading 
control. (B) Control and ADR-treated cells were subjected to cell cycle analysis by flow cytometry, 
after 48 hours of post-treatment culture. Loss of G1 peak in ADR-treated HCT116-p53-/- was noticed.  
(C) Distribution of cells at different phases of the cell cycle at different post-treatment time points, 
following exposure to increasing doses of ADR (0.0 to 0.5 µmol/L). Plyp; polyploid cells.  
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4.5.2 Absence of p53 accumulation and lack of cell cycle arrest in response to AFB1-
induced DNA damage 
 
Next, we compared the BrdU incorporation of HCT116 cells and we observed that 5 
µM AFB1 treatment for 24 hours did not affect DNA synthesis, regardless of p53 
status. The lack of response did not change for an additional 24 hours after the 
removal of AFB1 from the cell culture medium (Figure 4.5.4A). Comparative 
analysis of cell cycle changes in HCT116 and HCT116-p53-/- cells (Figure 4.5.4B) 
showed no major change in the fraction of S phase cells in both cell lines after 24 
hours of AFB1 treatment, and for an additional 24 hours post-treatment. HCT116 
cells displayed a weak decrease in G1 cells associated with a weak increase in G2/M 
cells at 24 hours. But, this effect was not stable because it vanished during the post-
treatment cell growth (Figure 4.5.4B). The response of HCT116-p53-/- cells to AFB1 
exposure was not remarkable either, except a slight increase in G2/M cells. When we 
analyzed the response of HCT116 and HCT116-p53-/- cells to AFB1 (Figure 4.5.4) in 
comparison with ADR (Figure 4.5.3), we noticed major discrepancies. While ADR 
was able to trigger a response with a dose as low as 0.05 µM, AFB1 was ineffective 
with 60-100-fold higher molar doses (3-5 µM). This remarkable difference in cellular 
response contrasted with our other findings that indicated that both AFB1 and ADR 
induced 8-OHdG lesions (Figure 4.5.1A) and double strand breaks (Figure 4.5.1B) 
with similar intensities.  
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Figure 4.5.4 Lack of cell cycle arrest in response to AFB1-induced DNA damage. HCT116 and 
HCT116-p53-/- cells were treated with 5 µM AFB1 (+) or DMSO (-) in the presence of S9-activating 
system for 24 hours, followed by additional incubation without treatment up to 24 hours. Cell cycle 
analysis was performed by flow cytometry after labeling of cells with BrdU and propidium iodide at 
indicated post-exposure times.  (B) Representative flow cytometry plots of AFB-treated (+) and 
DMSO-treated (-) cells. (C) Distribution of cells at G1, S and G2/M phases at different time points 
after exposure to AFB1 (+) or DMSO (-). 
 
4.5.3 DNA damage checkpoint response to AFB1 was incomplete 
 
The accumulation of 53BP1 and phospho-H2AX foci after exposure of these cells to 
AFB1 (Figure 4.5.2) indicated that AFB1-induced DNA damage initiated a 
checkpoint response, but this initial response did not conduct to a cell cycle arrest or 
apoptosis response (Figure 4.5.4), despite sustained DNA damage (Figure 4.5.1). 
Therefore, we examined the status of critical DNA damage signaling proteins in 
HCT116 cells by Western blot assay following 5 µM AFB1 exposure, as compared to 
0.5 µM ADR exposure (Figure 4.5.5). Following the 24 hours of exposure to AFB1, 
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we observed a clear increase in phospho-ATM and phospho-H2AX, but not in 
phospho-Chk2, and phospho-p53ser15 and phospho-p53ser20 levels. The difference 
between control and AFB1-exposed cells in ATM and H2AX phosphorylation 
remained discernible, albeit not flagrant, after an additional 24 hours post-treatment. 
These findings indicated that AFB1-induced DNA damage response was attenuated 
and incomplete in HCT116 cells. In contrast, a 10-fold lower molar dose of ADR (0.5 
µM) was sufficient for strong induction of ATM, H2AX, Chk2 and p53ser15 
phosphorylation (Figure 4.5.5A). As the ATR/Chk1 activation pathway can also 
activate p53 through phosphorylation, we also tested the status of Chk1 
phosphorylation after the AFB1 exposure. Cells treated with hydroxyurea (HU) were 
used as positive control. HCT116 cells displayed increased Chk1 phosphorylation 
upon HU exposure, but they were unresponsive to AFB1 treatment  (Figure 4.5.5B).  
The lack of association between ATM and p53ser15 phosphorylation in AFB1-treated 
cells was unexpected. 
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Figure 4.5.5 Incomplete DNA damage checkpoint response to AFB1. HCT116 cells were treated with 
5 µM AFB1 or DMSO in the presence of S9-activating system for 4 hours and 24 hours, and tested 
immediately (4h+0h and 24h+0h), or after 24 hours (24h+24h), 24 hours of incubation without 
treatment. HCT116 cells treated with 0.5 µM ADR (A) or 5 mM Hydroxyurea (HU) (B) were used as 
positive control. Total cell lysates were subjected to Western blot analysis with the antibodies against 
phospho-ATM, phospho-H2AX, phospho-Chk2, chk2 total, p53 total, phospho-p53ser15, phospho-
p53ser20, phospho-chk1, chk1 total. Calnexin was used as a loading control. 
 
 
Therefore, we verified the co-expression of these marks using double-
immunofluorescence assay with an independent anti-phospho-ATM antibody. As 
shown in Figure 4.5.6, increased nuclear staining and clearly discernible foci were 
detected with both AFB1- and ADR-treated cells. Most phospho-ATM-positive nuclei 
in ADR-treated cells also displayed increased phospho-p53ser15 staining. However, 
phospho-ATM-positive nuclei in AFB1-treated cells did not show increased phospho-
p53 staining.  
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Figure 4.5.6 Demonstration of the lack of phospho-p53ser15 accumulation in phospho-ATMser1981-
positive nuclei after aflatoxin B1 exposure.  HCT116 cells were exposed to AFB1 (5 µM) or DMSO in 
the presence of S9-activating system, or treated with ADR (0.5 µM) for 24 hours and subjected to 
rabbit phospho-ATMser1981 and mouse phospho-p53ser15 co-staining. Rabbit anti-phospho-ATM and 
mouse anti-phospho-p53 antibodies were detected with Alexa-568-conjugated (red) anti-rabbit and 
Alexa 488-conjugated (green) anti-mouse antibodies, respectively. Scale bar = 20 µm. 
 
4.6 Mechanism of p53 activation bypass after AFB1 induced DNA damage  
 
Overall, all the data generated in this study suggested that the AFB1 induced DNA 
damage response was not enough to generate a complete growth control response. 
The checkpoint response was either delayed or deficient with the bypass of efficient 
p53 protein phosphorylation. Hence, we compared the response of HCT116 cells to 
AFB1-induced DNA damage. First, a 3 µM AFB1 treatment for 24 hours did not 
induce detectable changes in p53 levels in HCT116 cells. In fact, there was no 
detectable increase in p21Cip1 levels either in HCT116 or in HCT116-p53-/- cells 
(Figure 4.6.1A). As shown in figure 4.6.1A, after the Adriamycin treatment, both p53 
and p21cip1 levels increased in a dose dependent manner in HCT116 cells and the 
increase in p21cip1 was p53-dependent since no p21cip1 accumulation was observed 
in HCT116 p53-/- cells. On the other hand, AFB1 exposure did not induce any 
significant p53 accumulation and p21cip1 induction in both HCT116 and HCT116-
p53-/- cells. Taken together, these data suggested that AFB1 was either implicated in 
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the inhibition of successful DNA damage induced cell cycle checkpoint response or 
the damage caused by AFB1 was not enough to accomplish a threshold level that is 
necessary for the full and efficient checkpoint activation, which was also previously 
suggested in studies with low-dose ionizing radiation [247]. In order to test our 
hypothesis, HCT116 cells were co-treated with rising doses of Adriamycin in the 
presence or in the absence of AFB1. Figure 4.6.1 B indicates that the accumulation of 
p53 and p21cip1 did not change significantly upon Adriamycin and AFB1 co-
treatment. In fact, a slight increase was observed in p21cip1 accumulation after co-
treatment. The same response was also observed in HCT116-p53-/- cells. These 
findings suggested that AFB1 did not inhibit the DNA damage checkpoint response 
under the tested conditions, but increased the checkpoint response to Adriamycin very 
slightly.  
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Figure 4.6.1 Comparative analysis of wild-type p53 response of HCT116 cells to AFB1 and  
Adriamycin treatment indicates that AFB1 cannot induce effective p53 activation.   
(A) Wild-type 53 HCT116 and p53-deficient HCT116-p53-/- cells were treated with AFB1 (3  
µM) or DMSO (in the presence of the S9-activating system) or Adriamycin (ADR; 1 µM) for 24 hours, 
followed by additional cell culture in the absence of this chemical for another 24 hours. (B, C) HCT116 
(B) and HCT116-p53-/- (C) cells were co-treated with ADR, increasing doses: 0, 0.1, 0.5 and 1 µM, 
respectively) in the absence (DMSO) or in the presence of 3 µM AFB1, as described in A for 24 hours 
(24 hours pre-exposure to AFB1, followed by 24 hours of co-exposure). Total cell lysates were used 
for Western blot using anti-p53 and anti-p21Cip1 antibodies. Calnexin was used as a loading control.  
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CHAPTER 5. DISCUSSION & FUTURE PERSPECTIVES 
 
 
 
5.1 AKT activation is required for selenium deficiency induced resistance. 
 
Selenium is essential for human health as a dietary supplement. Many diseases have 
been reported to be related to selenium deficiency [280]. Consequently, many 
epidemiological research data indicated an opposite correlation in selenium levels in 
patients with various cancer types [281-286]. Nevertheless, the mechanism of 
selenium’s protecting effect in cancer especially in HCC is still not well documented.  
 
Our group contributed to the current knowledge related to Se-deficiency and HCC in 
terms of its association with malignancy. Our in vitro model in well-differentiated and 
poorly-differentiated HCC cell lines demonstrated the selective response of those cell 
lines to Se-deficiency induced oxidative stress response. Accordingly, our previous 
data on HCC cell lines with different etiologies showed the close relationship of HBV 
and genotoxic stress with the selenium deficiency tolerance. 9 out of 10 tolerant HCC 
cells have HBV integration in their genome. Isogenic cell lines HepG2 and HBV 
transfected HepG2-2.2.15 cell line also strengthened this association with the 
observed tolerance of HepG2-2.2.15 to Se-deficiency induced oxidative stress and its 
deadly consequences.  
 
Apoptosis induced by oxidative stress has been implicated in several biological and 
pathological processes including senescence, inflammation, and carcinogenesis [287]. 
Even though the effects of oxidative damage are well known such as mitochondria 
failure and calcium homeostasis change [288], the underlying mechanism of cell 
death through oxidative damage is not yet clear. Oxidative stress is important in liver 
malignancy as well [289]. Selenium deficiency and its contribution to the ROS 
accumulation are frequent in chronic liver diseases and may cause hepatic 
malignancies [11, 290]. Therefore, the acquired tolerance of HCC cells to selenium 
deficiency and ROS accumulation may occur in vivo as well.  
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In this part of our research we aimed to clarify the gained tolerance of HCC to 
apoptosis under selenium deficient oxidative stress conditions. The results presented 
here provide the evidence for the involvement of various stress activated cell-
signaling pathways under Se-deficiency (Figure 5.1.1).  
 
 
Figure 5.1.1 Activated signaling pathways and cell fate upon oxidative stress 
 
One possible mechanism of Se-deficiency induced apoptosis is through the activation 
of p38MAPK pathway. Apoptosis observed under oxidative stress was triggered upon 
the activation of a couple of MAPK signaling elements including the p38MAPK 
pathway in HepG2 cells. Although STAT1, the transcriptional target of p38MAPK 
[266] was not activated, other targets or other phosphorylation sites that may be 
responsible for apoptosis should be checked under these conditions. ERK signaling 
has a crucial role in numerous steps of tumorigenesis including cancer cell 
proliferation, migration, and invasion [291, 292]. The MAPK/ERK pathway 
activation in HepG2-2.2.15 under Se-deficient conditions may contribute to the 
previously reported resistance to apoptosis. Thus subsequent targets of the ERK 
pathway such as the well-known Ras oncogene [293] or the anti-apoptotic protein 
MCL- 1 [294] should be checked.  
 
It is believed that genotoxic stress activate the PI3K/AKT pathway and inhibits 
apoptosis. In apoptosis resistant HBV integrated HepG2-2.2.15 cell line a time 
dependant increase in Akt phosphorylation, yet the detectable phosphorylation of Akt 
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in Se-adequate conditions, pointed out the involvement of HBV in AKT activation. 
Inhibition of AKT with a specific PI3K inhibitor reactivated the apoptosis phenotype 
under both Se-deficient and Se-adequate conditions, demonstrating the direct 
contribution of PI3K/Akt in the acquired selective survival in our model. Other HCC 
cell lines, which have a PTEN deletion and a constitutively active AKT 
phosphorylation, were also checked, but we failed to recapitulate apoptosis in those 
cell lines. This may be due to either the partial inhibition of Akt phosphorylation by 
Wortmannin or the different etiologies of those cell lines. Additionally, the 
transcriptional targets of PI3K/Akt in this survival process should be further clarified. 
We tried to check the targets of the Akt pathway; NFκB and its inhibitor IKK, 
however we failed to get any significant findings. Other known or novel Akt targets 
should be checked in order to understand the role of Akt induced survival capacity of 
some HCC cell lines.  
 
Our in vitro model with the unique HBV integration difference and respective 
apoptosis resistance provided a useful model for the investigation of possible 
mechanisms of the observed resistance. Therefore, we recently performed a 
microarray analysis study. We believe that this study would provide evidence for the 
contribution of MAPK pathway and their target genes with the differential expression 
profile to the selective survival advantage in HCC. Differential expression of novel 
targets of both MAPK and Akt survival pathway may be involved in this selective 
survival ability. 
 
In conclusion, this study further enlightened the association of selenium deficiency 
and HCC through the activation/inactivation of MAPK and cell survival pathways and 
provided evidence for its contribution to HCC, nevertheless the transcriptional targets 
and the exact mechanism needs to be further investigated. 
 
 
5.2 R249S p53 status did not lead to significant growth advantage. 
 
The data presented in this part of our research project is mainly concentrated on the 
oncogenic functions of R249S p53 mutation. Mutant p53 might trigger different 
pathways that constitute to the molecular basis of a wide range of gain-of-function 
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activities, such as resistance to anticancer treatments [241], genomic instability [240], 
increased cell growth and metastasis [237, 238]. Despite rapidly accumulating 
evidence, the molecular detail of the transcriptional activity of mutant p53 is still not 
clarified. In our study, we failed to observe any significant growth advantage of cells 
bearing this hot spot mutation. Phenotypic changes after various treatments including 
TGF-β1, Adriamycin and Aflatoxin were remained common in both p53 
backgrounds. On contrary to the findings indicating the increased mitotic activity and 
colony formation in Hep3B cell line transfected with R249S p53, our model 
presenting the wild type p53 and R249S p53 on the same background failed to show 
any significant growth advantages. This may be due to the fact that wild type p53 
might be still functional and it would be interesting to inactivate the wild type p53 
after the transfection of R249S p53, which would mimic the case in real life as well. It 
is also noteworthy that, due to the clonal selection effects after transfection protocol, 6 
selected R249S clones from 2 separate parental clones along with the controls were 
considered together in each group and the individual phenotypic effects were ignored. 
Our mutant protein functionality and stability were detected by indirect methods; we 
were not able to check the exact mutant p53 levels neither after transfection nor after 
several treatments. There may be no selective pressure in cells to keep exogeneous 
mutant p53; therefore they might lose the ectopic expression after a while.  
 
The lack of significant phenotypic change due to R249S prompted us to check the fact 
that p53 R249S might be selective via epigenetic modulation-derived mechanisms. In 
6 249ser subclones, H3K27me3, H3K36me3, H4K20me3, H3R17me2 and H3K9me3 
residues were heterogeneously and strongly stained compared to the 4 control 
subclones. Global histone methylation might be altered through the presence of 
R249S hot spot mutation suggesting the possible involvement of p53 mutants in 
epigenetic modulation.  
 
In conclusion, our findings indicated that R249S does not provide survival advantage 
at heterozygous state. Therefore the selection of this hot spot mutation could be at the 
mutation induction stage. The lack of p53 activation in AFB1 exposed HCC cells led 
us to test the functional DDR induction after AFB1 exposure.  
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5.3 After AFB1 exposure DNA damage checkpoint response was incomplete without 
a p53 activation response.  
 
Aflatoxins are the major environmental HCC risk. Aflatoxin’s hepatocellular 
biochemistry, its DNA interacting forms, the types of DNA damage induced by 
aflatoxins and their repair mechanism by NER, and its in vitro and in vivo mutagenic 
specificity for G->T transversions are well established facts [295]. We addressed here 
a less well understood, but a critical component of aflatoxin genotoxicity, namely 
DNA damage checkpoint response. The in vitro experimental model system used here 
was designed after careful consideration of previously described features associated 
with aflatoxin-related carcinogenicity. Human cells with wild-type p53 expression 
were preferred because of the fact that a specific hotspot mutation of this gene was 
observed only in human HCC, but not in other aflatoxin-induced mammalian tumors 
[31]. We considered estimated chronic aflatoxin exposure levels in humans (0.01-0.3 
µg/kg/day) [218] and hepatocarcinogenic doses (0.015-1 ppm)  in rat [277]. We also 
considered that 30 minutes exposure to 1.6 µmol/L AFB1 was sufficient to induce 
p53-249 G->T mutations in HepG2 cells, [278], and 0.2-5 µmol/L doses induced 
reporter gene mutations in mouse fibroblasts [279]. Thus, AFB1 doses that we used 
here (3-5 µmol/L) were at the upper limits of in vitro mutagenic activity in 
mammalian cells and they were estimably superior to carcinogenic doses in humans 
and rats. We performed our cell response studies over a period of several days so that 
we could determine both immediate and delayed effects.  
 
Our findings demonstrate that AFB1, when tested under conditions comparable to 
mutagenic and carcinogenic exposure levels, create DNA adducts and oxidative-stress 
induced DNA lesions, as well as persistent single and double strand breaks. These 
effects were expected based on previously published findings. AFB1-FAPY adducts 
are repaired by NER [228]. However, their removal is slow [221], and they remain at 
maximum levels for several days and are detectable over several weeks in rat liver 
cells [221, 222]. The unusual stability of AFB1-FAPY adducts together with a slow 
repair process could account for their sustained genotoxic effects. The lack of a 
detectable cell cycle arrest or apoptosis response during the same time period was 
unexpected. Our findings with both HepG2 and HCT116 cell lines clearly indicate 
that these human cells were unable to develop a protective response to AFB1-induced 
  119 
genotoxicity, although they responded by cell cycle arrest, senescence and apoptosis 
to ADR, another genotoxic agent with comparable effects on DNA stability.   
 
Our careful analysis of DNA damage checkpoint proteins provides a plausible 
explanation for the uncoupling between DNA damage and growth control following 
AFB1 exposure. The lack of an efficient coordination between DNA damage and 
growth control was due to an incomplete checkpoint response that occurred 
selectively after AFB1 exposure, but not after ADR exposure. Studies with both 
HepG2 and HCT116 cells indicated that DNA damage sensor protein ATM, the 
adaptor protein 53BP1 and H2AX were activated with both chemicals, probably in 
response to double strand breaks [246, 247]. ATM/53BP1/H2AX type initiating 
response was followed by chk2, p53 and p21Cip1 activation, as well as G1 and G2/M 
arrest after ADR exposure, but not after AFB1 exposure. Our comparative studies 
with HCT116 and HCT116-p53-/- cells indicated that G1 arrest was p53-dependent, 
but G2/M arrest was p53-independent. Thus, cells exposed to genotoxic effects of 
AFB1 failed to develop both p53-dependent G1 and p53-independent G2/M arrest 
responses.  The lack of Chk2 and p53 phosphorylation, associated with a lack of 
p21Cip1 accumulation after AFB1 exposure provide evidence for an incomplete 
transmission of DNA damage signal from ATM and 53BP1.   
  
The mechanisms of checkpoint signal interruption between ATM and Chk2 in AFB1-
exposed cells are not known. We first hypothesized an inhibitory effect of AFB1 for 
the induction of an uninterrupted DNA damage checkpoint response mechanism. 
However, cotreatment of AFB1 with Adriamycin did not end up with such an 
inhibition of p53 or p21Cip1 accumulation. Thus, we would like to speculate that one 
reason could be the weakness of signal intensity at AFB1 doses used in this study. It 
has been previously reported that AFB1 exposure could induce p21Cip1 upregulation 
in rat liver [296]. Therefore, AFB1 could induce a checkpoint response, presumably 
mediated by ATM/Chk2/p53 pathway. However AFB1 dose used in this particular 
study was 5 mg/kg and induced necrosis in the liver, strongly suggesting that it is well 
above the doses used here, as well as the non-lethal doses that both humans and rats 
are exposed for a carcinogenic effect. Such a dose would probably cause lethal 
aflatoxicosis in humans [217]. As stressed earlier, cancer-causing dietary exposure to 
AFB1 occurs at low levels, a condition that is similar to our in vitro conditions that 
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provided evidence for a defective checkpoint response. Defective or negligent G2/M 
checkpoint response to low ionizing radiation exposure has been postulated by 
Löbrich and Jeggo [247] as a potential cause of genomic instability and cancer risk. 
The authors also proposed that a master p53-dependent G1 checkpoint might remain 
effective during negligent G2/M checkpoint for later elimination of escaping cells. 
Our observations strongly suggest that such a salvage pathway would also be 
ineffective against AFB1-induced DNA damage.  
 
In conclusion, our findings provide evidence for a negligent G1 and G2/M checkpoint 
response to AFB1-induced DNA damage. While the permanent G1 and/or G2/M 
arrest, together with apoptosis after Adriamycin treatment protect cells from the 
accumulation of DNA damage induced mutations, partial or negligent G2/M arrest 
and continuation of proliferation of cells in the presence of persistent DNA damage 
after AFB1 exposure may provide a scaffold to the accumulation of mutations (Figure 
5.3.1). This defective response may contribute significantly to potent mutagenicity 
and carcinogenicity of aflatoxins associated with frequent 249 G->T mutations 
affecting TP53 tumor suppressor gene in humans. 
 
 
Figure 5.3.1 Schematic representation of proposed mechanism of response after Adriamycin and AFB1 
exposure 
 
 
 
 
 
 
  121 
1. Parkin, D.M., et al., Estimating the world cancer burden: Globocan 2000. Int 
J Cancer, 2001. 94(2): p. 153-6. 
2. Di Bisceglie, A.M., et al., NIH conference. Hepatocellular carcinoma. Ann 
Intern Med, 1988. 108(3): p. 390-401. 
3. Bosch, F.X., J. Ribes, and J. Borras, Epidemiology of primary liver cancer. 
Semin Liver Dis, 1999. 19(3): p. 271-85. 
4. Parkin, D.M., P. Pisani, and J. Ferlay, Estimates of the worldwide incidence of 
25 major cancers in 1990. Int J Cancer, 1999. 80(6): p. 827-41. 
5. Deuffic, S., et al., Trends in primary liver cancer. Lancet, 1998. 351(9097): p. 
214-5. 
6. El-Serag, H.B. and A.C. Mason, Rising incidence of hepatocellular carcinoma 
in the United States. N Engl J Med, 1999. 340(10): p. 745-50. 
7. Edmondson, H.A. and R.L. Peters, Tumors of the liver: pathologic features. 
Semin Roentgenol, 1983. 18(2): p. 75-83. 
8. Chen, C.J., M.W. Yu, and Y.F. Liaw, Epidemiological characteristics and risk 
factors of hepatocellular carcinoma. J Gastroenterol Hepatol, 1997. 12(9-10): 
p. S294-308. 
9. Hofseth, L.J., et al., Nitric oxide in cancer and chemoprevention. Free Radic 
Biol Med, 2003. 34(8): p. 955-68. 
10. Thorgeirsson, S.S. and J.W. Grisham, Molecular pathogenesis of human 
hepatocellular carcinoma. Nat Genet, 2002. 31(4): p. 339-46. 
11. Ozturk, M., Genetic aspects of hepatocellular carcinogenesis. Semin Liver 
Dis, 1999. 19(3): p. 235-42. 
12. Tannapfel, A. and C. Wittekind, Genes involved in hepatocellular carcinoma: 
deregulation in cell cycling and apoptosis. Virchows Arch, 2002. 440(4): p. 
345-52. 
13. Farazi, P.A. and R.A. DePinho, Hepatocellular carcinoma pathogenesis: from 
genes to environment. Nat Rev Cancer, 2006. 6(9): p. 674-87. 
14. Staib, F., et al., TP53 and liver carcinogenesis. Hum Mutat, 2003. 21(3): p. 
201-16. 
15. Lavanchy, D., Hepatitis B virus epidemiology, disease burden, treatment, and 
current and emerging prevention and control measures. J Viral Hepat, 2004. 
11(2): p. 97-107. 
16. Chisari, F.V., Unscrambling hepatitis C virus-host interactions. Nature, 2005. 
436(7053): p. 930-2. 
17. Bowen, D.G. and C.M. Walker, Adaptive immune responses in acute and 
chronic hepatitis C virus infection. Nature, 2005. 436(7053): p. 946-52. 
18. Aoki, H., et al., Molecular cloning of a rat chromosome putative 
recombinogenic sequence homologous to the hepatitis B virus encapsidation 
signal. Proc Natl Acad Sci U S A, 1996. 93(14): p. 7300-4. 
19. Dejean, A., et al., Hepatitis B virus DNA integration in a sequence 
homologous to v-erb-A and steroid receptor genes in a hepatocellular 
carcinoma. Nature, 1986. 322(6074): p. 70-2. 
20. Wang, J., et al., Hepatitis B virus integration in a cyclin A gene in a 
hepatocellular carcinoma. Nature, 1990. 343(6258): p. 555-7. 
21. Murakami, Y., et al., Large scaled analysis of hepatitis B virus (HBV) DNA 
integration in HBV related hepatocellular carcinomas. Gut, 2005. 54(8): p. 
1162-8. 
22. Ferber, M.J., et al., Integrations of the hepatitis B virus (HBV) and human 
papillomavirus (HPV) into the human telomerase reverse transcriptase 
  122 
(hTERT) gene in liver and cervical cancers. Oncogene, 2003. 22(24): p. 3813-
20. 
23. Horikawa, I. and J.C. Barrett, Transcriptional regulation of the telomerase 
hTERT gene as a target for cellular and viral oncogenic mechanisms. 
Carcinogenesis, 2003. 24(7): p. 1167-76. 
24. Paterlini-Brechot, P., et al., Hepatitis B virus-related insertional mutagenesis 
occurs frequently in human liver cancers and recurrently targets human 
telomerase gene. Oncogene, 2003. 22(25): p. 3911-6. 
25. Andrisani, O.M. and S. Barnabas, The transcriptional function of the hepatitis 
B virus X protein and its role in hepatocarcinogenesis (Review). Int J Oncol, 
1999. 15(2): p. 373-9. 
26. Diao, J., R. Garces, and C.D. Richardson, X protein of hepatitis B virus 
modulates cytokine and growth factor related signal transduction pathways 
during the course of viral infections and hepatocarcinogenesis. Cytokine 
Growth Factor Rev, 2001. 12(2-3): p. 189-205. 
27. Diao, J., et al., X protein of hepatitis B virus inhibits Fas-mediated apoptosis 
and is associated with up-regulation of the SAPK/JNK pathway. J Biol Chem, 
2001. 276(11): p. 8328-40. 
28. Henkler, F., et al., Erk-independent partial activation of AP-1 sites by the 
hepatitis B virus HBx protein. J Gen Virol, 1998. 79 ( Pt 11): p. 2737-42. 
29. Feitelson, M.A., et al., Hepatitis B x antigen and p53 are associated in vitro 
and in liver tissues from patients with primary hepatocellular carcinoma. 
Oncogene, 1993. 8(5): p. 1109-17. 
30. Ueno, Y., et al., Irregular regeneration of hepatocytes is an important factor 
in the hepatocarcinogenesis of liver disease. Hepatology, 2001. 33(2): p. 357-
62. 
31. Gouas, D., H. Shi, and P. Hainaut, The aflatoxin-induced TP53 mutation at 
codon 249 (R249S): biomarker of exposure, early detection and target for 
therapy. Cancer Lett, 2009. 286(1): p. 29-37. 
32. Rehermann, B. and M. Nascimbeni, Immunology of hepatitis B virus and 
hepatitis C virus infection. Nat Rev Immunol, 2005. 5(3): p. 215-29. 
33. Ghosh, A.K., et al., Hepatitis C virus NS5A protein modulates cell cycle 
regulatory genes and promotes cell growth. J Gen Virol, 1999. 80 ( Pt 5): p. 
1179-83. 
34. Shimotohno, K., Hepatitis C virus and its pathogenesis. Semin Cancer Biol, 
2000. 10(3): p. 233-40. 
35. Ray, R.B. and R. Ray, Hepatitis C virus core protein: intriguing properties 
and functional relevance. FEMS Microbiol Lett, 2001. 202(2): p. 149-56. 
36. Dubourdeau, M., et al., Infection of HepG2 cells with recombinant adenovirus 
encoding the HCV core protein induces p21(WAF1) down-regulation -- effect 
of transforming growth factor beta. J Hepatol, 2002. 37(4): p. 486-92. 
37. Shimotohno, K., et al., Hepatitis C virus and its roles in cell proliferation. J 
Gastroenterol, 2002. 37 Suppl 13: p. 50-4. 
38. Qadri, I., M. Iwahashi, and F. Simon, Hepatitis C virus NS5A protein binds 
TBP and p53, inhibiting their DNA binding and p53 interactions with TBP 
and ERCC3. Biochim Biophys Acta, 2002. 1592(2): p. 193-204. 
39. Ray, R.B., et al., Transcriptional repression of p53 promoter by hepatitis C 
virus core protein. J Biol Chem, 1997. 272(17): p. 10983-6. 
  123 
40. Pontisso, P., et al., Hepatitis C virus infection associated with human 
hepatocellular carcinoma: lack of correlation with p53 abnormalities in 
Caucasian patients. Cancer, 1998. 83(8): p. 1489-94. 
41. Ishido, S. and H. Hotta, Complex formation of the nonstructural protein 3 of 
hepatitis C virus with the p53 tumor suppressor. FEBS Lett, 1998. 438(3): p. 
258-62. 
42. Majumder, M., et al., Hepatitis C virus NS5A physically associates with p53 
and regulates p21/waf1 gene expression in a p53-dependent manner. J Virol, 
2001. 75(3): p. 1401-7. 
43. Suriawinata, A. and R. Xu, An update on the molecular genetics of 
hepatocellular carcinoma. Semin Liver Dis, 2004. 24(1): p. 77-88. 
44. Boige, V. and P. Laurent-Puig, [Genetic alterations associated with 
hepatocellular carcinoma]. Gastroenterol Clin Biol, 1997. 21(1): p. 34-44. 
45. Nagai, H., et al., Comprehensive allelotyping of human hepatocellular 
carcinoma. Oncogene, 1997. 14(24): p. 2927-33. 
46. Piao, Z., et al., Allelotype analysis of hepatocellular carcinoma. Int J Cancer, 
1998. 75(1): p. 29-33. 
47. Okabe, H., et al., Comprehensive allelotype study of hepatocellular 
carcinoma: potential differences in pathways to hepatocellular carcinoma 
between hepatitis B virus-positive and -negative tumors. Hepatology, 2000. 
31(5): p. 1073-9. 
48. Laurent-Puig, P., et al., Genetic alterations associated with hepatocellular 
carcinomas define distinct pathways of hepatocarcinogenesis. 
Gastroenterology, 2001. 120(7): p. 1763-73. 
49. Adcox, K., et al., Suppression of hadrons with large transverse momentum in 
central Au+Au collisions at root square[s(NN)] = 130 GeV. Phys Rev Lett, 
2002. 88(2): p. 022301. 
50. Wang, G., et al., Allelic loss and gain, but not genomic instability, as the 
major somatic mutation in primary hepatocellular carcinoma. Genes 
Chromosomes Cancer, 2001. 31(3): p. 221-7. 
51. Nishimura, T., et al., Comprehensive allelotyping of well-differentiated human 
hepatocellular carcinoma with semiquantitative determination of 
chromosomal gain or loss. Genes Chromosomes Cancer, 2002. 35(4): p. 329-
39. 
52. Wong, I.H., et al., Detection of aberrant p16 methylation in the plasma and 
serum of liver cancer patients. Cancer Res, 1999. 59(1): p. 71-3. 
53. Marchio, A., et al., Recurrent chromosomal abnormalities in hepatocellular 
carcinoma detected by comparative genomic hybridization. Genes 
Chromosomes Cancer, 1997. 18(1): p. 59-65. 
54. Marchio, A., et al., Distinct chromosomal abnormality pattern in primary liver 
cancer of non-B, non-C patients. Oncogene, 2000. 19(33): p. 3733-8. 
55. Kusano, N., et al., Genetic aberrations detected by comparative genomic 
hybridization in hepatocellular carcinomas: their relationship to 
clinicopathological features. Hepatology, 1999. 29(6): p. 1858-62. 
56. Sakakura, C., et al., Gains, losses, and amplifications of genomic materials in 
primary gastric cancers analyzed by comparative genomic hybridization. 
Genes Chromosomes Cancer, 1999. 24(4): p. 299-305. 
57. Guan, X.Y., et al., Recurrent chromosome alterations in hepatocellular 
carcinoma detected by comparative genomic hybridization. Genes 
Chromosomes Cancer, 2000. 29(2): p. 110-6. 
  124 
58. Tornillo, L., et al., Marked genetic similarities between hepatitis B virus-
positive and hepatitis C virus-positive hepatocellular carcinomas. J Pathol, 
2000. 192(3): p. 307-12. 
59. Niketeghad, F., et al., Frequent genomic imbalances suggest commonly 
altered tumour genes in human hepatocarcinogenesis. Br J Cancer, 2001. 
85(5): p. 697-704. 
60. Miyoshi, Y., et al., Frequent mutations in the beta-catenin gene in desmoid 
tumors from patients without familial adenomatous polyposis. Oncol Res, 
1998. 10(11-12): p. 591-4. 
61. Oka, Y., et al., M6P/IGF2R tumor suppressor gene mutated in hepatocellular 
carcinomas in Japan. Hepatology, 2002. 35(5): p. 1153-63. 
62. Lengauer, C., K.W. Kinzler, and B. Vogelstein, Genetic instabilities in human 
cancers. Nature, 1998. 396(6712): p. 643-9. 
63. Yano, M., et al., Close correlation between a p53 or hMSH2 gene mutation in 
the tumor and survival of hepatocellular carcinoma patients. Int J Oncol, 
1999. 14(3): p. 447-51. 
64. Kita, R., et al., Infrequent alterations of the p16INK4A gene in liver cancer. 
Int J Cancer, 1996. 67(2): p. 176-80. 
65. Matsuda, Y., et al., p16(INK4) is inactivated by extensive CpG methylation in 
human hepatocellular carcinoma. Gastroenterology, 1999. 116(2): p. 394-400. 
66. Azechi, H., et al., Disruption of the p16/cyclin D1/retinoblastoma protein 
pathway in the majority of human hepatocellular carcinomas. Oncology, 
2001. 60(4): p. 346-54. 
67. Tannapfel, A., et al., INK4a-ARF alterations and p53 mutations in 
hepatocellular carcinomas. Oncogene, 2001. 20(48): p. 7104-9. 
68. Kawamura, N., et al., PTEN/MMAC1 mutations in hepatocellular carcinomas: 
somatic inactivation of both alleles in tumors. Jpn J Cancer Res, 1999. 90(4): 
p. 413-8. 
69. Fujiwara, Y., et al., PTEN / MMAC1 mutation and frequent loss of 
heterozygosity identified in chromosome 10q in a subset of hepatocellular 
carcinomas. Jpn J Cancer Res, 2000. 91(3): p. 287-92. 
70. Nishida, N., et al., Amplification and overexpression of the cyclin D1 gene in 
aggressive human hepatocellular carcinoma. Cancer Res, 1994. 54(12): p. 
3107-10. 
71. Zhang, X., et al., Deletions of chromosome 13q, mutations in Retinoblastoma 
1, and retinoblastoma protein state in human hepatocellular carcinoma. 
Cancer Res, 1994. 54(15): p. 4177-82. 
72. Katagiri, T., Y. Nakamura, and Y. Miki, Mutations in the BRCA2 gene in 
hepatocellular carcinomas. Cancer Res, 1996. 56(20): p. 4575-7. 
73. Satoh, S., et al., AXIN1 mutations in hepatocellular carcinomas, and growth 
suppression in cancer cells by virus-mediated transfer of AXIN1. Nat Genet, 
2000. 24(3): p. 245-50. 
74. Friend, S.H., et al., A human DNA segment with properties of the gene that 
predisposes to retinoblastoma and osteosarcoma. Nature, 1986. 323(6089): p. 
643-6. 
75. Hirai, H., et al., Novel INK4 proteins, p19 and p18, are specific inhibitors of 
the cyclin D-dependent kinases CDK4 and CDK6. Mol Cell Biol, 1995. 15(5): 
p. 2672-81. 
76. Chellappan, S.P., et al., The E2F transcription factor is a cellular target for 
the RB protein. Cell, 1991. 65(6): p. 1053-61. 
  125 
77. Lees, J.A., et al., The retinoblastoma protein is phosphorylated on multiple 
sites by human cdc2. EMBO J, 1991. 10(13): p. 4279-90. 
78. Mittnacht, S., et al., Distinct sub-populations of the retinoblastoma protein 
show a distinct pattern of phosphorylation. EMBO J, 1994. 13(1): p. 118-27. 
79. Conner, E.A., et al., Dual functions of E2F-1 in a transgenic mouse model of 
liver carcinogenesis. Oncogene, 2000. 19(44): p. 5054-62. 
80. Santoni-Rugiu, E., et al., Evolution of neoplastic development in the liver of 
transgenic mice co-expressing c-myc and transforming growth factor-alpha. 
Am J Pathol, 1996. 149(2): p. 407-28. 
81. Nelsen, C.J., et al., Transient expression of cyclin D1 is sufficient to promote 
hepatocyte replication and liver growth in vivo. Cancer Res, 2001. 61(23): p. 
8564-8. 
82. Nelsen, C.J., et al., Evidence that cyclin D1 mediates both growth and 
proliferation downstream of TOR in hepatocytes. J Biol Chem, 2003. 278(6): 
p. 3656-63. 
83. Nelsen, C.J., et al., Amino acids regulate hepatocyte proliferation through 
modulation of cyclin D1 expression. J Biol Chem, 2003. 278(28): p. 25853-8. 
84. Rickheim, D.G., et al., Differential regulation of cyclins D1 and D3 in 
hepatocyte proliferation. Hepatology, 2002. 36(1): p. 30-8. 
85. Iakova, P., S.S. Awad, and N.A. Timchenko, Aging reduces proliferative 
capacities of liver by switching pathways of C/EBPalpha growth arrest. Cell, 
2003. 113(4): p. 495-506. 
86. Kamijo, T., et al., Functional and physical interactions of the ARF tumor 
suppressor with p53 and Mdm2. Proc Natl Acad Sci U S A, 1998. 95(14): p. 
8292-7. 
87. Liew, C.T., et al., Frequent allelic loss on chromosome 9 in hepatocellular 
carcinoma. Int J Cancer, 1999. 81(3): p. 319-24. 
88. Akhurst, R.J. and R. Derynck, TGF-beta signaling in cancer--a double-edged 
sword. Trends Cell Biol, 2001. 11(11): p. S44-51. 
89. Schnur, J., et al., Chemical hepatocarcinogenesis in transgenic mice 
overexpressing mature TGF beta-1 in liver. Eur J Cancer, 1999. 35(13): p. 
1842-5. 
90. Ghosh, P., et al., Cardiac reoperations in octogenerians. Eur J Cardiothorac 
Surg, 1999. 15(6): p. 809-15. 
91. Im, Y.H., et al., Heterozygous mice for the transforming growth factor-beta 
type II receptor gene have increased susceptibility to hepatocellular 
carcinogenesis. Cancer Res, 2001. 61(18): p. 6665-8. 
92. Paik, S.Y., et al., Expression of transforming growth factor-beta1 and 
transforming growth factor-beta receptors in hepatocellular carcinoma and 
dysplastic nodules. Mod Pathol, 2003. 16(1): p. 86-96. 
93. Senturk, S., et al., Transforming growth factor-beta induces senescence in 
hepatocellular carcinoma cells and inhibits tumor growth. Hepatology, 2010. 
94. Vivanco, I. and C.L. Sawyers, The phosphatidylinositol 3-Kinase AKT 
pathway in human cancer. Nat Rev Cancer, 2002. 2(7): p. 489-501. 
95. Wang, L., et al., Epigenetic and genetic alterations of PTEN in hepatocellular 
carcinoma. Hepatol Res, 2007. 37(5): p. 389-396. 
96. Villanueva, A., et al., Pivotal role of mTOR signaling in hepatocellular 
carcinoma. Gastroenterology, 2008. 135(6): p. 1972-83, 1983 e1-11. 
97. Bellacosa, A., et al., Akt activation by growth factors is a multiple-step 
process: the role of the PH domain. Oncogene, 1998. 17(3): p. 313-25. 
  126 
98. Schmitz, K.J., et al., Activation of the ERK and AKT signalling pathway 
predicts poor prognosis in hepatocellular carcinoma and ERK activation in 
cancer tissue is associated with hepatitis C virus infection. J Hepatol, 2008. 
48(1): p. 83-90. 
99. Amaravadi, R. and C.B. Thompson, The survival kinases Akt and Pim as 
potential pharmacological targets. J Clin Invest, 2005. 115(10): p. 2618-24. 
100. Lee, T.K., et al., FTY720 induces apoptosis of human hepatoma cell lines 
through PI3-K-mediated Akt dephosphorylation. Carcinogenesis, 2004. 
25(12): p. 2397-405. 
101. Huynh, H., et al., RAD001 (everolimus) inhibits tumour growth in xenograft 
models of human hepatocellular carcinoma. J Cell Mol Med, 2009. 13(7): p. 
1371-80. 
102. Pang, J.Z., et al., Loss of heterozygosity at D8S298 is a predictor for long-term 
survival of patients with tumor-node-metastasis stage I of hepatocellular 
carcinoma. Clin Cancer Res, 2007. 13(24): p. 7363-9. 
103. Rizell, M., et al., Effects of the mTOR inhibitor sirolimus in patients with 
hepatocellular and cholangiocellular cancer. Int J Clin Oncol, 2008. 13(1): p. 
66-70. 
104. Huynh, H., Tyrosine kinase inhibitors to treat liver cancer. Expert Opin 
Emerg Drugs, 2010. 15(1): p. 13-26. 
105. Hussain, S.P. and C.C. Harris, p53 biological network: at the crossroads of 
the cellular-stress response pathway and molecular carcinogenesis. J Nippon 
Med Sch, 2006. 73(2): p. 54-64. 
106. Lane, D.P., Cancer. p53, guardian of the genome. Nature, 1992. 358(6381): p. 
15-6. 
107. Venkatachalam, S., et al., Retention of wild-type p53 in tumors from p53 
heterozygous mice: reduction of p53 dosage can promote cancer formation. 
EMBO J, 1998. 17(16): p. 4657-67. 
108. Lynch, C.J. and J. Milner, Loss of one p53 allele results in four-fold reduction 
of p53 mRNA and protein: a basis for p53 haplo-insufficiency. Oncogene, 
2006. 25(24): p. 3463-70. 
109. Vousden, K.H. and D.P. Lane, p53 in health and disease. Nat Rev Mol Cell 
Biol, 2007. 8(4): p. 275-83. 
110. Hollstein, M., et al., p53 mutations in human cancers. Science, 1991. 
253(5015): p. 49-53. 
111. Iwakuma, T., G. Lozano, and E.R. Flores, Li-Fraumeni syndrome: a p53 
family affair. Cell Cycle, 2005. 4(7): p. 865-7. 
112. Harms, K.L. and X. Chen, The functional domains in p53 family proteins 
exhibit both common and distinct properties. Cell Death Differ, 2006. 13(6): 
p. 890-7. 
113. Oliner, J.D., et al., Oncoprotein MDM2 conceals the activation domain of 
tumour suppressor p53. Nature, 1993. 362(6423): p. 857-60. 
114. Honda, R., H. Tanaka, and H. Yasuda, Oncoprotein MDM2 is a ubiquitin 
ligase E3 for tumor suppressor p53. FEBS Lett, 1997. 420(1): p. 25-7. 
115. Riley, T., et al., Transcriptional control of human p53-regulated genes. Nat 
Rev Mol Cell Biol, 2008. 9(5): p. 402-12. 
116. Bell, H.S., et al., A p53-derived apoptotic peptide derepresses p73 to cause 
tumor regression in vivo. J Clin Invest, 2007. 117(4): p. 1008-18. 
117. Hernandez-Boussard, T., et al., IARC p53 mutation database: a relational 
database to compile and analyze p53 mutations in human tumors and cell 
  127 
lines. International Agency for Research on Cancer. Hum Mutat, 1999. 14(1): 
p. 1-8. 
118. Soussi, T., p53 alterations in human cancer: more questions than answers. 
Oncogene, 2007. 26(15): p. 2145-56. 
119. Bykov, V.J., G. Selivanova, and K.G. Wiman, Small molecules that reactivate 
mutant p53. Eur J Cancer, 2003. 39(13): p. 1828-34. 
120. Cho, Y., et al., Crystal structure of a p53 tumor suppressor-DNA complex: 
understanding tumorigenic mutations. Science, 1994. 265(5170): p. 346-55. 
121. Bossi, G., et al., Mutant p53 gain of function: reduction of tumor malignancy 
of human cancer cell lines through abrogation of mutant p53 expression. 
Oncogene, 2006. 25(2): p. 304-9. 
122. Cadwell, C. and G.P. Zambetti, The effects of wild-type p53 tumor suppressor 
activity and mutant p53 gain-of-function on cell growth. Gene, 2001. 277(1-
2): p. 15-30. 
123. Lang, G.A., et al., Gain of function of a p53 hot spot mutation in a mouse 
model of Li-Fraumeni syndrome. Cell, 2004. 119(6): p. 861-72. 
124. Olive, K.P., et al., Mutant p53 gain of function in two mouse models of Li-
Fraumeni syndrome. Cell, 2004. 119(6): p. 847-60. 
125. Kastan, M.B. and E. Berkovich, p53: a two-faced cancer gene. Nat Cell Biol, 
2007. 9(5): p. 489-91. 
126. Qin, L.X. and Z.Y. Tang, The prognostic molecular markers in hepatocellular 
carcinoma. World J Gastroenterol, 2002. 8(3): p. 385-92. 
127. Xue, W., et al., Senescence and tumour clearance is triggered by p53 
restoration in murine liver carcinomas. Nature, 2007. 445(7128): p. 656-60. 
128. Teoh, N.C., et al., Defective DNA strand break repair causes chromosomal 
instability and accelerates liver carcinogenesis in mice. Hepatology, 2008. 
47(6): p. 2078-88. 
129. Farazi, P.A., et al., Differential impact of telomere dysfunction on initiation 
and progression of hepatocellular carcinoma. Cancer Res, 2003. 63(16): p. 
5021-7. 
130. Wiemann, S.U., et al., Hepatocyte telomere shortening and senescence are 
general markers of human liver cirrhosis. FASEB J, 2002. 16(9): p. 935-42. 
131. Plentz, R.R., et al., Hepatocellular telomere shortening correlates with 
chromosomal instability and the development of human hepatoma. 
Hepatology, 2004. 40(1): p. 80-6. 
132. Lund, A.H. and M. van Lohuizen, Epigenetics and cancer. Genes Dev, 2004. 
18(19): p. 2315-35. 
133. Esteller, M., Epigenetics in cancer. N Engl J Med, 2008. 358(11): p. 1148-59. 
134. Kouzarides, T., Chromatin modifications and their function. Cell, 2007. 
128(4): p. 693-705. 
135. Heintzman, N.D., et al., Histone modifications at human enhancers reflect 
global cell-type-specific gene expression. Nature, 2009. 459(7243): p. 108-12. 
136. Komashko, V.M., et al., Using ChIP-chip technology to reveal common 
principles of transcriptional repression in normal and cancer cells. Genome 
Res, 2008. 18(4): p. 521-32. 
137. Abbott, D.P. and N.A. Edmondson, Neuronal ceroid-lipofuscin storage in a 
cynomolgus monkey (Macaca fascicularis). Lab Anim, 1983. 17(1): p. 18-20. 
138. Ke, X.S., et al., Genome-wide profiling of histone h3 lysine 4 and lysine 27 
trimethylation reveals an epigenetic signature in prostate carcinogenesis. 
PLoS One, 2009. 4(3): p. e4687. 
  128 
139. Kondo, Y., et al., Gene silencing in cancer by histone H3 lysine 27 
trimethylation independent of promoter DNA methylation. Nat Genet, 2008. 
40(6): p. 741-50. 
140. Yu, J., et al., A polycomb repression signature in metastatic prostate cancer 
predicts cancer outcome. Cancer Res, 2007. 67(22): p. 10657-63. 
141. Wu, J., et al., Diverse histone modifications on histone 3 lysine 9 and their 
relation to DNA methylation in specifying gene silencing. BMC Genomics, 
2007. 8: p. 131. 
142. Krivtsov, A.V., et al., H3K79 methylation profiles define murine and human 
MLL-AF4 leukemias. Cancer Cell, 2008. 14(5): p. 355-68. 
143. Fraga, M.F., et al., Loss of acetylation at Lys16 and trimethylation at Lys20 of 
histone H4 is a common hallmark of human cancer. Nat Genet, 2005. 37(4): p. 
391-400. 
144. Pogribny, I.P., et al., Histone H3 lysine 9 and H4 lysine 20 trimethylation and 
the expression of Suv4-20h2 and Suv-39h1 histone methyltransferases in 
hepatocarcinogenesis induced by methyl deficiency in rats. Carcinogenesis, 
2006. 27(6): p. 1180-6. 
145. Boffetta, P. and M. Hashibe, Alcohol and cancer. Lancet Oncol, 2006. 7(2): p. 
149-56. 
146. Donato, F., et al., Southern Europe as an example of interaction between 
various environmental factors: a systematic review of the epidemiologic 
evidence. Oncogene, 2006. 25(27): p. 3756-70. 
147. Kuper, H., et al., The risk of liver and bile duct cancer in patients with chronic 
viral hepatitis, alcoholism, or cirrhosis. Hepatology, 2001. 34(4 Pt 1): p. 714-
8. 
148. Ekstrom, G. and M. Ingelman-Sundberg, Rat liver microsomal NADPH-
supported oxidase activity and lipid peroxidation dependent on ethanol-
inducible cytochrome P-450 (P-450IIE1). Biochem Pharmacol, 1989. 38(8): p. 
1313-9. 
149. Albano, E., S.W. French, and M. Ingelman-Sundberg, Hydroxyethyl radicals 
in ethanol hepatotoxicity. Front Biosci, 1999. 4: p. D533-40. 
150. Dreosti, I.E., et al., The effect of ethanol and acetaldehyde on DNA synthesis 
in growing cells and on fetal development in the rat. Alcohol Clin Exp Res, 
1981. 5(3): p. 357-62. 
151. Sun, A.Y., et al., Ethanol and oxidative stress. Alcohol Clin Exp Res, 2001. 
25(5 Suppl ISBRA): p. 237S-243S. 
152. Lieber, C.S., Biochemical mechanisms of alcohol-induced hepatic injury. 
Alcohol Alcohol Suppl, 1991. 1: p. 283-90. 
153. McKillop, I.H. and L.W. Schrum, Alcohol and liver cancer. Alcohol, 2005. 
35(3): p. 195-203. 
154. Caldwell, S.H., et al., Obesity and hepatocellular carcinoma. 
Gastroenterology, 2004. 127(5 Suppl 1): p. S97-103. 
155. Bugianesi, E., et al., Expanding the natural history of nonalcoholic 
steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma. 
Gastroenterology, 2002. 123(1): p. 134-40. 
156. Wolk, A., et al., A prospective study of obesity and cancer risk (Sweden). 
Cancer Causes Control, 2001. 12(1): p. 13-21. 
157. Bugianesi, E., Non-alcoholic steatohepatitis and cancer. Clin Liver Dis, 2007. 
11(1): p. 191-207, x-xi. 
  129 
158. Navarro-Alarcon, M., et al., Selenium concentrations in serum of individuals 
with liver diseases (cirrhosis or hepatitis): relationship with some nutritional 
and biochemical markers. Sci Total Environ, 2002. 291(1-3): p. 135-41. 
159. Bellinger, F.P., et al., Regulation and function of selenoproteins in human 
disease. Biochem J, 2009. 422(1): p. 11-22. 
160. Hartikainen, H., Biogeochemistry of selenium and its impact on food chain 
quality and human health. J Trace Elem Med Biol, 2005. 18(4): p. 309-18. 
161. Caurant, F., M. Navarro, and J.C. Amiard, Mercury in pilot whales: possible 
limits to the detoxification process. Sci Total Environ, 1996. 186(1-2): p. 95-
104. 
162. Thorne, M.C., Estimation of animal transfer factors for radioactive isotopes of 
iodine, technetium, selenium and uranium. J Environ Radioact, 2003. 70(1-2): 
p. 3-20. 
163. Cabanero, A.I., Y. Madrid, and C. Camara, Mercury-selenium species ratio in 
representative fish samples and their bioaccessibility by an in vitro digestion 
method. Biol Trace Elem Res, 2007. 119(3): p. 195-211. 
164. Kibriya, M.G., et al., Changes in gene expression profiles in response to 
selenium supplementation among individuals with arsenic-induced pre-
malignant skin lesions. Toxicol Lett, 2007. 169(2): p. 162-76. 
165. Mousa, S.A., et al., Pro-angiogenesis action of arsenic and its reversal by 
selenium-derived compounds. Carcinogenesis, 2007. 28(5): p. 962-7. 
166. Beck, M.A. and C.C. Matthews, Micronutrients and host resistance to viral 
infection. Proc Nutr Soc, 2000. 59(4): p. 581-5. 
167. Beck, M.A., et al., Selenium deficiency increases the pathology of an influenza 
virus infection. FASEB J, 2001. 15(8): p. 1481-3. 
168. Beck, M.A., et al., Benign human enterovirus becomes virulent in selenium-
deficient mice. J Med Virol, 1994. 43(2): p. 166-70. 
169. Hori, K., et al., Selenium supplementation suppresses tumor necrosis factor 
alpha-induced human immunodeficiency virus type 1 replication in vitro. 
AIDS Res Hum Retroviruses, 1997. 13(15): p. 1325-32. 
170. Goldstein, B.J., et al., Role of insulin-induced reactive oxygen species in the 
insulin signaling pathway. Antioxid Redox Signal, 2005. 7(7-8): p. 1021-31. 
171. Dizdaroglu, M., Oxidative damage to DNA in mammalian chromatin. Mutat 
Res, 1992. 275(3-6): p. 331-42. 
172. Papp, L.V., et al., From selenium to selenoproteins: synthesis, identity, and 
their role in human health. Antioxid Redox Signal, 2007. 9(7): p. 775-806. 
173. Maiorino, M., et al., Probing the presumed catalytic triad of selenium-
containing peroxidases by mutational analysis of phospholipid hydroperoxide 
glutathione peroxidase (PHGPx). Biol Chem Hoppe Seyler, 1995. 376(11): p. 
651-60. 
174. Gladyshev, V.N., K.T. Jeang, and T.C. Stadtman, Selenocysteine, identified as 
the penultimate C-terminal residue in human T-cell thioredoxin reductase, 
corresponds to TGA in the human placental gene. Proc Natl Acad Sci U S A, 
1996. 93(12): p. 6146-51. 
175. Brigelius-Flohe, R., Tissue-specific functions of individual glutathione 
peroxidases. Free Radic Biol Med, 1999. 27(9-10): p. 951-65. 
176. Bjornstedt, M., S. Kumar, and A. Holmgren, Selenite and selenodiglutathione: 
reactions with thioredoxin systems. Methods Enzymol, 1995. 252: p. 209-19. 
177. Zhong, L., E.S. Arner, and A. Holmgren, Structure and mechanism of 
mammalian thioredoxin reductase: the active site is a redox-active 
  130 
selenolthiol/selenenylsulfide formed from the conserved cysteine-
selenocysteine sequence. Proc Natl Acad Sci U S A, 2000. 97(11): p. 5854-9. 
178. Rubartelli, A., et al., Secretion of thioredoxin by normal and neoplastic cells 
through a leaderless secretory pathway. J Biol Chem, 1992. 267(34): p. 
24161-4. 
179. Rhee, S.G., H.Z. Chae, and K. Kim, Peroxiredoxins: a historical overview and 
speculative preview of novel mechanisms and emerging concepts in cell 
signaling. Free Radic Biol Med, 2005. 38(12): p. 1543-52. 
180. Claycombe, K.J. and S.N. Meydani, Vitamin E and genome stability. Mutat 
Res, 2001. 475(1-2): p. 37-44. 
181. Jackson, M.I. and G.F. Combs, Jr., Selenium and anticarcinogenesis: 
underlying mechanisms. Curr Opin Clin Nutr Metab Care, 2008. 11(6): p. 718-
26. 
182. Squires, J. and M.J. Berry, Selenium, selenoproteins, and cancer. Hawaii Med 
J, 2006. 65(8): p. 239-40. 
183. Foster, C.B., et al., Polymorphism analysis of six selenoprotein genes: support 
for a selective sweep at the glutathione peroxidase 1 locus (3p21) in Asian 
populations. BMC Genet, 2006. 7: p. 56. 
184. Hu, Y., et al., Allelic loss of the gene for the GPX1 selenium-containing 
protein is a common event in cancer. J Nutr, 2005. 135(12 Suppl): p. 3021S-
3024S. 
185. Hu, Y.J. and A.M. Diamond, Role of glutathione peroxidase 1 in breast 
cancer: loss of heterozygosity and allelic differences in the response to 
selenium. Cancer Res, 2003. 63(12): p. 3347-51. 
186. Al-Taie, O.H., et al., Expression profiling and genetic alterations of the 
selenoproteins GI-GPx and SePP in colorectal carcinogenesis. Nutr Cancer, 
2004. 48(1): p. 6-14. 
187. Bermano, G., et al., Evidence that a polymorphism within the 3'UTR of 
glutathione peroxidase 4 is functional and is associated with susceptibility to 
colorectal cancer. Genes Nutr, 2007. 2(2): p. 225-32. 
188. Jablonska, E., et al., Association between GPx1 Pro198Leu polymorphism, 
GPx1 activity and plasma selenium concentration in humans. Eur J Nutr, 
2009. 48(6): p. 383-6. 
189. Diwadkar-Navsariwala, V. and A.M. Diamond, The link between selenium 
and chemoprevention: a case for selenoproteins. J Nutr, 2004. 134(11): p. 
2899-902. 
190. Geoghegan, M., et al., Selenium in critical illness. Curr Opin Crit Care, 2006. 
12(2): p. 136-41. 
191. Berry, M.J., et al., Selenocysteine incorporation directed from the 3'UTR: 
characterization of eukaryotic EFsec and mechanistic implications. 
Biofactors, 2001. 14(1-4): p. 17-24. 
192. Czuczejko, J., et al., Selenium, glutathione and glutathione peroxidases in 
blood of patients with chronic liver diseases. Acta Biochim Pol, 2003. 50(4): 
p. 1147-54. 
193. Navarro-Alarcon, M. and C. Cabrera-Vique, Selenium in food and the human 
body: a review. Sci Total Environ, 2008. 400(1-3): p. 115-41. 
194. Yu, S.Y., Y.J. Zhu, and W.G. Li, Protective role of selenium against hepatitis 
B virus and primary liver cancer in Qidong. Biol Trace Elem Res, 1997. 
56(1): p. 117-24. 
  131 
195. Nakabayashi, H., et al., Growth of human hepatoma cells lines with 
differentiated functions in chemically defined medium. Cancer Res, 1982. 
42(9): p. 3858-63. 
196. Baker, R.D., et al., Selenium regulation of glutathione peroxidase in human 
hepatoma cell line Hep3B. Arch Biochem Biophys, 1993. 304(1): p. 53-7. 
197. Irmak, M.B., et al., Acquired tolerance of hepatocellular carcinoma cells to 
selenium deficiency: a selective survival mechanism? Cancer Res, 2003. 
63(20): p. 6707-15. 
198. Clark, L.C., et al., Effects of selenium supplementation for cancer prevention 
in patients with carcinoma of the skin. A randomized controlled trial. 
Nutritional Prevention of Cancer Study Group. JAMA, 1996. 276(24): p. 
1957-63. 
199. Combs, G.F., Jr., Chemopreventive mechanisms of selenium. Med Klin 
(Munich), 1999. 94 Suppl 3: p. 18-24. 
200. Martindale, J.L. and N.J. Holbrook, Cellular response to oxidative stress: 
signaling for suicide and survival. J Cell Physiol, 2002. 192(1): p. 1-15. 
201. Kim, I.Y. and T.C. Stadtman, Inhibition of NF-kappaB DNA binding and 
nitric oxide induction in human T cells and lung adenocarcinoma cells by 
selenite treatment. Proc Natl Acad Sci U S A, 1997. 94(24): p. 12904-7. 
202. Park, H.S., et al., Selenite inhibits the c-Jun N-terminal kinase/stress-activated 
protein kinase (JNK/SAPK) through a thiol redox mechanism. J Biol Chem, 
2000. 275(4): p. 2527-31. 
203. Park, H.S., et al., Selenite negatively regulates caspase-3 through a redox 
mechanism. J Biol Chem, 2000. 275(12): p. 8487-91. 
204. Yoon, S.O., et al., Selenite suppresses hydrogen peroxide-induced cell 
apoptosis through inhibition of ASK1/JNK and activation of PI3-K/Akt 
pathways. FASEB J, 2002. 16(1): p. 111-3. 
205. Lee, Y.C., et al., Selenite-induced survival of HuH7 hepatoma cells involves 
activation of focal adhesion kinase-phosphatidylinositol 3-kinase-Akt pathway 
and Rac1. J Biol Chem, 2003. 278(41): p. 39615-24. 
206. IARC monographs on the evaluation of carcinogenic risks to humans. Volume 
97. 1,3-butadiene, ethylene oxide and vinyl halides (vinyl fluoride, vinyl 
chloride and vinyl bromide). IARC Monogr Eval Carcinog Risks Hum, 2008. 
97: p. 3-471. 
207. Cumulative Index to IARC monographs on the evaluation of the carcinogenic 
risk of chemicals to humans. IARC Monogr Eval Carcinog Risk Chem Hum, 
1986. 39: p. 379-403. 
208. Chen, C.J., et al., Cancer potential in liver, lung, bladder and kidney due to 
ingested inorganic arsenic in drinking water. Br J Cancer, 1992. 66(5): p. 
888-92. 
209. Vainio, H., E. Heseltine, and J. Wilbourn, Report on an IARC working group 
meeting on some naturally occurring substances. Int J Cancer, 1993. 53(4): p. 
535-7. 
210. Puisieux, A., et al., Selective targeting of p53 gene mutational hotspots in 
human cancers by etiologically defined carcinogens. Cancer Res, 1991. 
51(22): p. 6185-9. 
211. Barbin, A., et al., p53 gene mutation pattern in rat liver tumors induced by 
vinyl chloride. Cancer Res, 1997. 57(9): p. 1695-8. 
212. Bressac, B., et al., Selective G to T mutations of p53 gene in hepatocellular 
carcinoma from southern Africa. Nature, 1991. 350(6317): p. 429-31. 
  132 
213. Hsu, I.C., et al., Mutational hotspot in the p53 gene in human hepatocellular 
carcinomas. Nature, 1991. 350(6317): p. 427-8. 
214. Lee, Y.I., et al., Activation of the insulin-like growth factor II transcription by 
aflatoxin B1 induced p53 mutant 249 is caused by activation of transcription 
complexes; implications for a gain-of-function during the formation of 
hepatocellular carcinoma. Oncogene, 2000. 19(33): p. 3717-26. 
215. Busby, W.F., Jr., et al., Tumorigenicity of fluoranthene in a newborn mouse 
lung adenoma bioassay. Carcinogenesis, 1984. 5(10): p. 1311-6. 
216. Galvano, F., et al., Survey of the occurrence of aflatoxin M1 in dairy products 
marketed in Italy: second year of observation. Food Addit Contam, 2001. 
18(7): p. 644-6. 
217. Wild, C.P. and Y.Y. Gong, Mycotoxins and human disease: a largely ignored 
global health issue. Carcinogenesis, 2010. 31(1): p. 71-82. 
218. Liu, Y. and F. Wu, Global burden of aflatoxin-induced hepatocellular 
carcinoma: a risk assessment. Environ Health Perspect, 2010. 118(6): p. 818-
24. 
219. Wild, C.P. and R. Montesano, A model of interaction: aflatoxins and hepatitis 
viruses in liver cancer aetiology and prevention. Cancer Lett, 2009. 286(1): p. 
22-8. 
220. Smela, M.E., et al., The chemistry and biology of aflatoxin B(1): from 
mutational spectrometry to carcinogenesis. Carcinogenesis, 2001. 22(4): p. 
535-45. 
221. Croy, R.G. and G.N. Wogan, Temporal patterns of covalent DNA adducts in 
rat liver after single and multiple doses of aflatoxin B1. Cancer Res, 1981. 
41(1): p. 197-203. 
222. Smela, M.E., et al., The aflatoxin B(1) formamidopyrimidine adduct plays a 
major role in causing the types of mutations observed in human hepatocellular 
carcinoma. Proc Natl Acad Sci U S A, 2002. 99(10): p. 6655-60. 
223. Shen, H.M., et al., Aflatoxin B1-induced 8-hydroxydeoxyguanosine formation 
in rat hepatic DNA. Carcinogenesis, 1995. 16(2): p. 419-22. 
224. Yarborough, A., et al., Immunoperoxidase detection of 8-
hydroxydeoxyguanosine in aflatoxin B1-treated rat liver and human oral 
mucosal cells. Cancer Res, 1996. 56(4): p. 683-8. 
225. Wang, J.S. and J.D. Groopman, DNA damage by mycotoxins. Mutat Res, 
1999. 424(1-2): p. 167-81. 
226. Foster, P.L., E. Eisenstadt, and J.H. Miller, Base substitution mutations 
induced by metabolically activated aflatoxin B1. Proc Natl Acad Sci U S A, 
1983. 80(9): p. 2695-8. 
227. Loechler, E.L., A violation of the Swain-Scott principle, and not SN1 versus 
SN2 reaction mechanisms, explains why carcinogenic alkylating agents can 
form different proportions of adducts at oxygen versus nitrogen in DNA. 
Chem Res Toxicol, 1994. 7(3): p. 277-80. 
228. Bedard, L.L. and T.E. Massey, Aflatoxin B1-induced DNA damage and its 
repair. Cancer Lett, 2006. 241(2): p. 174-83. 
229. Ozturk, M., p53 mutation in hepatocellular carcinoma after aflatoxin 
exposure. Lancet, 1991. 338(8779): p. 1356-9. 
230. Aguilar, F., et al., Geographic variation of p53 mutational profile in 
nonmalignant human liver. Science, 1994. 264(5163): p. 1317-9. 
  133 
231. Kirk, G.D., et al., 249(ser) TP53 mutation in plasma DNA, hepatitis B viral 
infection, and risk of hepatocellular carcinoma. Oncogene, 2005. 24(38): p. 
5858-67. 
232. Bullock, A.N., J. Henckel, and A.R. Fersht, Quantitative analysis of residual 
folding and DNA binding in mutant p53 core domain: definition of mutant 
states for rescue in cancer therapy. Oncogene, 2000. 19(10): p. 1245-56. 
233. Song, H., M. Hollstein, and Y. Xu, p53 gain-of-function cancer mutants 
induce genetic instability by inactivating ATM. Nat Cell Biol, 2007. 9(5): p. 
573-80. 
234. Finlay, C.A., P.W. Hinds, and A.J. Levine, The p53 proto-oncogene can act as 
a suppressor of transformation. Cell, 1989. 57(7): p. 1083-93. 
235. Hinds, P.W., et al., Mutant p53 DNA clones from human colon carcinomas 
cooperate with ras in transforming primary rat cells: a comparison of the "hot 
spot" mutant phenotypes. Cell Growth Differ, 1990. 1(12): p. 571-80. 
236. Preuss, U., R. Kreutzfeld, and K.H. Scheidtmann, Tumor-derived p53 mutant 
C174Y is a gain-of-function mutant which activates the fos promoter and 
enhances colony formation. Int J Cancer, 2000. 88(2): p. 162-71. 
237. Ponchel, F., et al., Hepatocarcinoma-specific mutant p53-249ser induces 
mitotic activity but has no effect on transforming growth factor beta 1-
mediated apoptosis. Cancer Res, 1994. 54(8): p. 2064-8. 
238. Ghebranious, N. and S. Sell, The mouse equivalent of the human p53ser249 
mutation p53ser246 enhances aflatoxin hepatocarcinogenesis in hepatitis B 
surface antigen transgenic and p53 heterozygous null mice. Hepatology, 1998. 
27(4): p. 967-73. 
239. Schleger, C., et al., The human p53 gene mutated at position 249 per se is not 
sufficient to immortalize human liver cells. Hepatology, 1999. 29(3): p. 834-8. 
240. Yin, L., et al., Control of mouse hepatocyte proliferation and ploidy by p53 
and p53ser246 mutation in vivo. Hepatology, 1998. 27(1): p. 73-80. 
241. Shi, H., et al., In vitro and in vivo cytotoxic effects of PRIMA-1 on 
hepatocellular carcinoma cells expressing mutant p53ser249. Carcinogenesis, 
2008. 29(7): p. 1428-34. 
242. Bykov, V.J., et al., Restoration of the tumor suppressor function to mutant p53 
by a low-molecular-weight compound. Nat Med, 2002. 8(3): p. 282-8. 
243. Hulla, J.E., Z.Y. Chen, and D.L. Eaton, Aflatoxin B1-induced rat hepatic 
hyperplastic nodules do not exhibit a site-specific mutation within the p53 
gene. Cancer Res, 1993. 53(1): p. 9-11. 
244. Tong, W.M., et al., Aflatoxin-B exposure does not lead to p53 mutations but 
results in enhanced liver cancer of Hupki (human p53 knock-in) mice. Int J 
Cancer, 2006. 119(4): p. 745-9. 
245. Lee, M.K. and K. Sabapathy, The R246S hot-spot p53 mutant exerts 
dominant-negative effects in embryonic stem cells in vitro and in vivo. J Cell 
Sci, 2008. 121(Pt 11): p. 1899-906. 
246. Sancar, A., et al., Molecular mechanisms of mammalian DNA repair and the 
DNA damage checkpoints. Annu Rev Biochem, 2004. 73: p. 39-85. 
247. Lobrich, M. and P.A. Jeggo, The impact of a negligent G2/M checkpoint on 
genomic instability and cancer induction. Nat Rev Cancer, 2007. 7(11): p. 
861-9. 
248. Oleykowski, C.A., et al., Repair of aflatoxin B1 DNA adducts by the UvrABC 
endonuclease of Escherichia coli. J Biol Chem, 1993. 268(11): p. 7990-8002. 
  134 
249. Guo, Y., et al., Expression of a human cytochrome p450 in yeast permits 
analysis of pathways for response to and repair of aflatoxin-induced DNA 
damage. Mol Cell Biol, 2005. 25(14): p. 5823-33. 
250. Keller-Seitz, M.U., et al., Transcriptional response of yeast to aflatoxin B1: 
recombinational repair involving RAD51 and RAD1. Mol Biol Cell, 2004. 
15(9): p. 4321-36. 
251. Leadon, S.A., R.M. Tyrrell, and P.A. Cerutti, Excision repair of aflatoxin B1-
DNA adducts in human fibroblasts. Cancer Res, 1981. 41(12 Pt 1): p. 5125-9. 
252. Levy, D.D., et al., Sequence specificity of aflatoxin B1-induced mutations in a 
plasmid replicated in xeroderma pigmentosum and DNA repair proficient 
human cells. Cancer Res, 1992. 52(20): p. 5668-73. 
253. Friedberg, E.C., R. Wagner, and M. Radman, Specialized DNA polymerases, 
cellular survival, and the genesis of mutations. Science, 2002. 296(5573): p. 
1627-30. 
254. Bedard, L.L., et al., Susceptibility to aflatoxin B1-induced carcinogenesis 
correlates with tissue-specific differences in DNA repair activity in mouse and 
in rat. Cancer Res, 2005. 65(4): p. 1265-70. 
255. Bailey, E.A., et al., Mutational properties of the primary aflatoxin B1-DNA 
adduct. Proc Natl Acad Sci U S A, 1996. 93(4): p. 1535-9. 
256. Cagatay, T. and M. Ozturk, P53 mutation as a source of aberrant beta-catenin 
accumulation in cancer cells. Oncogene, 2002. 21(52): p. 7971-80. 
257. Bunz, F., et al., Requirement for p53 and p21 to sustain G2 arrest after DNA 
damage. Science, 1998. 282(5393): p. 1497-501. 
258. Dreiem, A. and F. Fonnum, Thiophene is toxic to cerebellar granule cells in 
culture after bioactivation by rat liver enzymes. Neurotoxicology, 2004. 25(6): 
p. 959-66. 
259. Erexson, G.L., M.V. Periago, and C.S. Spicer, Differential sensitivity of 
Chinese hamster V79 and Chinese hamster ovary (CHO) cells in the in vitro 
micronucleus screening assay. Mutat Res, 2001. 495(1-2): p. 75-80. 
260. Dimri, G.P., et al., A biomarker that identifies senescent human cells in 
culture and in aging skin in vivo. Proc Natl Acad Sci U S A, 1995. 92(20): p. 
9363-7. 
261. Hsieh, L.L., et al., Immunological detection of aflatoxin B1-DNA adducts 
formed in vivo. Cancer Res, 1988. 48(22): p. 6328-31. 
262. Olive, P.L. and J.P. Banath, Detection of DNA double-strand breaks through 
the cell cycle after exposure to X-rays, bleomycin, etoposide and 125IdUrd. 
Int J Radiat Biol, 1993. 64(4): p. 349-58. 
263. Olive, P.L., et al., Gel electrophoresis of individual cells to quantify hypoxic 
fraction in human breast cancers. Cancer Res, 1993. 53(4): p. 733-6. 
264. Chandna, S., Single-cell gel electrophoresis assay monitors precise kinetics of 
DNA fragmentation induced during programmed cell death. Cytometry A, 
2004. 61(2): p. 127-33. 
265. Klaunig, J.E. and L.M. Kamendulis, The role of oxidative stress in 
carcinogenesis. Annu Rev Pharmacol Toxicol, 2004. 44: p. 239-67. 
266. Kim, H.S. and M.S. Lee, Essential role of STAT1 in caspase-independent cell 
death of activated macrophages through the p38 mitogen-activated protein 
kinase/STAT1/reactive oxygen species pathway. Mol Cell Biol, 2005. 25(15): 
p. 6821-33. 
267. Boyault, S., et al., Transcriptome classification of HCC is related to gene 
alterations and to new therapeutic targets. Hepatology, 2007. 45(1): p. 42-52. 
  135 
268. Cooray, S., The pivotal role of phosphatidylinositol 3-kinase-Akt signal 
transduction in virus survival. J Gen Virol, 2004. 85(Pt 5): p. 1065-76. 
269. Ozes, O.N., et al., NF-kappaB activation by tumour necrosis factor requires 
the Akt serine-threonine kinase. Nature, 1999. 401(6748): p. 82-5. 
270. el-Deiry, W.S., et al., WAF1, a potential mediator of p53 tumor suppression. 
Cell, 1993. 75(4): p. 817-25. 
271. el-Deiry, W.S., et al., WAF1/CIP1 is induced in p53-mediated G1 arrest and 
apoptosis. Cancer Res, 1994. 54(5): p. 1169-74. 
272. Waldman, T., K.W. Kinzler, and B. Vogelstein, p21 is necessary for the p53-
mediated G1 arrest in human cancer cells. Cancer Res, 1995. 55(22): p. 5187-
90. 
273. Schwartz, J.D. and A.S. Beutler, Therapy for unresectable hepatocellular 
carcinoma: review of the randomized clinical trials-II: systemic and local 
non-embolization-based therapies in unresectable and advanced 
hepatocellular carcinoma. Anticancer Drugs, 2004. 15(5): p. 439-52. 
274. Gewirtz, D.A., A critical evaluation of the mechanisms of action proposed for 
the antitumor effects of the anthracycline antibiotics adriamycin and 
daunorubicin. Biochem Pharmacol, 1999. 57(7): p. 727-41. 
275. Park, S.S., Y.W. Eom, and K.S. Choi, Cdc2 and Cdk2 play critical roles in 
low dose doxorubicin-induced cell death through mitotic catastrophe but not 
in high dose doxorubicin-induced apoptosis. Biochem Biophys Res Commun, 
2005. 334(4): p. 1014-21. 
276. Soini, Y., et al., An aflatoxin-associated mutational hotspot at codon 249 in 
the p53 tumor suppressor gene occurs in hepatocellular carcinomas from 
Mexico. Carcinogenesis, 1996. 17(5): p. 1007-12. 
277. Newberne, P.M. and G.N. Wogan, Sequential morphologic changes in 
aflatoxin B carcinogenesis in the rat. Cancer Res, 1968. 28(4): p. 770-81. 
278. Aguilar, F., S.P. Hussain, and P. Cerutti, Aflatoxin B1 induces the transversion 
of G-->T in codon 249 of the p53 tumor suppressor gene in human 
hepatocytes. Proc Natl Acad Sci U S A, 1993. 90(18): p. 8586-90. 
279. Besaratinia, A., et al., In vitro recapitulating of TP53 mutagenesis in 
hepatocellular carcinoma associated with dietary aflatoxin B1 exposure. 
Gastroenterology, 2009. 137(3): p. 1127-37, 1137 e1-5. 
280. Rayman, M.P., The importance of selenium to human health. Lancet, 2000. 
356(9225): p. 233-41. 
281. Duffield-Lillico, A.J., et al., Selenium supplementation, baseline plasma 
selenium status and incidence of prostate cancer: an analysis of the complete 
treatment period of the Nutritional Prevention of Cancer Trial. BJU Int, 2003. 
91(7): p. 608-12. 
282. Duffield-Lillico, A.J., et al., Selenium supplementation and secondary 
prevention of nonmelanoma skin cancer in a randomized trial. J Natl Cancer 
Inst, 2003. 95(19): p. 1477-81. 
283. Yoshizawa, K., et al., Study of prediagnostic selenium level in toenails and the 
risk of advanced prostate cancer. J Natl Cancer Inst, 1998. 90(16): p. 1219-24. 
284. Knekt, P., et al., Is low selenium status a risk factor for lung cancer? Am J 
Epidemiol, 1998. 148(10): p. 975-82. 
285. Willett, W.C., et al., Prediagnostic serum selenium and risk of cancer. Lancet, 
1983. 2(8342): p. 130-4. 
  136 
286. Corrocher, R., et al., Reduction of liver glutathione peroxidase activity and 
deficiency of serum selenium in patients with hepatocellular carcinoma. 
Tumori, 1986. 72(6): p. 617-9. 
287. Chandra, J., A. Samali, and S. Orrenius, Triggering and modulation of 
apoptosis by oxidative stress. Free Radic Biol Med, 2000. 29(3-4): p. 323-33. 
288. Hyslop, P.A., et al., Mechanisms of oxidant-mediated cell injury. The 
glycolytic and mitochondrial pathways of ADP phosphorylation are major 
intracellular targets inactivated by hydrogen peroxide. J Biol Chem, 1988. 
263(4): p. 1665-75. 
289. Toyokuni, S., et al., Persistent oxidative stress in cancer. FEBS Lett, 1995. 
358(1): p. 1-3. 
290. Lieber, C.S., Role of oxidative stress and antioxidant therapy in alcoholic and 
nonalcoholic liver diseases. Adv Pharmacol, 1997. 38: p. 601-28. 
291. Voisin, L., et al., Activation of MEK1 or MEK2 isoform is sufficient to fully 
transform intestinal epithelial cells and induce the formation of metastatic 
tumors. BMC Cancer, 2008. 8: p. 337. 
292. Balmanno, K. and S.J. Cook, Tumour cell survival signalling by the ERK1/2 
pathway. Cell Death Differ, 2009. 16(3): p. 368-77. 
293. Schubbert, S., K. Shannon, and G. Bollag, Hyperactive Ras in developmental 
disorders and cancer. Nat Rev Cancer, 2007. 7(4): p. 295-308. 
294. Huang, H.M., C.J. Huang, and J.J. Yen, Mcl-1 is a common target of stem cell 
factor and interleukin-5 for apoptosis prevention activity via MEK/MAPK and 
PI-3K/Akt pathways. Blood, 2000. 96(5): p. 1764-71. 
295. Groopman, J.D., T.W. Kensler, and C.P. Wild, Protective interventions to 
prevent aflatoxin-induced carcinogenesis in developing countries. Annu Rev 
Public Health, 2008. 29: p. 187-203. 
296. Ellinger-Ziegelbauer, H., et al., Characteristic expression profiles induced by 
genotoxic carcinogens in rat liver. Toxicol Sci, 2004. 77(1): p. 19-34. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  137 
 
 
 
 
 
 
 
 
BAS IC STUDIES
A£atoxin genotoxicity is associatedwith a defectiveDNAdamage
response bypassing p53 activation
Ozge Gursoy-Yuzugullu1,2, Haluk Yuzugullu1,2, Mustafa Yilmaz2 and Mehmet Ozturk1,2
1 Centre de Recherche INSERM, Institut Albert Bonniot, Universite´ Joseph Fourier U823, Grenoble, France
2 Department of Molecular Biology and Genetics, BilGen Genetics and Biotechnology Research Center, Bilkent University, Ankara, Turkey
Keywords
aflatoxin – checkpoint – DNA damage
response – liver cancer – p53
Abbreviations
AFB1, aflatoxin B1; DMSO, dimethyl
sulphoxide; HCC, hepatocellular carcinoma.
Correspondence
Mehmet Ozturk, PhD, Centre de Recherche
INSERM/UJF U823, Institut Albert Bonniot,
Universite´ Joseph Fourier U823, Grenoble,
France
Tel:133476549410
Fax: 133476549413
e-mail: ozturkm@ujf-grenoble.fr
Received 14 September 2010
Accepted 10 January 2011
DOI:10.1111/j.1478-3231.2011.02474.x
Abstract
Background: Hepatocellular carcinoma (HCC) is a leading cause of cancer
deaths. Aflatoxins, which may play a causative role in 5–28% of HCCs
worldwide, are activated in liver cells and induce principally G! T muta-
tions, including the TP53 codon 249(G! T) hotspot mutation. The DNA
damage checkpoint response acts as an antitumour mechanism against
genotoxic agents, but its role in aflatoxin-induced DNA damage is unknown.
Aim: We studied the DNA damage checkpoint response of human cells to
aflatoxin B1 (AFB1). Methods and results: The treatment of HepG2 hepatoma
cells with mutation-inducing doses (3–5mmol/l) of AFB1 induced DNA adducts,
8-hydroxyguanine lesions and DNA strand breaks that lasted several days.
Persistent phospho-H2AX and 53BP1 foci were also detected, but cell growth
was not affected. AFB1-exposed HepG2cells formed phospho-H2AX and 53BP1
foci, but failed to phosphorylate both Chk1 and Chk2. Huh7 hepatoma and
HCT116 colorectal cancer cell lines also exhibited a similarly incomplete
checkpoint response. p53 phosphorylation also failed, and AFB1-exposed cells
did not show p53-dependent G1 arrest or a sustained G2/M arrest. These
observations contrasted sharply with the fully functional DNA damage response
of cells to Adriamycin. Cotreatment of cells with AFB1 did not inhibit p53 and
p21Cip1 accumulation induced by Adriamycin. Thus, the deficient checkpoint
response to AFB1 was not due to an inhibitory effect, but could be explained by an
inefficient activation.Conclusion: Genotoxic doses of AFB1 induce an incomplete
and inefficient checkpoint response in human cells. This defective response may
contribute to the mutagenic and carcinogenic potencies of aflatoxins.
More than 600 000 people die each year from hepatocel-
lular carcinoma (HCC), mostly (4 80%) in developing
countries (1). Dietary exposure to aflatoxins and infec-
tion with the hepatitis B virus are the major risk factors
for HCC, the most frequent liver cancer in these areas
(2). According to a recent study, about 25 200–155 000 of
global HCCs may be attributable to aflatoxin exposure.
Most cases occur in sub-Saharan Africa, Southeast Asia
and China, where populations suffer both from a high
hepatitis B virus prevalence and largely uncontrolled
aflatoxin exposure in food. Thus, aflatoxins may play a
causative role in 5–28% of all global HCC cases (3).
Aflatoxins are potent liver toxins, lethal when consumed
in large doses. Sublethal exposures can induce chronic
toxicity, and low levels of chronic exposure can result in
neoplasia, primarily HCC, in many animal species (4).
Aflatoxin exposure in humans may occur at high or low
levels, depending on the level of dietary Aspergillus con-
tamination. Acute exposure to high levels leads to lethal
aflatoxicosis associated with liver necrosis. Chronic expo-
sure to low levels of aflatoxin is not lethal, but highly
hepatocarcinogenic. Acute exposure to high levels of afla-
toxins (4 20mg/kg/day) with aflatoxicosis rarely occurs (5).
In contrast, 4 90% of people at a high risk for aflatoxin-
caused HCC are exposed to very low doses (0.01–0.3mg/kg/
day), but the exposition is chronic (3, 5).
Aflatoxin B1 (AFB1), the major aflatoxin product, is
metabolized mainly in the liver to AFB1-8,9-exo-epoxide
and 8,9-endo-epoxide. The exo-epoxide form of AFB1
binds to DNA to form the predominant 8,9-dihydro-
8-(N7-guanyl)-9-hydroxy AFB1 adduct, leading to a more
stable imidozole ring-opened AFB1–formamidopyrimidine
adduct (5). The pseudo-half-life for loss of 8,9-dihydro-8-
(N7-guanyl)-9-hydroxy AFB1 is short, but AFB1–formami-
dopyrimidine adducts are stable, accumulate for several
days and remain detectable for several weeks in rat liver (6,
7). The initial 8,9-dihydro-8-(N7-guanyl)-9-hydroxy AFB1
adduct and AFB1–formamidopyrimidine adduct, individu-
ally or collectively, represent the likely chemical precursors
responsible for the genotoxic effects of AFB1 (8). In
addition, common oxidative DNA damage, leading to 8-
hydroxydeoxyguanosine lesions, was observed in rat hepatic
DNA following exposure to AFB1 (4, 9). AFB1 induces
mainly G:C to T:A transversions (4). We (10, 11) and others
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(12) have identified a hotspot G! T mutation at codon
249 of the TP53 gene (encoding the mutant p53ser249
protein) in HCC tissues in patients exposed to aflatoxins.
Later studies demonstrated that this mutation was also
detectable in non-tumour liver samples (13), as well as in
the plasma of 6% of healthy individuals, 15% of cirrhotic
patients and 40% of HCC patients living in aflatoxin-
contaminated areas (14). Thus, the AFB1-specific G! T
mutation ofTP53 is frequently present in people exposed to
aflatoxins before any clinically detectable liver tumour.
Taken together, these observations provide strong evidence
that low levels of AFB1 are highly mutagenic in people
chronically exposed to this hepatocarcinogenic agent.
Eukaryotic cells have developed a powerful DNA
damage response system to protect their genome integ-
rity. DNA damage induces several cellular responses that
enable the cell either to eliminate the damage or to
activate senescence and apoptosis processes. DNA da-
mage checkpoint proteins play a central role in co-
ordinating repair and cell cycle progression to prevent
mutation. Several kinases, including ATM, ATR, Chk1
and Chk2, adaptor proteins such as 53BP1 and down-
stream cell cycle control proteins such as p53 and Cdc25,
are involved in damage sensing and cell cycle control.
DNA repair mechanisms include direct repair, base
excision repair, nucleotide excision repair, double-strand
break repair and cross-link repair (15, 16).
8,9-Dihydro-8-(N7-guanyl)-9-hydroxy AFB1 and AFB1–
formamidopyrimidine adducts appear to be removed pri-
marily by nucleotide excision repair in mammalian cells,
but other repair systems have also been implicated in
bacteria and yeast (8). The mechanisms of the DNA
damage checkpoint response to AFB1 are poorly known.
Here, we explored the DNAdamage checkpoint response of
wild-type p53 human cells to AFB1 exposure. Our findings
indicate that the checkpoint response to genotoxic and
mutagenic doses of AFB1 is incomplete. AFB1-exposed cells
failed to activate p53 and did not undergo cell cycle arrest
or apoptosis, despite the presence of DNA adducts and the
accumulation of DNA strand breaks.
Material and methods
Cell lines
HepG2 and Huh7 cell lines were cultivated as described
previously (10). HCT116 and HCT116–p53! cell lines
(17), gifts from B. Vogelstein, were cultivated in McCoy’s
cell growth medium (Gibco) supplemented with 10%
heat-inactivated fetal calf serum and 1% penicillin and
streptomycin solution (Gibco).
Cell treatment
Aflatoxin B1 (SigmaQ1 ) was dissolved in dimethyl sulph-
oxideQ2 (DMSO, Carlo Erba). Adriamycin (Sigma) and
hydroxyurea (Sigma) were dissolved in distilled water.
Aliquots were stored at ! 20 1C. Working dilutions were
prepared fresh and added in a complete cell culture
medium. DMSO (o 10!3 v/v dilution) and distilled
water were used for negative control experiments. AFB1
treatment was performed in the presence of the S9-
activation system for all HCT116, HCT116–p53!/! and
some HepG2 experiments for enzymatic activation into
the AFB1-8,9-exo-epoxide form. The S9 activation sys-
tem was prepared as described previously (18, 19), with
minor changes. Briefly, the S9-activation mixture was
prepared with 0.20 g/l S9 fraction from Sprague–Dawley
rat Q3liver (Xenotech), 10.5mmol/l isocitric acid (Sigma)
and 1.8mmol/l b-nicotinamide adenine dinucleotide
phosphate sodium salt hydrate (Sigma). This mixture
was filtered (0.45 mm) and used at a 1:10 dilution in the
cell culture medium.
Aflatoxin B1-DNA adduct and 8-hydroxy-deoxyguanosine
immunoperoxidase assays
Aflatoxin B1-DNA adducts and 8-hydroxydeoxyguanosine
lesions were detected by immunoperoxidase assays, as
described previously (20), with minor changes. Briefly,
cells were treated with AFB1 or DMSO on coverslips,
washed with phosphate-buffered saline and then fixed in
ice-cold methanol. AFB1-DNA adducts were detected
using a monoclonal antibody (6A10) against an imidazole
ring-opened persistent form of the major N7-guanine
adduct of AFB1 (21). Before the immunoperoxidase assay
of AFB1 adducts, cells were treated with a buffer containing
15mmol/l Na2CO3 and 30mmol/l NaHCO3 (pH 9.6) for
2 h at room temperature. For the AFB1 adducts and
8-hydroxydeoxyguanosine lesions, cells were treated with
RNAse (100mg/ml) in Tris buffer (10mmol/l Trizma Base,
1mmol/l EDTA and 0.4mol/l NaCl; pH 7.5) for 1 h at
37 1C. After washing with phosphate-buffered saline, pro-
teinase K (10mg/ml) treatment was carried out for 7min at
room temperature. After rinsing with phosphate-buffered
saline, DNA was denatured with 2N HCl for 10min and
cells were neutralized by soaking coverslips in 50mmol/l
Tris base for 5min. After blocking for 1 h, cells were
incubated with Q4mouse 6A10 (Santa Cruz) or mouse
anti-8-hydroxydeoxyguanosine (Trevigen) monoclonal
antibody overnight at 41C. Anti-mouse HRP-conjugated
secondary Q5antibodies (Invitrogen) were used for 30min for
primary antibody detection. Cells were stained with dia-
minobenzidine solution (Dako), counterstained Q6with hae-
matoxylin (Sigma), mounted with 80% glycerol and
observed under an Olympus light microscope.
Post-treatment cell survival – colony-forming ability
assay
Cell survival was determined by assessing cell growth in
100mm dishes after exposure to AFB1 or Adriamycin.
HepG2 cells were seeded in six-well plates and semicon-
fluent cells were exposed to AFB1 (0–50mmol/l) in the
presence of the S9-activation system for 4 and 24 h
respectively. Control cells were exposed to Adriamycin
(0–5 mmol/l) in parallel experiments. Following
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exposure, 104 cells were seeded into 100mm dishes. After
10 days of cell culture, colonies were fixed in cold
methanol, stained with Crystal Violet (Sigma) and
counted in triplicate experiments. Cell survival was
calculated as the percent ratio of cell numbers in treated
vs untreated cells. Survival parameters were determined
by plotting survival data on a semi-log plot.
Western immunoblotting
These experiments were carried out as described previously
(22). Proteins were subjected to electrophoresis using 10%
or 4–12% Bis-Tris NuPAGE Novex Mini gel systems
(Invitrogen), according to the manufacturer’s instructions.
For the detection of phosphorylated proteins, cell lysates
were prepared according to the protocol provided by the
supplier using the following lysis buffer: 20mmol/l Tris
(pH 7.5), 150mmol/l NaCl, 1mmol/l EDTA, 1mmol/l
EGTA, 1% Triton X-100, 1mmol/l Na3VO4, 1mg/ml
leupeptin and 1mmol/l phenylmethylsulphonyl fluoride.
Following electrophoresis, proteins were transferred onto
nitrocellulose membranes and analysed using antibodies
against cleavedQ7 caspase-3 (Cell Signaling), total p53Q8 (Santa
Cruz), p21Cip1 (Calbiochem), phospho-H2AX (Millipore),
phospho-Chk2, phospho-p53ser15, phospho-p53ser20
(all from Cell Signaling) and Calnexin (Sigma).
Senescence-associated b-galactosidase assay
Senescence-associated b-galactosidase activity was de-
tected as described previously (22), using a senescent cell
staining kit (Sigma).
Single-cell gel electrophoresis (comet) assay
Single- and double-strand DNA breaks were detected
using alkaline and neutral comet assays respectively (23,
24). The alkaline comet was performed exactly as de-
scribed (23). The neutral comet assay was conducted as
described (24), using the lysis protocol described by
Chandna (25). Following electrophoresis, slides were
rinsed, stainedQ9 with 5 mg/ml 40,6-diamidino-2-phenylin-
dole (Roche) and analysed under an Apotome (Zeiss)
microscope. Images were captured with an Axiocam HRc
colour CCD camera (Zeiss) and digitally saved using AXIO
VISION software (Zeiss). Data were analysed by CASP
(Comet Assay Software Project), which measures tail
moment, using the DNA content in the tail and head
along with the distance between the means of the head
and tail distributions (http://casplab.com). At least 30
nuclei were analysed for each experimental condition.
Indirect immunofluorescence
Cells were fixed with 4% formaldehyde and permeabilized
with phosphate-buffered saline supplemented with 0.5%
saponine (Sigma) and 0.3% Triton X-100 (Sigma). After
blocking for 1 h, cells were incubated overnight at 41C,
with antibodies against Ser139-phosphorylated H2AX
(phospho-H2AX; Millipore) or against Q1053BP1 (Abcam).
After incubation with Alexa 568-conjugated secondary
antibodies (Invitrogen), cells were counterstained with
40,6-diamidino-2-phenylindole (Roche) and observed
using an Apotome (Zeiss) microscope. Images were cap-
tured with an Axiocam HRc colour CCD camera (Zeiss)
and digitally saved using AXIO VISION software (Zeiss).
Cell cycle analysis and bromodeoxyuridine incorporation
assay
Cells were washed twice in phosphate-buffered saline and
fixed in ice-cold ethanol for 10min. After two phosphate-
buffered saline washes, cells were incubated Q11with 20mg/ml
of RNase A (Fermentas) at 371C for 10min and stained
with propidium iodide (10mg/ml; Sigma). Cell cycle
distribution was determined by flow cytometry using
FACSCAN and CELLQUEST software (Becton Dickinson). Cell
cycle analysis combined with the bromodeoxyuridine
incorporation assay was performed using cells first labelled
with 10mmol/l bromodeoxyuridine (Sigma) for 2 h before
each testing time. Cells were incubated with FITC-con-
jugated antibromodeoxyuridine antibody (BD Bioscience)
at room Q12temperature in the dark, following DNAdenatura-
tion with 4N HCl for 30min (26).
Results
Induction of DNA adducts, 8-hydroxydeoxyguanosine
lesions and DNA breaks by aflatoxin B1 in HepG2 cells
The human hepatoma line HepG2 has retained the activ-
ities of various phase I and phase II enzymes that play a
crucial role in the activation and detoxification of geno-
toxic procarcinogens. It has been used successfully for
genotoxicity assays for various classes of environmental
carcinogens including aflatoxins, nitrosamines, aromatic
and heterocyclic amines and polycyclic aromatic hydro-
carbons, as well as for antimutagenicity studies (27).
Furthermore, HepG2 has retained the wild-type activity of
the p53 gene, a well-established DNA damage response
gene (28, 29). Therefore, we first used the HepG2 cell line
to test the genotoxic effects of AFB1. Cells were treated
with 3–5mmol/l of AFB1 in the absence or the presence of
the S9-activating system that allows the activation of AFB1
into AFB1-8,9 epoxide (18). Following 24 h of exposure,
cells were subjected to immmunoperoxidase assays to
detect the imidazole ring-opened persistent form of the
major N7-guanine adduct of AFB1 and 8-hydroxydeoxy-
guanosine DNA lesions. Our results verified the detection
of AFB1 adducts in the nuclei of most cells with 3 or
5mmol/l AFB1 (Fig. S1A). Adduct detection levels were
quite similar between these two doses, indicating
that AFB1 was capable of inducing highly abundant
DNA adducts when tested at micromolar levels. We also
observed the detection of 8-hydroxydeoxyguanosine-posi-
tive nuclear foci (Fig. S1B). The same results were obtained
in the presence or in the absence of the S9-activating
system (Fig. S1).
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The genotoxic effects of AFB1 were studied by alkaline
and neutral comet assays that detect single- and double-
strand DNA breaks respectively (23, 24). Examples of
comet assay results are shown in Figure 1A. Both AFB1-
and Adriamycin-exposed cells, tested by an alkaline
comet assay at 72 h post-exposure time, displayed a
statistically significant increase in comet tail moments
(Po 0.0001), indicating the presence of abundant sin-
gle-strand DNA breaks (Fig. 1B, left). A neutral comet
assay also detected a statistically significant (Po 0.0001)
increase in tail moments with both chemicals that lasted
at least 48 h after the removal of chemicals from the cell
culture medium (Fig. 1B, right). Tail moments obtained
with the neutral comet were nearly 10-fold fewer than
those obtained with the alkaline comet (Fig. 1B). Thus,
AFB1 induced many more single-strand breaks than
double-strand breaks
Lack of significant growth inhibition in response to
aflatoxin B1 exposure
Next, we studied the cellular response to AFB1-induced
genotoxicity using cell growth, senescence and apoptosis
assays. Cell survival was determined by assessing colony
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Fig. 1. Induction of persistent single- and double-strand DNA breaks in HepG2 cells following AFB1 exposure. (A) HepG2 cells were exposed
to DMSO, AFB1 (5 mmol/l) or Adriamycin (0.5–1mmol/l) as a positive control for 24 h, followed by a culture in the absence of test chemicals for
up to 72h, and subjected to alkaline comet or neutral comet assays to detect single- and double-strand breaks respectively. (B) Quantitative
analysis of AFB1-induced DNA breaks by automated tail moment measurement. Black, white and grey columns indicate cells exposed to
DMSO, AFB1 and Adriamycin respectively. Error bars indicate SD. AFB1- and Adriamycin-treated cells displayed significantly increased tail
moments at all time-points tested (Po 0.0001). AFB1, aflatoxin B1; DMSO, dimethyl sulphoxide; SD, standard deviation.
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growth in 100mm dishes after exposure to AFB1 or
Adriamycin. HepG2 cells were seeded in six-well plates
and semiconfluent cells were exposed to AFB1
(0–50 mmol/l) in the presence of the S9-activation sys-
tem. Control cells were treated with Adriamycin
(0–5 mmol/l). Following 4 and 24 h of exposure, 104 cells
were seeded into 100-mm dishes and colonies were
counted 10 days later. Cell survival was calculated as the
percent ratio of cell numbers in treated vs untreated cells.
Survival parameters were determined by plotting survival
data on a semi-log plot. AFB1 did not affect colony
survival after 4 or 24 h of treatment at doses ! 5 mmol/l
(Fig. 2, closed circles). In contrast, Adriamycin displayed
a strong inhibition of colony survival, even with 50 times
less concentrated molar doses (Fig. 2, open circles).
Detectable effects of AFB1 were observed only when cells
were exposed for 24 h at doses reaching 50mmol/l (Fig. 2,
bottom, inset).
We noticed that both AFB1 and Adriamycin displayed
genotoxic effects that caused DNA breaks at comparable
intensities (Fig. 1), but their effects on cell survival were
highly different (Fig. 2). DNA damage usually triggers a
strong cytotoxic response as observed here with Adria-
mycin (Fig. 2, open circles). This was not the case for
AFB1-induced DNA damage that resulted in only a weak
colony-inhibitory effect (Fig. 2, closed circles). In con-
firmation of these observations, 3 days of exposure to
AFB1 did not induce a senescence response as tested by a
senescence-associated b-galactosidase assay (Fig. S2A)
nor apoptosis as tested by an activated caspase-3 assay
(Fig. S2B). These findings prompted us to further explore
the DNA damage response of HepG2 cells to AFB1.
DNA damage checkpoint foci induction by aflatoxin B1
To test the checkpoint response, we first used 53BP1 and
phospho-H2AX foci assays (15) by immunofluorescence.
Both AFB1 and Adriamycin induced 53BP1 and phos-
pho-H2AX foci that were detectable after 3 days of
culture, but AFB1-induced foci formation appeared to
be less strong (Fig. 3). These findings provided evidence
for a double-strand DNA break response (15, 16) to both
agents, although the response appeared to be slightly
different. We tested the statistical significance of AFB1-
induced foci formation by counting cells with 53BP1-
positive foci (4 5 foci/cell). Cells exposed to AFB1 be-
tween 1 and 72 h showed a progressive and statistically
significant (Po 0.0001) accumulation of 53BP1 foci
(Fig. S3). To test the duration of 53BP1 foci following a
fixed time of exposure to AFB1, cells were first treated
with AFB1 for 24 h and then cultivated in the absence of
chemical treatment for up to 120 h. Cells with positive
53BP1 foci were detected by an indirect immunofluores-
cence assay (Fig. S4A) and then counted. As shown in
Fig. S4B, the accumulation of 53BP1 foci peaked at 48 h
of post-treatment, with 40% positive cells. A residual foci
activity with 15–20% positive cells was detectable for at
least 120 h in cells no longer exposed to AFB1. In
contrast, cells exposed to DMSO only displayed low foci
activity (o 5%) throughout the experiment, indicating
that increased foci formation was because of AFB1
exposure. Western blot analysis of the total 53BP1
protein demonstrated its higher expression in cells ex-
posed to AFB1 for at least 72 h (Fig. S4C). Taken
together, our findings indicated that following exposure
to AFB1, HepG2 cells develop persistent 53BP1 foci that
are compatible with a double-strand DNA break re-
sponse lasting for several days.
Effects of aflatoxin B1 on HepG2 cell cycle progression
Based on observations indicating a defective growth
response to AFB1 (Fig. 2), despite the formation of
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Fig. 2. The effects of AFB1 (closed circles) or Adriamycin (open circles)
treatment of HepG2 cells for 4h (top) or 24h (bottom) on cell survival
colony-forming ability. Cell survival was calculated as the per cent ratio
of cell numbers in treated vs untreated cells (n=3). Survival parameters
were determined by plotting survival data on a semi-log plot. Insets:
cell survival at higher AFB1 (up to 50mmol/l) and Adriamycin (up to
5mmol/l) doses. Error bars: SD. cell survival was determined by
assessing cell growth in 100mm dishes after exposure to AFB1 or
Adriamycin. HepG2 cells were seeded in six-well plates and
semiconfluent cells were exposed to AFB1 (0, 1, 3, 5, 10 and 50mmol/l)
or Adriamycin (0, 0.1, 0.3, 0.5, 1 and 5mmol/l) for 4 or 24h. Following
exposure, 104 cells were seeded into 100-mm dishes and colonies
were counted 10 days later. AFB1, aflatoxin B1; SD, standard deviation.
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persistent AFB1-DNA adducts (Fig. S1), DNA strand
breaks (Fig. 1) and DNA damage foci (Figs. 3, S3 and
S4), we performed time-course studies on cell cycle
progression of HepG2 cells following AFB1 exposure. As
shown in Figure 4, AFB1 exposure resulted in a transient
accumulation of cells at the S phase (up to 26% from
13%, one-fold increase) at 24 h, followed by a return to
control levels at 48 and 72 h. These changes were accom-
panied by a slight increase (40%) in G2/M-phase cells at
48 and 72 h, together with a slight decrease (18–26%) in
G1-phase cells. These observations provided evidence for
a transient and weak growth inhibition in HepG2 cells
following AFB1 exposure (Fig. 4). The lack of a total cell
cycle block under AFB1 exposure was compatible with a
nearly complete colony survival after 5mmol/l AFB1
exposure (Fig. 2). Of particular interest, AFB1-exposed
HepG2 cells did not undergo G1 arrest despite the
expression of wild-type p53, strongly suggesting that
AFB1-induced DNA damage did not trigger a p53-
dependent DNA damage response in these cells.
Incomplete DNA damage checkpoint response to
aflatoxin B1 in different cell types
p53-dependent response to DNA damage is a strong
mechanism protecting cells against the accumulation of
deleterious mutations (15, 17, 30). Based on the current
model for p53 activation upon DNA damage (15), we
tested the status of critical components of DNA damage
signalling after AFB1 exposure. Adriamycin and hydro-
xyurea were used for control experiments. As shown in
Figure 5, Adriamycin treatment induced a typical dou-
ble-strand break response in HepG2 cells by induced
phosphorylations of H2AX, Chk2 and p53ser15, together
with a weak induction of p53ser20 phosphorylation.
Hydroxyurea treatment resulted in a weak phosphoryla-
tion of Chk1. As expected, we noted time-dependent
differences in these responses. The response to AFB1 was
globally weak or even absent. The only detectable
response was observed with H2AX phosphorylation that
was detectable after 24 h of AFB1 exposure, as well as
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Fig. 3. Induction of 53BP1 and phospho-H2AX foci following AFB1 exposure in HepG2. Cells were treated with AFB1 (3mmol/l) for 3 days and
then subjected to 53BP1 and phoshpo-H2AX foci detection by indirect immunofluorescence. Control cells were exposed to DMSO only.
Adriamycin (0.1mmol/l) was used as a positive control. Scale bar = 20mm. ADR, Adriamycin; AFB1, aflatoxin B1; DMSO, dimethyl sulphoxide.
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after 24 h post-exposure. We performed additional stu-
dies with Huh7, an HCC cell line with retained activities
for AFB1 activation (31), but displaying a homozygous
p53 mutation (28). As shown in Fig. S5, Huh7 cells
responded to Adriamycin by upregulation of phospho-
H2AX levels only, and there was no phospho-Chk1
phosphorylation in response to hydroxyurea treatment.
AFB1 did no affect phosphorylations of Chk1, chk2 or
p53ser15, and the effect on H2AX phosphorylation was
weakly detectable at 24 h of exposure. Taken together,
these studies indicated that, apart from H2AX phosphor-
ylation, critical components of DNA damage checkpoint
proteins were not affected in hepatoma cells. In addition,
the induction of p53 phosphorylation in response to
DNA damage by Adriamycin appeared to be dependent
on the wild type of the mutant status of p53 gene (see
Fig. 5 in comparison with Fig. S5).
In order to further investigate the role of AFB1 in DNA
damage response induction, we decided to explore wild-
type p53-expressing HCT116 colorectal cancer cells and
their p53 knockout HCT116–p53!/! derivatives (17). We
performed all AFB1 experiments in these cell lines in the
presence of the S9-activating system to allow the trans-
formation of AFB1 into epoxy-AFB1 (32). First, we
assessed the formation of DNA lesions following expo-
sure to AFB1 (5 mmol/l) and Adriamycin (1mmol/l). The
response of HCT116 cells to both AFB1 and Adriamycin
treatment was not different from the observations
obtained with HepG2 cells. The great majority of cells
stained positive for 8-hydroxydeoxyguanosine lesions
following drug exposure (Fig. S6A) and displayed DNA
double-strand breaks as tested by a neutral comet assay
(Fig. S6B). Furthermore, HCT116 cells exposed to
5 mmol/l AFB1 for 24 h displayed a statistically significant
(Po 0.0001) increase in both 53BP1 and phospho-
H2AX-positive foci that lasted at least 48 h post-expo-
sure, independent of TP53 status (Fig. S7). Western blot
analysis of critical components of DNA damage check-
point response also provided results quite similar to that
of HepG2. As shown in Fig. S8 and in comparison with
Adriamycin and hydroxyurea, AFB1 treatment induced
only a weak upregulation of phospho-H2AX levels at 24 h
of exposure, with a more pronounced increase at 24 h of
post-exposure.
Taken together, our observations with three different
cell lines indicated that AFB1 induced a weak and delayed
accumulation of phospho-H2AX. The phosphorylation
of H2AX strongly suggested that AFB1-induced DNA
damage triggered ATM activation by double-strand DNA
breaks (15, 33). However, this ATM response was not
accompanied by phosphorylations of Chk1, Chk2 or p53,
three key proteins involved in the DNA damage check-
point response. The lack of Chk1 phosphorylation after
AFB1 exposure also suggested that the ATR/Chk1 path-
way response was also inactive against AFB1-induced
DNA damage.
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24 h 48 h 72 h
DMSO
G1: 54%
S: 13%
G2/M: 33%
G1: 55%
S: 15%
G2/M: 30%
G1: 56%
S: 11%
G2/M: 33%
AFB1
G1: 40%
S: 26%
G2/M: 34%
G1: 45%
S: 13%
G2/M: 42%
G1: 46%
S: 11%
G2/M: 43%
Fig. 4. The effects of AFB1 on HepG2 cell cycle distribution. Cells were treated with either 5mmol/l AFB1 or DMSO up to 72h, and cell cycle
distribution was analysed by flow cytometry at 24, 48 and 72h. AFB1, aflatoxin B1; DMSO, dimethyl sulphoxide.
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The mechanism of the inefficient DNA damage response
to aflatoxin B1
As we observed similar responses of HCT116 and hepatoma
cells to both AFB1 and Adriamycin treatment, we decided
to further explore AFB1 effects using the isogenic HCT116
model, allowing us to better define its potential implications
in p53-mediated DNA damage response. Before testing of
AFB1 effects, we first examined the cell cycle responses of
HCT116 andHCT116–p53!/! cells to Adriamycin. HCT116
cells displayed G1 and G2/M arrests in response to Adria-
mycin, associated with low levels of apoptosis (subG1 peak)
and polyploidy formation at higher doses (Fig. S9A). There
was also a depletion of S-phase cells as an indication of
DNA synthesis inhibition that lasted at least 48h following
the removal of Adriamycin from the cell culture medium.
The response of HCT116–p53!/! cells to Adriamycin was
essentially similar, with the noticeable absence of a G1 peak
(Fig. S9A). Based on Fig. S9B, which compares Adriamycin-
induced cell cycle changes in wild-type and p53 knockout
HCT116 cells, we concluded that DNA damage induced by
Adriamycin is associated with a p53-dependent G1 arrest
and a p53-independent G2/M arrest.
Our cell cycle studies with AFB1 treatment in the same
cell lines are shown in Fig. S10. Unlike HepG2 cells, the
HCT116 cell lines did not display a significant increase
in S-phase cells. However, they displayed a weak decrease
in the G1 phase, in parallel to a weak increase in G2/M
cells, as observed with HepG2 cells. The response of
HCT116–p53!/! cells to AFB1 exposure was not remark-
able either, except for a slight increase in G2/M cells.
Taken together, these observations strongly suggested
that human cells exposed to AFB1 could not develop a
growth control response. The most likely reason for this
was a delayed and deficient checkpoint response, includ-
ing a lack of efficient phosphorylation of p53 protein.
Therefore, we also compared the effects of AFB1 and
Adriamycin on p53 and p21Cip1. As shown in Figure 6A,
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Fig. 5. Incomplete DNA damage checkpoint response of HepG2
cells to aflatoxin B1 (AFB1). HepG2 cells were treated with dimethyl
sulphoxide (DMSO) or AFB1 (5mmol/l) for 4 and 24h, and tested
immediately (410 h and 2410 h) or after 24 h of incubation without
treatment (24124h). HepG2 cells treated with 0.5mmol/l
Adriamycin (ADR) or 5mmol/l hydroxyurea (HU) were used as
positive controls for experiments shown in (A) and (B) respectively.
Total cell lysates were subjected to western blot analysis. Calnexin
was used as a loading control. p-H2AX, phospho-H2AX; p-
p53ser15, phospho-p53ser15; p-p53ser20, phospho-p53ser20;
p-Chk2, phospho-Chk2; p-Chk1, phospho-Chk1.
Fig. 6. Comparative analysis of the wild-type p53 response of
HCT116 cells to AFB1 and Adriamycin treatment indicates that AFB1
cannot induce effective p53 activation. (A) Wild-type 53 HCT116 and
p53-deficient HCT116-p53!/! cells were treated with AFB1 (3mmol/l)
or DMSO (in the presence of the S9-activating system) or Adriamycin
(ADR; 1mmol/l) for 24h, followed by an additional cell culture in the
absence of this chemical for another 24h. (B and C) HCT116 (B) and
HCT116-p53!/! (C) cells were cotreated with Adriamycin (ADR,
increasing doses: 0, 0.1, 0.5 and 1mmol/l respectively) in the absence
(DMSO) or in the presence of 3mmol/l AFB1, as described in (A) for
24h (24h pre-exposure to AFB1, followed by 24h of co-exposure).
Total cell lysates were used for western blot using anti-p53 and anti-
p21Cip1 antibodies. Calnexin was used as a loading control. AFB1,
aflatoxin B1; DMSO, dimethyl sulphoxide.
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7
both p53 and p21Cip1 responded to Adriamycin treatment
with a dose-dependent increase in HCT116 cells. The
increase in p21Cip1 levels was p53-dependent, because we
did not observe p21Cip1 response in HCT116–p53!/! cells.
In contrast, AFB1 treatment did not produce any detect-
able change in p53 levels in HCT116 cells. As a result, there
was no detectable increase in p21Cip1 in both HCT116 and
HCT116–p53!/! cells. These findings suggested that either
the AFB1 was actively involved in the inhibition of an
effective DNA damage checkpoint response or the damage
inflicted by AFB1 did not reach a threshold that is
necessary for checkpoint activation, similar to previous
observations with low-dose ionizing radiation (16). To test
whether AFB1 inhibits the checkpoint response, we co-
treated HCT116 cells with increasing doses of Adriamycin
(0, 0.1, 0.5 and 1mmol/l respectively) inQ13 the absence or
presence of 3mmol/l AFB1. As shown in Figure 6B and C,
the accumulation of p53 and p21Cip1 after Adriamycin
exposure was not inhibited by AFB1 in HCT116 cells.
Indeed, there was a slight increase in the accumulation
p21Cip1 after 0.1mmol/l Adriamycin treatment in the pre-
sence of AFB1. The p21Cip1 response of HCT116–p53!/!
cells to Adriamycin was not affected by AFB1, except for a
weak accumulation that was observed when cells were
cotreated with 1mmol/l Adriamycin and 3mmol/l AFB1.
These findings showed that AFB1 did not inhibit DNA
damage checkpoint response under the conditions tested.
Instead, AFB1 slightly stimulated the checkpoint response
to Adriamycin.
Discussion
Hepatocellular cancer risk from aflatoxins, as well as
aflatoxins’ hepatocellular biochemistry, DNA interacting
forms, the types of DNA damage and their repair by
nucleotide excision, and their in vitro and in vivo
mutagenic specificity for G ! T transversions are
well-established facts (34). Here, we addressed a less
well-understood, but critical component of aflatoxin
genotoxicity, namely the DNA damage checkpoint re-
sponse. The in vitro experimental model system used
here was designed after carefully considering previously
described features associated with aflatoxin-related carci-
nogenicity. Human cells with a wild-type p53 expression
were preferred because of the fact that a specific hotspot
mutation of this gene was observed only in human HCC,
not in other aflatoxin-induced mammalian tumours
(35). We considered estimated chronic aflatoxin expo-
sure levels in humans (0.01–0.3 mg/kg/day) (3) and
hepatocarcinogenic doses (0.015–1 ppm) in rats (36).
We also considered that 30min of exposure to 1.6mmol/
l AFB1 was sufficient to induce p53-249 G! T muta-
tions in HepG2 cells (37) and 0.2–5 mmol/l doses induced
reporter gene mutations in mouse fibroblasts (32). Thus,
the AFB1 doses that we used here (3–5 mmol/l) were at
the upper limits of in vitro mutagenic activity in mam-
malian cells and were estimably superior to carcinogenic
doses in humans and rats. We performed our cell
response studies over a period of several days so that we
could determine both immediate and delayed effects.
Our findings demonstrate that AFB1, when tested under
conditions comparable with mutagenic and carcinogenic
exposure levels, creates DNA adducts, 8-hydroxy-deoxy-
guanosine lesions and persistent strand breaks, but it does
not lead to a sustained cell cycle arrest and/or an apoptosis
response. AFB1 adducts are repaired by nucleotide excision
repair (8); however, their removal is slow (6) and they
remain at maximum levels for several days and are
detectable over several weeks in rat liver cells (6, 7). The
unusual stability of AFB1 adducts together with a slow
repair process could account for their strong genotoxic
effects. The expansion of cells with unrepaired DNA lesions
could cause mutations in their genomes. Therefore, such
cells are under the strict control of DNA damage check-
point proteins that block cell cycle and/or induce apoptosis
(15, 16, 30). Our in vitro findings and previously reported
in vivo studies strongly suggest that cells exposed to
mutagenic doses of AFB1 cannot develop a strong cell cycle
arrest and/or apoptosis response. Our detailed analysis of
DNA damage checkpoint proteins provides a plausible
explanation for the uncoupling between DNA damage
and growth control following AFB1 exposure. AB1-
exposed cells displayed DNA damage foci formation with
both 53BP1 and phospho-H2AX marker proteins. These
findings suggest that AFB1-induced DNA damage might
trigger a checkpoint response compatible with a double-
strand break-type response involving ATM. However, this
response was weak and delayed, as indicated by phospho-
H2AX levels tested by western blot analysis. Our western
blot studies for phospho-ATM levels after AFB1 exposure
provided inconsistent results with or without an increase
(data not shown), further indicating that ATM is not
activated consistently following AFB1-induced DNA da-
mage. In confirmation of this hypothesis, AFB1-induced
DNA damage failed to activate Chk2 and p53ser15 phos-
phorylations. The alternative DNA damage checkpoint
response mediated by ATR and Chk1 was also ineffective,
as tested by Chk1 and p53ser20 phosphorylation. Themost
important outcome of a deficient response to AFB1 was a
lack of cell growth control. Apart from a slight and
transient increase in the G2/M phase, cells did not undergo
stable cell cycle arrest, senescence and/or apoptosis. Con-
sequently, the overall cell survival was not affected even
after exposure to 5mmol/l AFB1. It was necessary to expose
cells to 50mmol/l AFB1 for at least 24 h in order to observe
a cytotoxic effect. Such a high dose represents a more than
150-fold higher value when compared with effective doses
of Adriamycin in the same type of cells.
The mechanisms of the failing checkpoint response to
AFB1 are currently unknown. We speculate that AFB1 is
able to induce DNA damage, without triggering an effective
damage response signal at doses " 5mmol/l. The delayed
and defective DNA damage response to AFB1 could be
related to the type of DNA and protein adducts that it
forms in exposed cells (5, 8). AFB1 DNA adducts that are
known to be repaired primarily by nucleotide excision
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repair (8) may not be sufficient to trigger directly a strong
DNA damage response, which usually requires single- and
double-strand DNA breaks (15, 16). Instead, the DNA
breaks could occur during the repair process causing a
delayed response, as suggested by a weak and delayed
occurrence of phospho-H2AX accumulation observed here.
Alternatively, or in addition, adducts of AFB1 formed with
critical cellular proteins may hamper an effective damage
response. This alternative is highly unlikely, as suggested by
the inability of AFB1 cotreatment to inhibit Adriamycin-
induced accumulation of p53 and p21Cip1 as an end-point
reporter for checkpoint response. Thus, our findings favour
the hypothesis that AFB1-induced DNA damage, tested
here at doses ! 5mmol/l, did not reach the threshold for
an efficient induction of checkpoint response. At higher
doses, AFB1 is probably effective to trigger a DNA damage
response. Indeed, it has been reported previously that
HepG2 cells exposed to 10mmol/l AFB1 can elicit a cell
cycle arrest response (38). When tested with 5mg/kg dose,
AFB1 exposure could induce p21Cip1 upregulation in rat
liver (39). However, as stressed earlier, cancer-causing diet-
ary exposure to AFB1 occurs at low levels, a condition that
is similar to our in vitro conditions that provided evidence
for a defective checkpoint response.
A defective or a negligent G2/M checkpoint response
to low ionizing radiation exposure has been postulated
by Lo¨brich and Jeggo (16) as a potential cause of genomic
instability and cancer risk. The authors also proposed
that a master p53-dependent G1 checkpoint might
remain effective during a negligent G2/M checkpoint for
later elimination of escaping cells. Our findings strongly
suggest that the DNA damage checkpoint in response to
low doses of AFB1 is defective, negligent or delayed. In
addition, a p53-dependent salvage pathway is apparently
ineffective against AFB1-induced DNA damage. The lack
of an efficient response to AFB1-induced DNA damage
may be because of the type of lesion(s) induced at the
DNA and/or protein levels by activated AFB1 in exposed
cells. It will be interesting to further investigate these
issues in future studies.
In conclusion, our findings provide in vitro evidence
for a negligent G1 and G2/M checkpoint response to
AFB1-induced DNA damage. This defective response
may contribute to the mutagenic and carcinogenic
potencies of aflatoxins.
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Di(2-ethylhexyl)-phthalate (DEHP) is the most abundantly used phthalate derivative, inevitable environ-
mental exposure of which is suspected to contribute to the increasing incidence of testicular dysgenesis
syndrome in humans. Oxidative stress and mitochondrial dysfunction in germ cells are suggested to
contribute to phthalate-induced disruption of spermatogenesis in rodents, and Leydig cells are one of the
main targets of phthalates’ testicular toxicity. Selenium is known to be involved in the modulation of
intracellular redox equilibrium, and plays a critical role in testis, sperm, and reproduction. This study was
aimed to investigate the oxidative stress potential of DEHP and its consequences in testicular cells, and
examine the possible protective effects of selenium using the MA-10 mouse Leydig tumor cell line as a
model. In the presence and absence of selenium compounds [30 nM sodium selenite (SS), and 10 μM
selenomethionine (SM)], the effects of exposure to DEHP and its main metabolite mono(2-ethylhexyl)-
phthalate (MEHP) on the cell viability, enzymatic and non-enzymatic antioxidant status, ROS production,
p53 expression, and DNA damage by alkaline Comet assay were investigated. The overall results of this study
demonstrated the cytotoxicity and genotoxicity potential of DEHP, where MEHP was found to be more
potent than the parent compound. SS and SM produced almost the same level of protection against
antioxidant status modifying effects, ROS and p53 inducing potentials, and DNA damaging effects of the two
phthalate derivatives. It was thus shown that DEHP produced oxidative stress in MA-10 cells, and selenium
supplementation appeared to be an effective redox regulator in the experimental conditions used in this
study, emphasizing the critical importance of the appropriate selenium status.
© 2010 Elsevier Inc. All rights reserved.
Introduction
Phthalic acid esters are the most abundantly produced plasticizers,
and known as endocrine disruptors and peroxisome proliferators
(PP). Their inevitable environmental exposures in humans have been
suspected to contribute to the increasing incidence of testicular
dysgenesis syndrome (TDS) that is a range of reproductive defects
including cryptorchidism and hypospadias in newborn boys, and
testicular cancer and reduced sperm quality in adult males (Swan,
2008). In fact, TDS has been shown to develop in male rats that are
exposed to phthalates in utero (Fisher et al., 2003). Di(2-ethylhexyl)-
phthalate (DEHP) is the most important phthalate derivative with its
high production, use and occurrence in the environment. It is mainly
used in polyvinyl chloride plastics in the form of numerous consumer
and personal care products and medical devices. The typical human
exposure to DEHP ranges from 3 to 30 μg/kg/day (Doull et al., 1999)
but, can be exceeded in speciﬁc medical conditions reaching 1.5 mg/
Toxicology and Applied Pharmacology 248 (2010) 52–62
Abbreviations: BCA, bicinchoninic acid assay.; CDNB, 1-chloro-2,4 dinitrobenzene.;
CM-H2DCFA, 5-(and 6-) chloromethyl-2′,7′-dichlorodihydroﬂuorescein diacetate.;
DAB, 3,3′-diaminobenzidine.; DCFH, 2′,7′-dichloroﬂuorescin.; DCF, 2′,7′-dichloroﬂuo-
rescein.; DEHP, di(2-ethylhexyl) phthalate.; DMEM/F-12, Dulbecco's Modiﬁed Eagle
Medium (1:1) Nutrient Mixture.; DMSO, dimethyl sulfoxide.; DTNB, 5,5′-dithiobis(2-
nitrobenzoic) acid.; FBS, fetal bovine serum.; GPx1, cytosolic glutathione peroxidase.;
GPx4, phospholipid hydroperoxide glutathione peroxidase.; GR, glutathione reductase.;
GSH, glutathione.; GSSG, oxidized glutathione.; GST, glutathione S-transferase.; H2Se,
hydrogen selenide.; hcG, human chorionic gonadotrophin.; MEHP, mono(2-ethylhexyl)
phthalate.; MTT, 3-(4,5-dimethyl-thiazol-2-yl)-2,5-diphenyl-tetrazolium bromide.;
Na2-EDTA, disodium ethylenediaminetetraacetic acid.; NADPH, nicotinamide adenine
dinucleotide phosphate, reduced form.; p53, protein 53.; PBS, phosphate-buffered
saline.; PP, peroxisome proliferators.; PPARα, peroxisome proliferator-activated
receptor α.; PPARβ, peroxisome proliferator-activated receptor β.; PPARγ, peroxisome
proliferator-activated receptor γ.; ROS, reactive oxygen species.; Se, selenium.; SEM,
standard error of mean.; Sepp1, selenoprotein P.; SM, selenomethionine.; SS, sodium
selenite.; TNB, 5-thio-2-nitrobenzoic acid.; TrxR, thioredoxin reductase.
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kg/day exposure in hemodialysis patients, or as high as 10–20 mg/
kg/day during neonatal transfusion or parenteral nutrition (Loff et al.,
2000; Kavlock et al., 2005).
The mechanisms by which phthalates and speciﬁcally DEHP exert
their toxic effects in reproductive system are not yet fully elucidated.
Some of the effects of phthalate are related to their anti-androgenic
potential (Ge et al., 2007; Noriega et al., 2009). A peroxisome
proliferator-activated receptor α (PPARα)-mediated pathway based
on their PP activity (Gazouli et al., 2002), and activation of metabolizing
enzymes leading to free radical production and oxidative stress have
also been suggested (O'Brien et al., 2005). Although Sertoli cells were
thought to be theprimary targets of phthalate exposure in testis (Grasso
et al., 1993), available data suggest that Leydig cells are one of the main
targets (Ge et al., 2007). Leydig cells are the primary source of
testosterone production in males, and differentiation of Leydig cells in
the testes is one of the primary events in the development of the male
body and fertility (Zhang et al., 2008). Using the MA-10 mouse Leydig
tumor cell line as amodel systemmay, therefore, offer a valuablemodel
in studying the direct effects of environmental chemicals, particularly
those of endocrine disruptors on Leydig cell function in vitro. MA-10
cells are by far the best characterized and more widely used lines of
cultured Leydig tumor cells that were independently derived from the
M5480 tumor, a hormonally responsive mouse Leydig tumor (Ascoli,
1981).
The essential trace element selenium (Se), is the important
component of cellular antioxidant defense and is involved in the
modulation of intracellular redox equilibriumwith its some 25 forms of
cellular selenoproteins, particularly with glutathione peroxidases
(GPx), and thioredoxin reductases (TrxR) (Oberley et al., 2000). Se is
actively involved in many fundamental biological processes ranging
from immune functions to apoptosis, and protection and repair of DNA
(Ganther, 1999). It is essential for theproductionof normal spermatozoa
and thus plays a critical role in testis, sperm, and reproduction (Flohé,
2007). The major role of Se in fertility is mediated by the membrane
bound phospholipid hydroperoxide glutathione peroxidase (GPx4)
which is the most abundant selenoprotein in testis (Flohé, 2007; Ursini
et al., 1999). Testis Se is known to be remarkably and preferentially
maintained in Se deﬁciency. Severe and prolonged deﬁciency results in
sterility as spermatogenesis was arrested, whereas in less severe Se
deprivation reduced sperm motility leading to impaired fertilization
capacity and abnormal sperm morphology were reported (Maiorino et
al., 2006). On the other hand, epidemiological studies have suggested
that low serum Se levels were associated with an increase in the
incidence of cancer (Clark et al., 1991). The chemopreventive and
chemotherapeutic mechanisms of Se still remain unclear. Protection
against oxidative damage, induction of apoptosis secondary to produc-
tion of reactive oxygen species (ROS), and regulation of the thioredoxin
(Trx) redox system are among the many potential mechanisms
proposed (Combs and Gray, 1998; Ganther, 1999; Kitahara et al.,
1993) which also seem to be closely related to the roles of Se in the
reproductive system.
Oxidative stress and, thus, ROS play an important role in the
modulation of several important physiological functions, but also
accounts for changes that can be detrimental to the cells (Dröge,
2002). ROS are shown to contribute to cellular damage, apoptosis and
cell death, but also involved in regulation of gene expression by
controlling signal transduction through direct participation in cell
signaling, and/or modulation of cell redox state (Dalton et al., 1999;
Finkel, 1998). ROS have also been suspected of being involved in the
formation of testicular atrophy in phthalate-exposed rats (Kasahara et
al., 2002). On the other hand, p53 tumor suppressor protein is a redox
sensitive protein known to play important roles in controlling the
integrity and correctness of all processes in each individual cell.
Activation of p53 by ROS and exogenous DNA damages can lead to
growth arrest of the cell, DNA repair induction or apoptosis (Kim et al.,
2009). Several environmental chemicals including phthalates have
been shown to induce apoptosis in the reproductive tract of rodents
through p53 induction (Chandrasekaran and Richburg, 2005).
On thebasis of these knowledge and available data, it seemsuseful to
examine modulation of cellular redox by Se and whether Se supple-
mentation is effective on the effects of phthalates in rat reproductive
system. In the current study, MA-10 mouse Leydig cells cultured with
and without Se supplementation were used as a model, and the effects
of exposure to DEHP and its major metabolite MEHP on the viability,
enzymatic and non-enzymatic antioxidant status, ROS production, p53
expression and DNA damage were investigated.
Materials and methods
Chemicals. MEHP was obtained from Cambridge Isotope Laborato-
ries® (Andover, MA, USA). The protein assay kit was from Uptima
Interchim® (Montluçon, France). NaOH was purchased from Carlo
Erba® (Rodano, Italy). Dulbecco'smodiﬁed Eaglemedium (1:1) nutrient
mixture (DMEM/F-12) was purchased from Gibco® (Courbevoie,
France). 5-(and 6-) chloromethyl-2’,7’-dichlorodihydroﬂuorescein
diacetate (CM-H2DCFA) was purchased from Molecular Probes De-
tection Technologies, Invitrogen® (Eugene, OR, USA). The EnVision
Plus staining kit was purchased from Dako® (Carpinteria, CA, USA).
All the other chemicals including DEHP, sodium selenite (SS),
selenomethionine (SM), dimethyl sulfoxide (DMSO), 3-(4,5-dimethyl-
thiazol-2-yl)-2,5-diphenyl-tetrazolium bromide (MTT), 5,5′-dithiobis
(2-nitrobenzoic) acid (DTNB), 1-chloro-2,4 dinitrobenzene (CDNB), fetal
bovine serum (FBS), Mayers hematoxylin nuclear stain, and saponin
from quillaja bark; colorimetric assay kits for thioredoxin reductase
(TrxR), and glutathione (GSH) measurements; Cell Lytic M cell lysis
reagent, protease inhibitor cocktail, were obtained from Sigma-Aldrich®
(St. Louis, MO, USA). Anti-p53, the mouse monoclonal antibody, sc-263
was obtained from Santa Cruz Biotechnology Inc® (Santa Cruz,
California, USA). The goat anti-mouse horseradish peroxidase (HRP)
conjugated secondary antibody was purchased from Invitrogen Molec-
ular Probes® (Oregon, USA).
Cell culture and treatment. MA-10mouse Leydig tumor cells were a
generous gift from Prof. Mario Ascoli (Department of Pharmacology,
University of Iowa College, Iowa City, USA) and maintained in
Waymouth medium containing 15% (v/v) heat-inactivated horse
serum, and 50 μg/mL gentamicin as previously described (Ascoli,
1981). Culturing of the MA-10 cells were accomplished in DMEM/F-
12 (1:1) medium supplemented with 15% horse serum and
gentamicin (50 μg/ml) using gelatin-coated culture ﬂasks, at 37 °C
in a humidiﬁed incubator under 5% CO2. For sub-cultivation cells were
trypsinized, washed with sterile phosphate-buffered saline (PBS) and
centrifuged at 1500× g for 5 min. For the experiments only the cells of
10–12 passages were used.
SS and SM stock solutionswere prepared in sterile, deionized water.
DEHP (50 mM) and MEHP (100 μM) stock solution were prepared in
0.1% DMSO, and fresh dilutions were made using culture medium to
achieve ﬁnal concentrations ranging from 1 to 10 mM for DEHP and
from 1 to 10 μM forMEHP. Cell viabilitymeasurementswere performed
inMA-10 cells incubated with various concentrations of DEHP orMEHP
for 24 h. For the assessment of protective effect of Se, MA-10 cells
supplementedwith 30 nM SS or 10 μMSMwere cultured for 72 h, then
exposed to various concentrations of DEHP or MEHP for 24 h while
continuing the Se supplementation. The doses of Se in the formof SS and
SM used in this study were chosen from preliminary experiments (not
shown) as concentrations do not inhibit cell growth and do not cause
cytotoxicity, but result in maximal GPx1 induction after 72 h of
incubation.
For the measurement of enzyme activities, ROS and total GSH
levels, p53 expression, and for alkaline single-cell gel electrophoresis
(SCGE, Comet assay), following treatment groups of MA-10 cells were
prepared: Non-treated cells (NT-C): MA-10 cells were cultured
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without any treatment for 72 h; SS-supplemented cells (SS-S): MA-10
cells were cultured with 30 nM SS for 72 h; SM-supplemented cells
(SM-S): MA-10 cells were cultured with 10 μM SM for 72 h; DEHP-
treated cells (DEHP-T): MA-10 cells were cultured with 3 mM DEHP
for 24 h; DEHP-treated SS-S cells (SS/DEHP-T): SS-S cells were
cultured with 3 mM DEHP for 24 h; DEHP-treated SM-S cells (SM/
DEHP-T): SM-S cells were cultured with 3 mM DEHP for 24 h; MEHP-
treated cells (MEHP-T): MA-10 cells were cultured with 3 μM MEHP
for 24 h; MEHP-treated SS-S cells (SS/MEHP-T): SS-S cells were
cultured with 3 μM MEHP for 24 h; MEHP-treated SM-S cells (SM/
MEHP-T): SM-S cells were cultured with 3 μM MEHP for 24 h.
Determination of cell viability. Cell viability was determined by a
modiﬁed MTT assay (Cory et al., 1991), in conjunction with trypan blue
counting. 3000 cells per well were plated onto 96-well microtiter plates
in 200 μL medium with or without DEHP, MEHP, SS or SM. After
incubation for speciﬁed times at 37 °C in a humidiﬁed incubator, the
medium was removed, cells were washed twice with PBS and 20μL of
MTT (5 mg/mL in PBS) was added to each well. The medium was
removed 2 h later, 200 μL of DMSO was added to dissolve the formazan
product and the absorbancewas read at 570 nmusingMultiscan Ascent
microtiter plate reader (Labsystems, France). The absorbance was
proportional to viable cell number, and cell survival was calculated as
the percentage of the staining values of untreated cultures. The
percentage viability was calculated as “% speciﬁc viability=[(A − B)/
(C − B)]/100” where A=absorbance of the treated cells at 570 nm,
B=absorbance of the medium at 570 nm, and C=absorbance of the
control cells at 570 nm.
Antioxidant enzyme assays and glutathione levels. After speciﬁed
incubation periods and trypsinization, cells were lysed using Cell
Lytic M Cell Lysis agent with a protease inhibitor cocktail, and then
centrifuged at 4000 rpm, 4 °C for 10 min. After further centrifugation
at 13.000 rpm, 4 °C, for 20 min, antioxidant enzyme activities and GSH
levels were measured in the supernatant.
The activity of cytosolic GPx (GPx1) was measured in a coupled
reaction with glutathione reductase (GR) as described earlier (Flohé
and Günzler, 1984; Günzler et al., 1974). The assay is based on the
instant and continous reduction of oxidized glutathione (GSSG)
formed during GPx1 reaction by an excess of GR activity providing
for a constant level of GSH. As a substrate, t-butyl hydroperoxide used
and concominant oxidation of NADPH was monitored spectrophoto-
metrically at 340 nm. One unit of enzyme was deﬁned as the amount
of GPx1 that transformed 1 μmol of NADPH to NADP per minute at
37 °C.
Cytosolic TrxR activity was determined colorimetrically using
Thioredoxin Reductase Assay kit. As described previously (Arner et al.,
1999), the method is based on the reduction of DTNB with NADPH to
5-thio-2-nitrobenzoic acid (TNB) that is measured at 412 nm. One
unit of TrxR activity was deﬁned as the enzyme that caused an
increase in A412 of 1.0 per minute per mL at pH 7.0 at 25 °C.
Cytosolic glutathione-S-transferase (GST) activity was determined
according to the method of Habig et al. (1974) using CDNB as a
substrate and measuring the change in absorbance at 340 nm. The
results were given as nmol/min/mg protein.
For the measurement of the total GSH levels, cells were diluted
with 5-sulphosalicylic acid for protein precipitation, and centrifuged
at 4000 rpm, 4 °C, for 10 min. Supernatants were used for total GSH
determinations by using Glutathione Assay kit. The assay was based
on the reduction of DTNB by NADPH by a reaction catalyzed by GR
using GSH at 412 nm (Akerboom and Sies, 1981). The results were
given as pmol GSH/mg protein.
Protein content of the samples was determined by bicinchoninic
acid assay (BCA) using a protein assay kit (Krieg et al., 2005). The
results were given as mg/mL protein.
Measurement of intracellular ROS production. Total intracellular ROS
production was measured using peroxide sensitive ﬂuorescent probe
CM-H2DCFA as described earlier (Loikkanen et al., 1998). The studywas
conducted in the dark, and 70–80% conﬂuent cells were used. MA-10
cells seeded in 96-well plateswith/without SS (30 nM) and SM(10μM)
incubated at 37 °C in a humidiﬁed incubator under 5% CO2 for 72 h.
After removal of the culture media, cells were loaded with CM-H2DCFA
in PBS buffer for 30 min at room temperature. The cellular esterase
activity results in the formation of the nonﬂuorescent compound, the
2′,7′-dichloroﬂuorescin (DCFH). DCFH is rapidly oxidized in the
presence of ROS to a highly ﬂuorescent 2′,7′-dichloroﬂuorescein
(DCF). The cells were washed, then incubated with with/without
DEHP (3 mM) orMEHP (3 μM) at 37 °C in a humidiﬁed incubator under
5% CO2 for 0, 30 and 60 min. DCF ﬂuorescence was measured with a
PerkinElmer Victor 3 1420 multiwell ﬂuorometer (Perkin Elmer®,
Buckinghamshire, UK) at an excitation wavelength of 485 nm and an
emission wavelength of 535 nm. After data acquisition, Wallac 1420
Manager software was used to analyze ROS production. Background
ﬂuorescence was obtained from cell-free wells containing 5μM DCF in
0.5 mL of PBS and subtracted from the ﬂuorescence values found. The
multiwell plate was kept in a cell culture incubator between the
measurements. The exposures were repeated 3–4 times with three
parallelmeasurements. Fluorescence valueswere normalized to the cell
numbers. For each condition, 8-wells with triplicate measurements
were used and the mean of three independent experiments was given
as a result.
p53 evaluation by immunocytochemistry. The expression of p53 in
MA-10 cells was examined immunocytochemically using the EnVision
Plus System. MA-10 cells, treated and cultured as described above,
were washed with PBS for 3 min shaking on a shaker gently, and ﬁxed
with 4% formaldehyde in PBS at room temperature. Cells were rinsed
with ddH20 once, and washed with PBS for 3 min as were done
between each step, then permeabilized with PBS/0.5% saponin/0.3%
Triton X-100 for 3 times, each 5 min on the shaker. Cells were blocked
with PBS/%10 FBS/0,3% Triton X-100 at 37 °C for 1 h, then PBSwashed
cells were incubated with diluted primary antibody overnight at 4 °C.
Secondary antibody was used directly and cells were incubated at
25 °C for 30 min. Cells were again washed with 1× PBS and later with
1× PBS/2% FBS/0,3% Triton X-100 3 times, and stained with 3,3'-
diaminobenzidine (DAB) Chromogen solution. The staining was
stopped by adding ddH20, and then hematoxylin was used as a
nuclear stain. Images were acquired with a DC490 digital camera
(Leica, Wetzlar, Germany). Cells were considered to be positive when
the brown staining was present in the nucleus. For each condition 3
slides were counted and the results were given as percentage of p53
nuclear stainings.
Alkaline single-cell gel electrophoresis (Comet assay). DNA damage
was evaluated using the alkaline Comet assay that allows the
measurement of single- and double-strand breaks together with
alkali-labile sites. The assay was performed as described earlier (Singh
et al., 1988; Tice et al., 2000) and measurements were made in two
consecutive days on triplicate slides and the results were given as the
mean value of the two days. Immediately after the treatments, the
cells were isolated, washed and re-suspended in PBS at a density of
~2.5×106 cells/ml. 50 μl of this suspension was mixed with 450 μl
solution of low melting point agarose (0.6% in PBS), and 100 μl of the
solution was spread on a microscope slide covered with 1% agarose.
Cells were lysed (2.5 M NaCl, 0.5 M Na2-EDTA, 10 mM Tris, 1% sodium
lauryl sulfate, 1% Triton X-100, 10% DMSO, pH 10) at 4 °C in the dark
for 1 h. After lysis, cells were immersed in freshly prepared alkaline
electrophoresis buffer (300 mM NaOH, 1 mM Na2-EDTA, pH 13) for
30 min to allow DNA unwinding. Electrophoresis was then performed
at 25 V/300 mA for 30 min. Slides were rinsed three times for 5 min
with neutralization buffer (0.4 M Tris-HCl, pH 7.4), and stained with
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ethidium bromide (20 μg/mL) in PBS. For quantiﬁcation, ﬂuorescence
microscope (Carl Zeiss®, Germany) was used which was connected to
a charge-coupled device (CDC) and a computer-based analysis system
(Comet assay IV software, Perceptive Instruments Ltd), and the extent
of DNA damage was determined after electrophoretic migration of
DNA fragments in the agarose gel. For each condition, 50 randomly
selected comets on each slide were scored, and the tail% intensities
(percentage of DNA in the tail) and the tail moments (product of
comet length and tail intensity) were determined as an average of
triplicate slides.
Statistical analysis. The data were expressed as mean±standard
error (SEM). Statistical signiﬁcances of differences among treatment
groups were determined by use of one-way analysis of variance and
covariance (ANOVA), followed by Student's t-test using a Statistical
Package for Social Sciences Program (SPSS). A p-valueb0.05 was
considered as statistically signiﬁcant.
Results
Cell viability
In Fig. 1, cell viability data produced by MTT assay for DEHP-, and
MEHP-treated MA-10 cells were presented as relative to zero dose of
DEHP or MEHP. DEHP had a ﬂat dose-cell viability response curve, so
that MA-10 cells showed ~80 to 60% survival at a dose range of 10 μM
to 0.5 mM DEHP (Fig. 1A). Whereas MEHP was highly toxic at μM
range with a very sharp dose-response curve, so that there was no cell
survival at doses 10 μM and higher (Fig. 1B). The IC50 values for DEHP
and MEHP were found to be approximately 3 mM and 3 μM,
respectively. This demonstrated that MEHP, the main metabolite of
DEHP, was themain active form inMA-10 cells with an almost ~1000-
fold higher cytotoxicity than the parent compound.
Se supplementation of the cells with either SS (30 nM) or SM
(10 μM)wasprotective against the cytotoxic effects ofDEHP, andMEHP.
Fig. 1. Cell viability in phthalate-exposed MA-10 mouse Leydig tumor cell line, and protective effect of selenium supplementation. Cell viability was determined by MTT assay and
data were presented as relative to zero dose of DEHP or MEHP. Values are given as mean±SEM of n=3 independent experiments and triplicate measurements. A. Cytotoxicity of
various concentrations of DEHP on MA-10 Leydig cells cultured with or without selenium supplementation. NT-C: non-treated MA-10 cells cultured for 72 h; SS-S: MA-10 cells
supplemented and cultured with 30 nM SS for 72 h; SM-S: MA-10 cells supplemented and cultured with 10 μM SM for 72 h; DEHP: MA-10 cells treated with various concentrations
of DEHP for 24 h; SS/DEHP: SS-S cells cultured with various concentrations of DEHP for 24 h; SM/DEHP: SM-S cells cultured with various concentrations of DEHP for 24 h. 24 h.
apb0.05 vs. NT-C, bpb0.05 vs. DEHP. B. Cytotoxicity of various concentrations of MEHP exposure on MA-10 Leydig cells cultured with or without selenium supplementation.
MEHP: MA-10 cells cultured with various concentrations of MEHP for 24 h; SS/MEHP: SS-S cells cultured with various concentrations of MEHP for 24 h; SM/MEHP: SM-S cells
cultured with various concentrations of MEHP for 24 h. apb0.05 vs. NT-C, bpb0.05 vs. MEHP.
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In DEHP-exposed cells, for concentrations up to 2 mM, Se was highly
protective providing ≥50% higher viability, and the effects of SS was
higher (pb0.05) than SM at 0.2, 0.5 and 1 mMDEHP exposures. In cells
exposed to an IC50 dose of DEHP, both SS and SM forms of Se provided
higher viability (~36 and 48%, respectively,pN0.05) than DEHP-treated
cells (Fig. 1A). Whereas a complete viability as control cells was
observed with SM supplementation in MA-10 cells exposed to an IC50
dose of MEHP (Fig. 1B), supplementation with SS maintained the cell
viability at a level of ~85%of control cells (NT-C), and thedifferenceof SS
and SM effects was signiﬁcant (pb0.05).
Enzymatic and non-enzymatic antioxidants
The results of the antioxidant status assessment of MA-10 cells are
illustrated in Fig. 2. Se supplementation of MA-10 cells with either SS
or SM (that is SS-S and SM-S cells) signiﬁcantly increased the
activities of GPx1 (1.7- and 1.6-fold, respectively) and TrxR (~1.6- and
1.7-fold, respectively) compared to non-treated control cells (NT-C);
but did not cause any change on the total GSH level and GST activity.
The difference between the effects of SS and SM was insigniﬁcant.
In cells exposed to DEHP or MEHP, GPx1 activity decreased ~2.5
and ~4-fold, respectively (Fig. 2A). Thus, the effect of MEHPwasmuch
higher. Se supplementation either with SS or SM in DEHP-exposed
cells was able to enhance the GPx1 activity signiﬁcantly even up to
those of SS-S and SM-S cells. In MEHP-exposed cells, SS supplemen-
tation maintained the GPx1 activity almost at the control level,
whereas the effect of SM was signiﬁcantly higher than that of SS,
elevating the activity of GPx1 to the level of SM-S cells.
The same level of decrease (~2.4-fold) was observed in cytosolic
TrxR activity of MA-10 cells exposed to the parent phthalate or the
main metabolite (Fig. 2B). Supplementation of Se with SS was able to
elevate the cytosolic TrxR activity of MEHP-exposed cells to the levels
of SS-S cells, and with SM to the level of control cells. However, in
DEHP-exposed cells, the increase of TrxR activity with Se supplemen-
tation was rather low reaching only ~75–80% of that of control cells.
GST activity also decreased signiﬁcantly in DEHP-T (60%) and
MEHP-T (53%) cells. Neither SS nor SM supplementation restored the
activity of the cytosolic GST in phthalate-exposed cells. In contrast, Se
supplementation in both SS and SM forms decreased the enzyme
activity in MEHP-exposed cells. Whereas, GST activity remained the
same with the presence of SS, but was found even lower with SM
supplementation in DEHP-exposed cells (Fig. 2C).
Total GSH levels decreased signiﬁcantly in DEHP-T (~40%) and
MEHP-T (~42%) cells (Fig. 2D). Se supplementation provided signiﬁcant
restoration in both groups elevating the GSH content up to ~75–80% of
the NT-C levels.
ROS production
Fig. 3 illustrates the intracellular production of ROS in MA-10 cells
at different time points. As shown in Fig. 3A, there was no signiﬁcant
ROS production in NT-C cells at time point 30 min, but after 60 min of
Fig. 2. Enzymatic and non-enzymatic antioxidant status in DEHP- or MEHP-treated MA-10 Leydig cells and effects of selenium supplementation. A. GPx1 activity. B. TrxR activity.
C. GST activity. D. Total GSH level. Values are given as mean±SEM of n=3 independent experiments and triplicate measurements. Bars that do not share same letters (superscripts)
are signiﬁcantly different from each other (pb0.05). Measurements were performed in the following treatment groups of cells: NT-C: non-treated MA-10 cells cultured for 72 h;
SS-S: MA-10 cells supplemented and cultured with 30 nM SS for 72 h; SM-S: MA-10 cells supplemented and cultured with 10 μM SM for 72 h; DEHP-T: MA-10 cells cultured with
3 mMDEHP for 24 h; SS/DEHP-T: SS-S cells cultured with 3 mMDEHP for 24 h; SM/DEHP-T: SM-S cells cultured with 3 mMDEHP for 24 h; MEHP-T: MA-10 cells cultured with 3 μM
MEHP for 24 h; SS/MEHP-T: SS-S cells cultured with 3 μM MEHP for 24 h; SM/MEHP-T: SM-S cells cultured with 3 μM MEHP for 24 h.
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incubation ROS production increased ~1.7-fold. Presence of Se in SS or
SM forms did not change the intracellular ROS levels when compared
to NT-C cells neither after 30 min nor 60 min of incubations.
DEHP and MEHP exposures caused strongly ampliﬁed production
of ROS. At time point 30 min, ROS levels of the DEHP-exposed cells
increased signiﬁcantly, reaching ~2.4-fold of the level of time zero,
and after 60 min of incubation the increase was ~3.5-fold (Fig. 3B).
Whereas in MEHP-treated MA-10 cells, very sharp elevation of ROS
production was observed reaching ~2.3-fold and ~11.4-fold of the
initial level, at time points 30 min and 60 min, respectively (Fig. 3C).
Both SS and SM supplementations were highly effective against
the generation of intracellular ROS induced by both phthalate
derivatives. In the presence of SS, ROS levels in DEHP-exposed cells
decreased ~2-fold and ~2.2-fold, at 30 and 60 min, respectively.
Whereas, the decrease with SM supplementation was ~1.4-fold at
both time points (Fig. 3B).
InMEHP-T cells, SS supplementation caused ~3.5-fold and ~1.8-fold
decrease of ROS production at 30 min and 60 min, respectively.
Whereas presence of Se in SM form provided ~2.6-fold and ~2.1-fold
decrease of ROS generation at 30 min and 60 min, respectively (Fig. 3C).
p53 immunocytochemistry
As shown in Table 1, p53 protein expression in Se treated MA-10
cells was signiﬁcantly lower (~65%) than the steady state level of the
control cells (NT-C), and there was no difference between the
protective effects of SS and SM. In MA-10 cells exposed to an IC50
dose of DEHP, p53 expression was not induced. But a signiﬁcant
induction (~1.7-fold) of p53 expression was observed in MA-10 cells
exposed to an IC50 dose of MEHP. SS or SM supplementation enabled
the phthalate-exposed cells to maintain the p53 expression almost at
the basal level, or even lower as in the case of SS/DEHP-T cells. Fig. 4
shows the images of p53 expression in MEHP-treated cells along with
the images of control groups.
DNA damage—Comet assay
Fig. 5 shows the results of the alkaline Comet assay performed on
MA-10 cells exposed to an IC50 dose of DEHP (3 mM) or MEHP (3 μM)
in the presence or absence of Se, with the illustrations of the examples
of comet images.
Both DEHP and MEHP produced high level of DNA damage as
evidenced by signiﬁcantly increased tail intensity (%) (~3.4-fold and
~3.8-fold, respectively), and tail moment (~4.2-fold and ~3.8-fold,
respectively) compared to non-treated MA-10 cells. The difference
between the DNA damaging effects of the parent compound and the
metabolite was insigniﬁcant.
Se supplementation itself did not cause any alteration on the
steady state levels of the DNA damage biomarkers of MA-10 cells. But
Se was highly effective to decrease the genotoxic effects of phthalate
esters. Increased tail % intensities by DEHP and MEHP exposure were
lowered ~50–55% with SS supplementation, whereas SM treatment
Fig. 3. ROS production in DEHP- or MEHP-exposed MA-10 Leydig cells and effects of
selenium supplementation. Total intracellular ROS was measured using peroxide
sensitive ﬂuorescent probe CM-H2DCFA at 0, 30, and 60 min. Values are given asmean±
SEM of n=3 independent experiments and triplicate measurements. Bars that do not
share same letters (superscripts) are signiﬁcantly different from each other (pb0.05).
A. ROS production in cells without phthalate exposure (NT-C: non-treated MA-10 cells
cultured for 72 h; SS-S: MA-10 cells supplemented and cultured with 30 nM SS for 72 h;
SM-S: MA-10 cells supplemented and cultured with 10 μM SM for 72 h). B. ROS
production in DEHP-treated cells (DEHP-T: MA-10 cells cultured with 3 mM DEHP for
24 h; SS/DEHP-T: SS-S cells cultured with 3 mMDEHP for 24 h; SM/DEHP-T: SM-S cells
cultured with 3 mMDEHP for 24 h). C. ROS production in MEHP-treated cells (MEHP-T:
MA-10 cells cultured with 3 μM MEHP for 24 h; SS/MEHP-T: SS-S cells cultured with
3 μMMEHP for 24 h; SM/MEHP-T: SM-S cells cultured with 3 μMMEHP for 24 h).
Table 1
p53 immunocytochemistry scorings for the study groups.
Study group % of nuclear p53 stained cells
NT-C 8.77a
SS-S 2.99b
SM-S 3.14b
DEHP-T 9.38a
SS/DEHP-T 6.72c
SM/DEHP-T 8.76a
MEHP-T 15.03d
SS/MEHP-T 8.86a
SM/MEHP-T 9.85a
p53 expression was determined using EnVision Plus staining kit as described in
Materials and Methods. Results were given as the percentage of p53 nuclear staining
(mean ± SEM). Means that do not share same letters (superscripts) are signiﬁcantly
different from each other (pb0.05).
Measurements were performed in the following treatment groups of cells: NT-C: non-
treated MA-10 cells cultured for 72 h; SS-S: MA-10 cells supplemented and cultured
with 30 nM SS for 72 h; SM-S: MA-10 cells supplemented and cultured with 10 μM SM
for 72 h; DEHP-T: MA-10 cells cultured with 3 mM DEHP for 24 h; SS/DEHP-T: SS-S
cells cultured with 3 mM DEHP for 24 h; SM/DEHP-T: SM-S cells cultured with 3 mM
DEHP for 24 h; MEHP-T: MA-10 cells cultured with 3 μM MEHP for 24 h; SS/MEHP-T:
SS-S cells cultured with 3 μM MEHP for 24 h; SM/MEHP-T: SM-S cells cultured with
3 μM MEHP for 24 h.
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provided ~30–40% protection. SS decreased the tail moments of the
DEHP- or MEHP-exposed cells by ~55–65%, whereas the protective
effect of SM on tail moments was signiﬁcantly lower than SS as being
~45% and ~34% for the effects of DEHP and MEHP, respectively.
However, both SS and SM reduced the tail moments of the DEHP- and
MEHP-exposed cells down to the levels that were not signiﬁcantly
different than that of control cells.
Discussion
DEHP is a well-known peroxisome proliferator, and regarded as a
non-classic type endocrine disruptor, that is, in contrast to the classical
endocrine disrupters which interfere with endocrine process at the
receptor level, alters reproductive function by affecting hormone
synthesis (Akingbemi et al., 2004; Gazouli et al., 2002; Wilson et al.,
2004). Exposures toDEHPor itsmainmetaboliteMEHPhavebeen found
to result in decreased testicular testosterone levels in mice, indicating
that testosterone producing Leydig cells were also the target of the
phthalates, besides Sertoli cells (Jones et al., 1993). In fact, inhibition of
LH-stimulated testosterone secretion by MEHP in MA-10 Leydig cells
was previously demonstrated (Freeman and Ascoli, 1983; Gazouli et al.,
2002), and co-administration of testosterone with DEHP was reported
to prevent the DEHP-induced testicular toxicity (Parma et al., 1987).
The induction of oxidative stress was previously suggested to
represent a common mechanism in endocrine disruptor-mediated
dysfunction, speciﬁc to certain testicular cells (Latchoumycandane and
Mathur, 2002). Recent data have also shown that phthalates were able
to produce free radicals by several pathways in germ cells including
activation of PPARα, suggesting the possibility that oxidative stress
and mitochondrial dysfunction in germ cells may contribute to
phthalate-induced disruption of spermatogenesis (Gazouli et al.,
2002; Suna et al., 2007). DEHP treatment, indeed, was reported to
provoke oxidative stress as measured by increases in ROS in
subsequently isolated rat spermatocytes (Kasahara et al., 2002).
MEHP was reported to increase peroxiredoxin 3 and cyclooxygenase-
2 levels in germ cells indicating that the disruption of cellular redox
mechanisms in spermatocytes (Onorato et al., 2008). Thus, at least one
of themechanismsunderlying the reproductive toxicity of DEHPmight
be the induction of intracellular ROS and/or to cause alterations on
intracellular enzymatic and non-enzymatic antioxidants, thereby to
produce oxidative stress.
In the current study, using a well-established cell model, the MA-
10 mouse Leydig tumor cell line (Ascoli, 1981), the effects of direct
exposure to DEHP and MEHP on Leydig cells, including cytotoxicity,
genotoxicity and oxidative stress potential were investigated. MA-10
cells produce more progesterone than testosterone, but otherwise
resemble normal Leydig cells (Mylchreest et al., 2002). They contain
Fig. 4. Immunocytochemistry of p53 expression, using EnVision Plus staining kit, in MEHP-treated MA-10 Leydig cells in the presence and absence of selenium p53 was visualized as
brown precipitate in the nucleus of the cells. Arrows indicate MA-10 cells with p53 positive staining. For each condition 3 slides were counted and the results were given as the
percentage of p53 nuclear staining. The images represent the p53 protein of the following treatment groups of cells: NT-C: non-treated MA-10 cells cultured for 72 h; SS-S: MA-10
cells supplemented and cultured with 30 nM SS for 72 h; SM-S: MA-10 cells supplemented and cultured with 10 μM SM for 72 h; MEHP-T: MA-10 cells cultured with 3 μMMEHP for
24 h; SS/MEHP-T: SS-S cells cultured with 3 μM MEHP for 24 h; SM/MEHP-T: SM-S cells cultured with 3 μM MEHP for 24 h.
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both PPARα and PPARβ, but not PPARγ (Dostal et al., 1988) as in the
case of both Leydig and Sertoli cells of adult rats (Braissant et al.,
1996).
Cytotoxicity, in the current study, was assessed using the MTT
assay of mitochondrial integrity, a marker of cell viability. Signiﬁ-
cantly decreased cell viability was observed with 10 μM and higher
concentrations of DEHP. However, in agreement with earlier reports
(Kambia et al., 2004), and with the results of our recent study
conducted on LNCaP cells (Erkekoglu et al., 2010), cytotoxicity of
MEHP was much higher than the parent compound, indicating the
toxicity of DEHP is mostly based on the activity of MEHP. In fact, the
difference between the IC50 values of the two agents was almost three
orders of magnitude. However, the toxicity range of MEHP reported
by two studies was signiﬁcantly different than ours. Dees et al. (2001)
examined the effects of various concentrations of MEHP on proges-
terone production, cell viability, protein content and cell morphology
in MA-10 cells in the presence of hCG, and they observed no effect for
the range of 0.3 μM to 1 mM MEHP, and markedly decreased cell
viability (to 16%) at 3 mM -10 mM. In a very recent study which was
published during the submission of the present study, it was also
reported that at concentrations as high as 300 μM, MEHP was not
toxic to the MA-10 cells (Fan et al., 2010). The reason for this
discrepancy is not known, however, might be due to the differences in
the experimental designs, the cell culturing conditions, particularly
cell density/number, and source and purity of the MEHP, and may be
the presence or absence of hCG.
Se supplementation was highly effective in maintaining the
viability of MA-10 cells exposed to various doses of DEHP, and
MEHP. The protective effect of 30 nM SS supplementation on the cell
survival was almost as the same level as the protection provided by 10
μM SM. Thus, more SM was required to achieve a similar effect as was
obtained with the more bioavailable form of Se, selenite. The doses of
Se in the form of SS and SM used in this study were chosen from
preliminary experiments (not shown) as the concentrations did not
inhibit cell growth and did not cause cytotoxicity, but result in
maximal GPx1 induction after 72 h of incubation. These concentra-
tions were also in the same range as those concentrations of SS and
SM that were shown previously with the same properties for several
other cell types (Bhamre et al., 2003; Chu et al., 1990; Mansur et al.,
2000). SS is commonly used for cell culture and animal studies, and
SM is the most common form of Se obtained from the diet. SM is
converted to H2Se through transulfuration and β-lyase cleavage,
whereas SS interacts with GSH to form GSSeSG which is subsequently
reduced to H2Se. H2Se derived via both pathways can be converted to
selenophosphate which is then used in the synthesis of selenopro-
teins. This difference in Se metabolism is likely to account for the
greater efﬁciency of SS over SM, as has been reported for a variety of
cell types (Zhuo et al., 2009).
Se plays a critical role in testis, sperm, and reproduction. In rodent
testis, Se concentrations are typically higher than for any other tissue
except kidney, and unlike most other tissues except brain and
endocrine tissues, generally do not decrease even with prolonged Se
deﬁciency, showing that Se is preferentially maintained in the rodent
testis (Behne and Höfer-Bosse, 1984; Behne et al., 1988). Selenoprotein
P (Sepp1) is the responsiblemolecule for the targeted trafﬁcking of Se to
testis (Hill et al., 2003; Schomburg et al., 2003). When Se supply is
limited due to Se deﬁciency, incoming Se as Sepp1 would be delivered
preferentially to the Sertoli cells, thereby maintaining testis Se
Fig. 5. Results of alkaline Comet assay in DEHP- or MEHP-treated MA-10 Leydig cells and effects of selenium supplementation. A. Typical images of Comets. B. Tail % intensities and tail
moments as ameasure of DNAdamage. Values are given asmean±SEMofn=2 independent experiments and triplicatemeasurements. Bars that donot share same letters (superscripts)
are signiﬁcantly different fromeach other (pb0.05).Measurementswere performed in the following treatment groups of cells: NT-C: non-treatedMA-10 cells cultured for 72 h; SS-S:MA-
10 cells supplemented and cultured with 30 nM SS for 72 h; SM-S: MA-10 cells supplemented and cultured with 10μM SM for 72 h; DEHP-T: MA-10 cells cultured with 3 mM DEHP for
24 h; SS/DEHP-T: SS-S cells culturedwith 3 mMDEHP for 24 h; SM/DEHP-T: SM-S cells culturedwith 3 mMDEHP for 24 h;MEHP-T:MA-10 cells culturedwith 3μMMEHP for 24 h; SS/
MEHP-T: SS-S cells cultured with 3 μMMEHP for 24 h; SM/MEHP-T: SM-S cells cultured with 3 μMMEHP for 24 h.
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concentrations. Selenoproteins identiﬁed in testis are Sepp1, mitocon-
drial and cytosolic TrxR, GPx1, andGPx4as themost abundantly present
selenoprotein in rat testis (Maiorino et al., 2006; Roveri et al., 1992;
Tramer et al., 1998). Leydig cells, on the other hand, do not contain
appreciable Sepp1 protein (Olson et al., 2007), but they are the major
cells expressing Sepp1 mRNA in testis (Koga et al., 1998; Steinert et al.,
1998). GPx1 has been implicated in antioxidant defense in Leydig cells
that are presumed to produce H2O2 during steroid hormone synthesis
(Peltola et al., 1996). It is thought that the seminiferous epithelium and
mature sperm also require a particularly efﬁcient protection against
oxidative stress (Tramer et al., 1998; Zini and Schlegel, 1997). GPx1, as
the selenoperoxidase most efﬁcient in H2O2 reduction would indeed be
the enzyme of choice to meet this demand (Ursini et al., 1995).
The induction of GPx1 activity inMA-10 cells that we observed with
Se supplementation was previously demonstrated in several tissues,
and reported as being due to enhanced translation and not transcription
of the enzyme (Hu and Diamond, 2003). The Se-containing cytosolic
enzyme GPx1 plays an important role in the defense mechanisms of
mammals against damage by catalyzing the reduction of H2O2 and a
large variety of hydroperoxides (Ursini et al., 1995). GPx1, in addition to
affecting GSH/GSSG, controls the cellular content of H2O2 (or other
organic hydroperoxides) and NADPH/NADP+, so that it may regulate
the cellular redox status. Taking into account the critical importance of
GPx1 activity and expression, theGPx1 activity reducing effects of DEHP
(~2.5-fold) and MEHP (~4-fold) shown in this study in MA-10 cells
might be considered as having important implications in testicular
function. Intracellular GSH is a key redox regulator that is crucial for
multiple biological functions. The decrease of GSH we observed in
phthalate treated cells was further supportive of the occurrence of
oxidative stress and disturbance of the intracellular redox equilibrium,
because removal ofH2O2 byGPx1 requiresGSHas a cofactor. Loss of GSH
also occurs through conjugation to endogenous and exogenous
electrophilic centers in reactions catalyzed by GSTs, the enzymes
capable of detoxifying genotoxic electrophilic compounds by catalyzing
their conjugation to GSH, and thus inactivate several environmental
chemicals (Hayes and Pulford, 1995). However, in this study the activity
of cytosolic GST was found to be reduced more than 50% in DEHP, and
MEHP-treated cells, indicating that the phthalate exposure disturbed
the GST expression and/or activity in MA-10 cells as it disturbed GPx1.
Se supplementation was not effective in restoring the GST activity and
even lowered more, a ﬁnding that remained to be explained.
The Trx system, together with TrxR enzymes and NADPH, comprises
an important defense system against oxidative stress and involved in
manybiological processes, suchasDNAmetabolismand repair, apoptosis,
protein folding and degradation, regulation of several transcription
factors and signal transduction (Björnstedt et al., 1997; Watson et al.,
2004). Multiple TrxR enzymes are present, and cytosolic TrxR is a
predominant form known for its antioxidant properties. Like GPx1, it
plays a role in reducing oxidative species either directly or by
regeneration of cellular antioxidants (Xia et al., 2003), and maintain the
redox balance in the cell (Mustacich and Powis, 2000). Available data also
indicate that cytosolic TrxR is regulated by the redox state of the cell
(Gandin et al., 2009), and its speciﬁc activity is highly sensitive to
concentration of Se in cellular milieu. Our ﬁndings showing ~2.4-fold
decrease in cytosolic TrxR activity by both DEHP and MEHP exposures
and signiﬁcant restoration by Se supplementation, thus, provided more
evidence for the alterations of cellular redox state induced by these two
phthalates. Interestingly, protectionbySe supplementationwascomplete
only inMEHP-exposed cells. Our results also suggested thepossibility that
the decrease of TrxR activity contributes to the cytotoxicity of DEHP, and
MEHP in MA-cells, as TrxR is essential for the normal growth of the cell,
and inhibition of TrxR activity to belownormal level has been reported to
cause inhibited cell growth (Mustacich and Powis, 2000).
Various recent data have shown that ROS were involved in the
modulation of cell redox state, and redox regulation of protein
functions is now accepted as an additional regulatory mechanism of
normal cell physiology (D'Autreaux and Toledano, 2007; Veal et al.,
2007). Thus, ROS recently gained attention as important second
messengers. However, excessive production of ROS may lead to
oxidative stress, loss of cell function, and cell death by apoptosis or
necrosis (Nose, 2000). The increased intracellular ROS production
with phthalate exposure in the current study, along with the
observation of decrease in intracellular GSH level, is the predominant
evidence of a shift in the redox equilibrium towards oxidation, thus
occurrence of oxidative stress. In agreement with our results, Fan et al.
(2010) also observed an increase in ROS generation with MEHP
exposure in MA-10 cells, and demonstrated that the increase of ROS
production even with the highest concentration of MEHP (300 μM)
used in their study was blocked by preincubation of the cells with N-
acetylcysteine (NAC). In this very recent study, the authors suggested
that the MEHP-induced expression of Cyp1a1 might be associated
with the excess ROS generation.
Alteration of cell redox status by ROS can also change thiol groups in
proteins and alter the activation of cell signaling proteins (Dalton et al.,
1999; Finkel, 1998). p53 tumor suppressor protein is one of those
various cell signaling proteins and known to be redox sensitive (Hainaut
and Milner, 1993). When cells are exposed to oxidative stress, p53 is
expressed at high levels by post-translational modiﬁcations (Burns and
El-Deiry, 1999). These modiﬁcations occur rapidly and lead to the
activation of p53, resulting in cell cycle arrest or apoptosis. Therefore,
ROS are reported to function as p53 activators or p53 downstream
effectors (Zhao et al., 2006). In fact, our results showed signiﬁcant
increase in nuclear p53 expression in MEHP-exposed cells further
evidencing the alteration of intracellular redox state by phthalate
exposure. Thus, our data suggested that MEHP, the main metabolite of
DEHP, and possibly at proper doses DEHP itself induce nuclear p53
activation by producing ROS to activate p53. Determination of nuclear
p53 is a good indicator of cell cycle arrest or apoptosis, because after the
transfer of p53 to nucleus or after its overexpression, it is bound to the
promoter regions of several genes including p21, thus, p53 acts as a
transcriptional regulator (Ozturk et al., 2009). The ultimate results of all
these alterations were themodulation of redox sensitive enzymes, DNA
damage as evidenced with the results of alkaline Comet assay, and
decreased cell viability. Our data also showed that, at the dose levels and
formsweused, Se supplementationwasprotective against those adverse
effects of DEHPandMEHP suggesting that Se exerted its protective effect
by regulating the intracellular redox equilibrium of MA-10 cells.
Thus, the results of this study clearly showed the genotoxic potential
of DEHP, and its main metabolite MEHP in MA-10 Leydig cells. This
mighthave a contributory role on theoverall effects of these compounds
which are known as nongenotoxic rodent carcinogens (Rusyn et al.,
2006). On the other hand, Se is known as bimodal in nature. At low
concentrations, Se compounds are antigenotoxic and anticarcinogenic,
whereas at high concentrations, they are mutagenic, toxic, and possibly
carcinogenic (Letavayová et al., 2006). In this regard, it appears that the
doses and the chemical forms of Se we used in this study were
appropriate, did not exert any genotoxicity, but provided protection
against the genotoxic effects of DEHP andMEHPonMA-10 cells at doses
used within the study. The protection of DNA damages by Se might be
through its involvement in DNA repair, but may also be due to a
preventive effect in relation to its intracellular redox modulation.
In conclusion, the overall results of this study demonstrated the
cytotoxicity and genotoxicity of DEHP, and its main metabolite MEHP
in MA-10 mouse Leydig tumor cells indicating the oxidative stress
induction as a main mechanism. Oxidative stress might also be one of
the mechanisms underlying the testicular testosterone suppressing
effect in Leydig cells, and in turn, the reproductive toxicity of DEHP.
Generated data also emphasized the critical role of Se inmodulation of
the redox state in the testicular cells and the importance of the
appropriate Se status. Therefore, it will be meaningful to study the
consequences of oxidative stress on the steroidogenic functions of the
MA-10 Leydig cells and particularly the primary Leydig cells; to
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examine whether there is a link between oxidative stress, cytotoxi-
city, genotoxicity and functional role of those cells; and the regulatory
effects of various doses of Se.
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Transforming Growth Factor-Beta Induces Senescence
in Hepatocellular Carcinoma Cells and Inhibits
Tumor Growth
Serif Senturk,1 Mine Mumcuoglu,1 Ozge Gursoy-Yuzugullu,1,2 Burcu Cingoz,1
Kamil Can Akcali,1 and Mehmet Ozturk1,2
Senescence induction could be used as an effective treatment for hepatocellular carcinoma
(HCC). However, major senescence inducers (p53 and p16Ink4a) are frequently inactivated in
these cancers. We tested whether transforming growth factor-b (TGF-b) could serve as a poten-
tial senescence inducer in HCC. First, we screened for HCC cell lines with intact TGF-b signal-
ing that leads to small mothers against decapentaplegic (Smad)-targeted gene activation. Five
cell lines met this condition, and all of them displayed a strong senescence response to TGF-b1
(1-5 ng/mL) treatment. Upon treatment, c-myc was down-regulated, p21Cip1 and p15Ink4b
were up-regulated, and cells were arrested at G1. The expression of p16
Ink4a was not induced,
and the senescence response was independent of p53 status. A short exposure of less than 1 mi-
nute was sufficient for a robust senescence response. Forced expression of p21Cip1 and p15Ink4b
recapitulated TGF-b1 effects. Senescence response was associated with reduced nicotinamide
adenine dinucleotide phosphate oxidase 4 (Nox4) induction and intracellular reactive oxygen
species (ROS) accumulation. The treatment of cells with the ROS scavengerN-acetyl-L-cyste-
ine, or silencing of the NOX4 gene, rescued p21Cip1 and p15Ink4b accumulation as well as the
growth arrest in response to TGF-b. Human HCC tumors raised in immunodeficient mice
also displayed TGF-b1–induced senescence. More importantly, peritumoral injection of TGF-
b1 (2 ng) at 4-day intervals reduced tumor growth by more than 75%. In contrast, the dele-
tion of TGF-b receptor 2 abolished in vitro senescence response and greatly accelerated in vivo
tumor growth. Conclusion: TGF-b induces p53-independent and p16Ink4a-independent, but
Nox4-dependent, p21Cip1-dependent, p15Ink4b-dependent, and ROS-dependent senescence
arrest in well-differentiated HCC cells. Moreover, TGF-b–induced senescence in vivo is associ-
ated with a strong antitumor response against HCC.(HEPATOLOGY 2010;52:966-974)
Cellular senescence is a permanent withdrawalfrom the cell cycle in response to diverse stressconditions such as dysfunctional telomeres,
DNA damage, strong mitotic signals, and disrupted
chromatin. Senescence is considered to be a major
cause of aging, but also a strong anticancer mecha-
nism.1 The relevance of senescence in chronic liver dis-
eases is poorly known, but it may play a central role.
Hepatocyte telomeres undergo shortening during
chronic liver disease progression,2 and this is accompa-
nied by a progressive decline of hepatocyte prolifera-
tion.3 Senescence-associated b-galactosidase (SA-b-
Gal)-positive cells have been detected in 3%-7% of
normal liver, 50% of chronic hepatitis, 70%-100% of
cirrhosis, and up to 60% of hepatocellular carcinoma
(HCC) tissues.2,4-7 Highly abundant senescence
observed in cirrhosis has been confined to hepatocytes2
and stellate cells.8 Because telomere-deficient mice
Abbreviations: BrdU, bromodeoxyuridine; cDNA, complementary DNA;
NAC, N-acetyl-L-cysteine; Nox4, NADPH oxidase-4; ROS, reactive oxygen
species; SA-b-Gal, senescence-associated-b-galactosidase; siRNA, small interfering
RNA; TERT, telomerase reverse transcriptase; TGF-b, transforming growth
factor-b; TGF-bR1,TGF-b receptor 1.
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develop cirrhosis,9 and cirrhotic hepatocytes display
shortened telomeres, telomere dysfunction was pro-
posed to cause senescence in cirrhosis.2 It is assumed
that HCC tumor cells bypass hepatocellular senescence
to become immortalized. Frequent inactivation of
TP53 (encoding the tumor protein p53) and
CDKN2A (cyclin-dependent kinase inhibitor 2A,
encoding p16Ink4a protein) genes in these tumors sup-
ports this hypothesis.10 Nevertheless, the detection of
senescent cells in some HCC tumors suggests that
transformed and presumably immortal hepatocytes
have maintained the capacity to undergo senescence
arrest under appropriate conditions.
With this regard, immortal HCC cell lines can sponta-
neously generate progeny that undergo replicative senes-
cence11; murine HCC tumors generated by the expres-
sion of a mutant Ras gene in p53-deficient hepatoblasts
can be cleared by a massive senescence response upon
reactivation of p53 expression12; c-myc oncogene inactiva-
tion in murine HCCs results in senescence-mediated tu-
mor regression.13 One of our goals is to identify novel
mechanisms of senescence induction in HCC cells. Here,
we identify the transforming growth factor-beta (TGF-b)
as a major cytokine that is able to trigger a massive senes-
cence response in well-differentiated HCC cell lines.
Reduced nicotinamide adenine dinucleotide phosphate
oxidase-4 (Nox4) and reactive oxygen species (ROS) were
key intermediates of TGF-b–induced growth arrest that
was mediated by p21Cip1 and p15Ink4b.
Materials and Methods
Detailed materials and methods are described in the
Supporting Information Materials and Methods. Cell
lines were tested under standard culture conditions in
the presence of 10% fetal bovine serum. Total RNA
was isolated using a NucleoSpin RNA II Kit
(Macherey-Nagel, Duren, Germany), and first-strand
complementary DNA (cDNA) was synthesized using
RevertAid First Strand cDNA synthesis kit (MBI Fer-
mentas, Leon-Rot, Germany). Genomic DNA was
extracted as described,11 and polymerase chain reaction
(PCR) assays were done using appropriate primers.
Quantitative PCR was performed using SYBR Green I
(Invitrogen, Carlsbad, CA). Glyceraldehyde 3-phos-
phate dehydrogenase and b-actin were used as internal
controls. The SA-b-Gal assay was performed as
described.11 Commercial and homemade antibodies
were used. Western blot assays were performed as
described,11 using a-tubulin or calnexin as internal
controls. For immunoperoxidase and immunofluores-
cence assays, cells were fixed with 4% formaldehyde,
permeabilized with phosphate-buffered saline supple-
mented with 0.5% saponin and 0.3% TritonX-100
(Sigma, St. Louis, MO), and subjected to indirect im-
munofluorescence and immunoperoxidase assays. To
test permanent cell cycle arrest, cells were labeled with
bromodeoxyuridine (BrdU) for 24 hours in freshly
added culture media, and the anti-BrdU immunofluo-
rescence assay was performed as described.11 Human
p15Ink4b and p21Cip1 were cloned into pcDNA3.1C/
Neo and pcDNA3.1(þ)/hygromycin (Invitrogen),
respectively. Cells were transfected with Lipofectamine
2000 (Invitrogen) and selected with either Geneticin
G418 (Gibco) or hygromycin-B (Roche, Indianapolis,
IN) for 8 days. The NOX4 gene was silenced using
previously described Nox4-specific small interfering
RNAs (siRNAs).14 A negative control siRNA was used
in parallel experiments. The siRNAs were transfected
with Lipofectamine RNAiMAX (Invitrogen). The
pSBE4-luc reporter was cotransfected with pRL-TK
(plasmid Renilla luciferase, with thymidine kinase pro-
moter; Promega, Madison, WI), using Lipofectamine
2000. The luciferase assay was performed using a
Dual-Glo luciferase kit (Promega). For cell cycle stud-
ies, fixed cells were labeled with propidium iodide and
analyzed using FACSCalibur Flow Cytometer (BD
Biosciences, San Jose, CA). Intracellular ROS were
detected with 20,70-dichlorofluorescein diacetate
(DCFH-DA; Sigma), using MitoTracker Red (Invitro-
gen) as a counterstain. Apoptosis was tested by Nega-
tive in Apoptosis (NAPO)15 and active caspase-3 anti-
body (Asp-175; Cell Signaling Technology, Danvers,
MA) immunoassays. Subcutaneous human HCC
tumors were obtained in CD1 nude mice using 5 "
106 live cells per injection. All animals received care
according to the Guide for the Care and Use of Labo-
ratory Animals. Results were expressed as mean6 stand-
ard deviation from at least three independent experi-
ments. Data between groups were analyzed by one-tailed
t test. A P value <0.05 was considered statistically sig-
nificant. TGF-b1 expression in liver disease was analyzed
using a publicly available global gene expression data,16
which were normalized using JustRMA tool from the
Bioconductor group.17 A two-sample t test with random
variance model was used with a 0.05 nominal signifi-
cance level of each univariate test.
Results
Differential Expression of TGF-b1 in Normal
Liver, Cirrhosis, and HCC. We first analyzed TGF-
b1 expression in normal liver, cirrhosis, and HCC,
using the publicly available clinical data sets.16 TGF-
b1 expression displayed a bell-shaped distribution with
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a sharp increase in cirrhosis (cirrhosis versus normal
liver, P < 0.001), followed by a progressive decrease
in early HCC (early HCC versus cirrhosis, P < 0.02)
and advanced HCCs (Supporting Information Fig. 1).
This expression pattern closely correlated with reported
frequencies of SA-b-Gal activities in normal liver, cir-
rhosis, and HCC.2,4-7
TGF-b Is an Autocrine Cytokine Inducing a
Senescence-Like Response in Well-Differentiated HCC
Cell Lines. We hypothesized that TGF-b signaling can
induce hepatocellular senescence response, because it is
a potent inducer of G1 arrest.
18 To test this hypothesis,
we first formed a panel of ‘‘well-differentiated’’ HCC
cell lines that display E-cadherin expression, epithelial-
like morphology, and hepatocyte-like gene expres-
sion.19 Well-differentiated cell lines also share the same
TGF-b early response gene expression patterns with
normal hepatocytes.20 All selected cell lines expressed
all critical components of TGF-b signaling including
TGF-b1, TGF-b receptor 1 (TGFBR1), TGFBR2,
small mothers against decapentaplegic homolog 2
(SMAD2), SMAD3, and SMAD4 (Supporting Informa-
tion Fig. 2A). Hep3B-TR clone displaying homozygous
deletion of TGFBR221 was used as a negative control
(Supporting Information Fig. 2). All cell lines, except
Hep3B-TR displayed intact TGF-b signaling activity
(Fig. 1A), as tested by pSBE4-Luc reporter activity.22
Treatment of cells with TGF-b1 (5 ng/mL) yielded
9-fold to 19-fold induction of pSBE4-Luc reporter activ-
ity in responsive cell lines. The expression of endogenous
plasminogen activator inhibitor-1 (PAI-1), a well-known
TGF-b target gene,23 was also induced (Supporting
Information Fig. 3). TGF-b1–treated cell lines were kept
in culture with medium changes (without TGF-b1)
every 3 days, examined morphologically, and subjected
to SA-b-Gal assay. All cell lines tested, except Hep3B-
TR, displayed growth inhibition associated with flattened
cell morphology and >50% positive SA-b-Gal activity,
as early as 3 days after TGF-b1 treatment (Fig. 1B).
Expression of TGF-b1 in all tested cell lines sug-
gested that it could act as an autocrine cytokine.
Therefore, we exposed Huh7 cells to either anti-TGF-
b1 antibody (5 lg/mL) or TGF-b1 (5 ng/mL) and
tested for total and SA-b-Gal–positive cells in isolated
colonies 10 days later. Cells treated with anti-TGF-b1
antibody displayed two-fold increased colony size (P <
0.04) and 50% decreased SA-b-Gal activity (P < 0.02;
Supporting Information Fig. 4). In contrast, ectopic
TGF-b1 treatment caused a seven-fold decrease in col-
ony size (P < 0.005) and five-fold increase in SA-b-
Gal activity (P < 0.0001). Thus, Huh7 cells produced
TGF-b1 acting as a weak autocrine senescence-induc-
ing signal that was inhibited by anti-TGF-b1 antibody,
and amplified by ectopic TGF-b1.
A Brief Exposure to TGF-b for a Robust
Senescence Response. To test the shortest time of ex-
posure to TGF-b1 for a full senescence response, three
cell lines were treated with TGF-b1 for durations
between <1 minute (!20 seconds) and 72 hours, and
subjected to SA-b-Gal staining. To our surprise, <1
minute exposure was sufficient for a robust senescence
response (Fig. 2). Thus, the senescence-initiating effect
of TGF-b1 was immediate, even though the senes-
cence phenotype (>50% SA-b-Gal–positive and flat-
tened cells) was manifested 3 days later.
Lack of Evidence for TGF-b–Induced Apoptosi-
s. Earlier studies indicated that TGF-b induces apo-
ptosis in hepatocytes and some HCC cell lines under
serum-free conditions.24-27 Under our experimental
conditions using 10% fetal bovine serum, all five cell
lines tested failed to enter apoptosis following TGF-b
Fig. 1. Well-differentiated HCC cell lines are competent for TGF-b
signaling activity and they respond to TGF-b by potent senescence-like
growth arrest. (A) Cells were cotransfected with pSBE4-Luc and control
pRL-TK plasmids, and treated with or without TGF-b1 (5 ng/mL) for
24 hours. The luciferase activity was measured and expressed as fold-
activity of pSBE4-Luc/pRL-TK (mean 6 standard deviation; n ¼ 3).
(B) Cells were plated at low density and treated with 1 or 5 ng/mL
TGF-b1, and tested for SA-b-Gal activity (blue) at days 3 and 7.
Counterstain: Fast Red. TGFBR2-deleted Hep3B-TR cells were used as
negative controls in (A) and (B).
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treatment, as examined by NAPO antibody15 and acti-
vated caspase-3–specific antibody tests (Supporting In-
formation Figs. 5 and 6).
TGF-b–Induced Senescence Is Associated with
Sustained Induction of p21Cip1 and p15Ink4b. Cellu-
lar senescence is usually associated with cell cycle arrest
induced by p53, p21Cip1, p16Ink4a, and/or p15Ink4b.1,28
TGF-b1 caused c-myc repression and p15Ink4b and
p21Cip1 induction (Fig. 3; Supporting Information Fig.
7A). Decreased pRb phosphorylation, together with
decreased p107 and increased p130 protein levels, was
also observed. These changes in retinoblastoma family
proteins correlate with exit from the cell cycle.29 The
TGF-b response was independent of p53. All HCC cell
lines tested here, except HepG2, display p53 muta-
tions.30 The levels of total p53 did not change following
TGF-b exposure, despite p21Cip1 accumulation (Fig.
3; Supporting Information Fig. 7B). Moreover, we
observed no phosphorylation of wild-type p53 in
HepG2 cells, following TGF-b exposure (Supporting In-
formation Fig. 7B). TGF-b also did not affect p16Ink4a
levels (Fig. 3). Indeed, the CDKN2A gene is frequently
silenced in HCC.31 Accordingly, p16Ink4a protein levels
were extremely low in all tested cell lines, except in
pRb-deficient Hep3B and Hep3B-TR cells (Supporting
Information Fig. 7C). On the other hand, our
Fig. 2. Induction of a strong se-
nescence-like response by TGF-b
after a very short exposure. Cells
were treated with TGF-b1 (5 ng/
mL) for the indicated times, and
SA-b-Gal activity (blue) was tested
at 72 hours. Control: no TGF-b1
treatment. Counterstain: Fast Red.
Fig. 3. TGF-b treatment of HCC cell lines
causes the induction of p15Ink4b and p21Cip1
that is associated with c-myc down-regulation,
pRb underphosphorylation, p107 decrease
and p130 increase. The levels of p53 and
p16Ink4a did not change. Untreated and TGF-
b1–treated cells were tested for indicated pro-
teins by western blotting on day 3. ppRb:
phospho-Ser807/Ser811-pRb, upRb: under-
phosphorylated pRb. The a-tubulin served as
an internal control. p16Ink4a blots were over-
exposed to visualize weak expression.
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observation of senescence arrest in Hep3B cells suggests
that pRb expression is also dispensable for TGF-b–
induced senescence in HCC cells. Taken together, these
findings suggested that TGF-b was able to induce senes-
cence in HCC cells independent of p53, p16Ink4a, or
pRb status.
TGF-b Induces a Permanent G1 Arrest that Can
Be Reproduced Either by p21Cip1 or p15Ink4b. Cellu-
lar senescence is defined as an irreversible arrest of mitotic
cells at the G1 phase, but some cancer cells enter senescence
at the G2 or S phases.
1 Initially, we used Huh7 cells for cell
cycle studies. These cells accumulated at G1 phase (from
59% to 81%) with a concomitant depletion of S phase
cells (from 18% to 8%), after TGF-b1 exposure (Fig. 4A).
Similar results were obtained with PLC/PRF/5 cells (Fig.
5) and other cell lines (data not shown). These observa-
tions suggested that p21Cip1 and/or p15Ink4b are involved
in TGF-b–mediated G1 arrest and senescence response.
Therefore, we tested respective contributions of p21Cip1
and p15Ink4b in these responses, by transient transfection
assays using Huh7 cells. The p21Cip1-transfected and
p15Ink4b-transfected cells demonstrated highly increased
p21Cip1 protein (Supporting Information Fig. 8A) and
moderately increased p15Ink4b expression (Supporting In-
formation Fig. 8B), respectively. The p21Cip1-overexpress-
ing cells accumulated at G1 (from 61% to 78%), together
with a depletion of S phase cells (from 26% to 13%; Fig.
4B). In association with these changes, SA-b-Gal activity
was increased (Supporting Information Fig. 9A) and BrdU
Fig. 4. G1 arrest induced by TGF-b treatment can be recapitulated
by ectopic expression of p21Cip1 and p15Ink4b. (A) Control and TGF-
b1–treated Huh7 cells were subjected to cell cycle analysis after 3
days of culture. (B, C) Huh7 cells were transiently transfected with (B)
p21Cip1 and (C) p15Ink4b expression vectors, and subjected to cell
cycle analysis after 8 days of culture. Control: cells transfected with
empty plasmid vectors (B,C). [Color figure can be viewed in the online
issue, which is available at wileyonlinelibrary.com.]
Fig. 5. Implication of Nox4 induction and ROS accumulation in TGF-
b–induced growth arrest. (A) TGF-b1 treatement induces the expression
of Nox4, p15Ink4b, and p21Cip1 together with ppRb down-regulation; ROS
scavenger NAC inhibits p15Ink4b and p21Cip1 induction, and ppRb down-
regulation, but not Nox4 accumulation. Cell lysates were collected at day
3, following treatment with TGF-b1 and/or NAC, and tested by western
blotting. (B-D) ROS accumulation observed in TGF-b1–treated cells is
inhibited by NAC cotreatment (B), and this results in (C) inhibition of G1
arrest, and (D) restoration of BrdU incorporation into cellular DNA. (A)
PLC/PRF/5 cells were treated for 3 days with either 10 mM NAC or 5
ng/mL TGF-b1 alone, or in combination, and tested for Nox4, p15Ink4b,
p21Cip1, and ppRb by western blotting. (B) Huh7 and PLC/PRF/5 (PLC)
cells were treated with either 10 mM NAC or 5 ng/mL TGF-b1 alone, or
in combination, and tested for ROS accumulation using a green fluores-
cent ROS indicator, and a red fluorescent mitochondrial marker as coun-
terstain. The effects of 10 mM NAC cotreatment on growth inhibition by
TGF-b1 (0, 1, or 5 ng/mL) were tested by (C) cell cycle analysis, and
(D) BrdU incorporation assay. Blue, red, and green columns in (C) repre-
sent cells at G1, S, and G2/M, respectively.
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incorporation into cellular DNA was inhibited (P <
0.001; Supporting Information Fig. 9B). The p15Ink4b
overexpression caused a moderate response (G1 cells rising
to 66% from 59%; S phase cells decreasing from 22%
from 15%; Fig. 4C). However, p15Ink4b overexpression
was also associated with increased SA-b-Gal activity (Sup-
porting Information Fig. 9C) and decreased BrdU incor-
poration (P< 0.001; Supporting Information Fig. 9D).
TGF-b–Induced Senescence Depends on Nox4
Induction and Intracellular Accumulation of
ROS. TGF-b induces Nox4 expression and ROS accu-
mulation in hepatocytes.32-34 Because ROS have been
implicated in Ras-induced senescence,35 we tested whether
TGF-b–induced senescence was associated with Nox4
induction and ROS accumulation. TGF-b1 induced Nox4
protein expression (Fig. 5A; Supporting Information Fig.
10A), as well as ROS accumulation (Fig. 5B). First, we
used N-acetyl-L-cysteine (NAC) as a physiological ROS
scavenger36 to test the role of ROS in TGF-b–induced se-
nescence. The cotreatment of 5 ng/mL TGF-b1–treated
cells with 10 mM NAC completely suppressed the accu-
mulation of ROS (Fig. 5B) and TGF-b1 effects on
p15Ink4b, p21Cip1, and pRb, but not Nox4 expression (Fig.
5A). More importantly, NAC cotreatment rescued cells
from TGF-b1–induced senescence response (Supporting
Information Fig. 10B) and growth arrest (Fig. 5C,D; Sup-
porting Information Fig. 11). Next, we silenced NOX4
gene in Huh7 cells using a previously described NOX4-
specific siRNA.14 NOX4-specific siRNA inhibited the
accumulation of Nox4 transcripts (!75%; Fig. 6A) and
protein (Fig. 6B) under TGF-b1 treatment. This resulted
in a strong inhibition of p21Cip1 accumulation and a mod-
erate inhibition of p15Ink4b accumulation in association
with restoration of pRb phosphorylation (Fig. 6B). More
importantly, Nox4 inhibition was sufficient to restore cell
proliferation under TGF-b treatment (Fig. 6C).
TGF-b–Induced Senescence and Antitumor Activity
In Vivo. We tested in vivo relevance of TGF-b–
induced senescence in human HCC tumors raised in
Fig. 6. Rescue of TGF-b–induced p21Cip1 and p15Ink4b accumulation and growth arrest by NOX4 gene silencing. (A) TGF-b–induced accumula-
tion of Nox4 transcripts was strongly inhibited by Nox4 siRNA, but not by control siRNA. Transcript analysis was performed by quantitative reverse
transcription PCR. (B) NOX4 gene silencing rescued TGF-b–induced Nox4, p21Cip1, and p15Ink4b protein accumulation, and the inhibition of pRb
phosphorylation, as tested by western blotting. Compared to others, the inhibition of p15Ink4b accumulation was modest. (C) NOX4 gene silenc-
ing also rescued TGF-b–induced inhibition of DNA synthesis, as tested by BrdU incorporation. Cells were labeled with BrdU for 24 hours prior to
day 3, and percent BrdU-positive cells were counted manually.
Fig. 7. TGF-b induces senescence and inhibits the growth of Huh7
tumors in nude mice. (A,B) TGF-b1–induced SA-b-Gal activity in Huh7
tumors. Huh7 tumors were obtained in nude mice and treated with TGF-b1
(!0.5 ng) or a vehicle only. (A) Animals were sacrificed 7 days later to col-
lect tumor tissues. (B) Cryostat sections from freshly frozen tumors were
subjected to SA-b-Gal staining (blue). Counterstain: Fast Red. (C) Huh7
tumors were treated with 2 ng TGF-b or vehicle only at 4-day intervals and
tumor sizes were measured. TGF-b–treated tumors were growth arrested,
resulting in>75% inhibition of tumor growth. *P < 0.05; **P < 0.01.
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immunodeficient mice. TGF-b1 (!50 lL of a 10 ng/
mL solution)-injected Huh7 tumors were removed 1
week later (Fig. 7A) and subjected to SA-b-Gal stain-
ing. TGF-b1 induced local but expanded SA-b-Gal ac-
tivity in three of four tumors tested; three tumors
treated with vehicle only were negative (Fig. 7B).
To test antitumor effects of TGF-b, early Huh7
tumors were treated with peritumoral injection of !2
ng TGF-b at 4 days of intervals. Vehicle-treated tumors
displayed exponential growth to reach 4 cm3 volume on
average within 24 days. In contrast, TGF-b–treated
tumors were growth arrested throughout the experiment
and remained <1 cm3 on average at the same time pe-
riod. Tumor inhibition was significant for at least 24
days (P < 0.01 to P < 0.05). The TGF-b treatment was
stopped at day 24 and animals were observed for an
additional period of 4 weeks. All vehicle-treated and
four TGF-b–treated animals died, whereas complete
remission was observed in two TGF-b–treated animals
(data not shown). We also compared TGFBR2-deleted
Hep3B-TR cells21 with parental Hep3B cells. Hep3B-
TR cells formed palpable tumors 2 weeks after subcuta-
neous injection, and host animals died within 4-6
weeks. In contrast, Hep3B cells formed tumors with a
latency of 6-7 weeks (Supporting Information Fig. 12).
Discussion
Our findings provide strong evidence for senescence
as a major response of HCC cells to TGF-b. Senes-
cence-associated changes included flattened morphol-
ogy, p21Cip1 and p15Ink4b accumulation, and positive
SA-b-Gal activity. This response has not been noticed
previously, probably because of its late occurrence, at
least 3 days after TGF-b treatment. The primary find-
ings of our mechanistic studies on TGF-b–induced se-
nescence in HCC cells are outlined in Fig. 8. TGF-b-
induced senescence response was associated with
p21Cip1-mediated and p15Ink4b-mediated G1 arrest, in-
dependent of p53 or p16Ink4a. This correlates with the
earlier observations showing that TGF-b uses p21Cip1
and p15Ink4b, but not p16Ink4a nor p53 to induce G1
arrest in other cell types.18 Although TGF-b–induced
senescence had been described many years ago,37 its
mechanisms are poorly understood. Here, we show
that the overexpression of p21Cip1, and p15Ink4b to a
lesser degree, recapitulates TGF-b–induced senescence
response. Thus, p21Cip1 and p15Ink4b are able to
induce G1 arrest and senescence response in HCC
cells, as it occurs in other cell types.10 Our most inter-
esting finding was the implication of both Nox4 and
ROS in the induction of p21Cip1 and p15Ink4b, and
G1 arrest by TGF-b. Either NOX4 gene silencing or
ROS scavenging was sufficient to interrupt the TGF-b
signaling toward growth arrest mediated by p21Cip1
and p15Ink4b induction. Thus, the accumulation of
both Nox4 protein and ROS is a critical step for
p21Cip1 and p15Ink4b accumulation in TGF-b–exposed
HCC cells (Fig. 8). Inhibition of p21Cip1-mediated
ROS accumulation has been previously shown to res-
cue senescence,38 and a feedback between p21Cip1 and
ROS production was necessary for stable growth
arrest.39
Our findings also provided preliminary evidence for
antitumor activity of TGF-b against HCC. This effect
was associated with in vivo induction of SA-b-Gal ac-
tivity in tumor cells. Thus,TGF-b–induced senescence
in human HCC cells, similar to p53-induced senes-
cence in mouse HCC cells,12 may be a potent tumor
suppressor mechanism. The accelerated tumorigenesis
of TGFBR2-deleted Hep3B-TR cells supports this hy-
pothesis. Previous studies indicated that the disruption
of TGF-b signaling in mice through dominant-nega-
tive Tgfr2 (transforming growth factor receptor 2)
accelerates chemically induced hepatocarcinogenesis.40
A similar disruption in b-spectrin embryonic liver
fodrin knockout mice also leads to hepatocellular can-
cer.41,42 However, our findings are limited to well-dif-
ferentiated HCC cells that represent early forms of
HCC.43 Poorly differentiated HCC cell lines appear to
Fig. 8. A hypothetical model summarizing major components of
TGF-b–induced senescence in HCC cells.
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be resistant to TGF-b-induced senescence (S. Senturk
and M. Ozturk, unpublished data). Nevertheless,
TGF-b treatment might be an attractive therapeutic
option for early HCCs.
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Abstract
Automated classification of proteins is indispensable for further in vivo investigation of excessive number of unknown sequences generated
by large scale molecular biology techniques. This study describes a discriminative system based on feature space mapping, called subsequence
profile map (SPMap) for functional classification of protein sequences. SPMap takes into account the information coming from the subsequences
of a protein. A group of protein sequences that belong to the same level of classification is decomposed into fixed-length subsequences and they
are clustered to obtain a representative feature space mapping. Mapping is defined as the distribution of the subsequences of a protein sequence
over these clusters. The resulting feature space representation is used to train discriminative classifiers for functional families. The aim of this
approach is to incorporate information coming from important subregions that are conserved over a family of proteins while avoiding the difficult
task of explicit motif identification. The performance of the method was assessed through tests on various protein classification tasks. Our results
showed that SPMap is capable of high accuracy classification in most of these tasks. Furthermore SPMap is fast and scalable enough to handle
large datasets.
© 2007 Elsevier Ltd. All rights reserved.
Keywords: Protein function prediction; Subsequence distribution; Function classification
1. Introduction
Along with the recent advances in genome sequencing
technologies, the number of protein sequences with missing
annotations increases rapidly. Thus, computational classifica-
tion methods become valuable for providing a road map for
the biologist for further investigation of the excessive number
of unknown sequences in vivo. In general, in silico course of
action for the classification of a new sequence is to find simi-
lar sequences whose functions are experimentally determined.
This is usually performed by searching public databases using
local alignment search tools such as BLAST or PSI-BLAST and
annotations for the highest scoring hits are transferred onto the
new sequence (Altschul et al., 1990, 1997). Although this sim-
ple method performs well in many cases, it has some important
drawbacks such as excessive transfer of annotations, propaga-
tion of errors in the source database, threshold relativity and low
∗ Corresponding author. Tel.: +90 312 210 5576; fax: +90 312 210 5544.
E-mail address: volkan@ceng.metu.edu.tr (V. Atalay).
sensitivity/specificity (Devos and Valencia, 2000; Gilks et al.,
2005; Sasson et al., 2006; Friedberg, 2006). It has been shown
recently that although inferring homology through sequence
similarity generally holds for the 3D structure, it is far less justi-
fied for the function. Additional information than just pairwise
similarity is needed to find more accurate annotations (Devos
and Valencia, 2000).
Existing approaches to the computational classification
beyond simple homology-based transfer can be grouped into
three classes: improved homology-based methods, feature-based
methods, and subsequence-based methods (Pandey et al., 2006).
Improved homology-based approach still uses sequence homol-
ogy, however it incorporates additional information (Andrade
et al., 1999; Riley et al., 2005; Martin et al., 2004), such as
multiple sequence alignments or classifications of similarity
results according to a hierarchical and structured organization
of functions like in Gene Ontology (GO) database (Ashburner
et al., 2000). On the other hand, both feature-based and
subsequence-based approaches pursue discriminative method-
ology that explicitly models the differences between positive and
negative examples. Two approaches differ in the way how they
1476-9271/$ – see front matter © 2007 Elsevier Ltd. All rights reserved.
doi:10.1016/j.compbiolchem.2007.11.004
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extract features from sequences. In the feature-based approach,
biologically meaningful properties of a protein such as fre-
quency of residues, molecular weight, secondary structure,
n-gram frequencies, are extracted from the primary sequence.
These properties are then arranged as feature vectors and used
as input to classification techniques such as artificial neural net-
works (ANNs) or support vector machines (SVMs) (Duda et
al., 2000; King et al., 2000; Pasquier et al., 2001; Jensen et
al., 2002; Cai et al., 2003; Karchin et al., 2002; Cheng et al.,
2005). On the other hand, conserved subsequences among a
class of proteins are employed in subsequence-based methods.
The main idea is that, conserved subsequences among different
proteins are strong indicators of functional or structural sim-
ilarity because functionally important regions (catalytic sites,
binding sites, structural motifs) are conserved over much wider
taxonomic distances than the sequences themselves. Thus, in
subsequence-based approach feature vectors are constructed
according to the existence of specific motifs or domains in
the protein sequences. The critical step in this approach is the
extraction and selection of motifs. One possibility is to use
motif information from protein databases (Ben-hur and Brutlag,
2003; Wang et al., 2003) in which motifs are assumed to be
already available for the family of proteins to be classified.
Most of the methods of subsequence-based approach attempt
to extract motifs explicitly for the given families (Hannenhalli
and Russell, 2000; Wang et al., 2001; Liu and Califano, 2001;
Kunik et al., 2005; Blekas et al., 2005). Although motifs are
powerful discriminators even in low similarity (remote homol-
ogy) situations, motif finding is a very difficult task, especially
for protein sequences since there are 20 different amino acids
and many plausible mutations. Multiple sequence alignments
and other computational pattern extraction algorithms are often
employed for motif finding. Unfortunately, algorithms that can
find optimal solutions in all of these methods have exponential
time complexities, hence approximation or heuristic algorithms
are used instead. As a consequence, there is always the risk
of missing some relatively implicit motifs. Furthermore, classi-
cal motif finding algorithms find a specified number of motifs
even if there are not that many biological motifs in the family.
These insignificant additional motifs might reduce the accuracy
of the classification. One other issue is that, depending on the
classification task, proteins to be classified might not have a
common motif at all. As an example, in the problem of subcel-
lular localization, when discriminating cytosolic proteins, it is
not possible to find motifs specific to this class. Methods that
consider overall sequence similarity may perform better in such
cases.
In this study, we describe a feature space mapping, called
subsequence profile map (SPMap), that takes into account the
information coming from the subsequences of a protein. Our
approach incorporates the information coming from important
subregions that are conserved over a family of proteins as well as
the overall sequence similarity. Instead of focusing on function
specific motifs, SPMap considers all of the subsequences as a
distribution over a quantized space by discretizing and reduc-
ing the dimension of an otherwise huge space of all possible
subsequences.
2. Systems and Methods
The system described in this study is based on a discrimina-
tive method which requires positive and negative examples to
classify and annotate proteins whose functions are not known.
Instead of looking for the overall similarity of protein sequences,
we make use of the distribution of short subsequences of
a given protein over a subsequence profile map. We gener-
ated the profiles using all possible fixed-length subsequences
of the protein sequences in the positive training set. Similar
subsequences were clustered together and clusters were repre-
sent as probabilistic profiles. The major reasoning behind this
approach is that, subsequences extracted from the conserved
regions are more frequent than any other subsequence extracted
from the positive training data. If the frequent subsequences
are represented as dimensions of feature vectors, discrimina-
tive methods can make use of this information. If there is a
conserved motif or a domain in the given sequences or there
is an overall similarity between sequences, they would pro-
duce similar distributions on the profile map. Classifiers such
as support vector machines (SVMs) may then identify these
similar distributions and hence improve the classification accu-
racy.
In order to perform the classification, SVMs were used. We
constructed fixed dimensional vectors that represent the subse-
quence distribution information. There are two critical steps in
SPMap as shown in Fig. 1:
A. subsequence profile map construction,
B. feature vector generation and classification.
2.1. Subsequence Profile Map Construction
In SPMap, feature space representation of a protein sequence
is the distribution of its subsequences over a map of generative
models. General framework for finding this generative feature
map is summarized as follows.
• Subsequence Extraction Module: Extract all possible subse-
quences of a given length from positive training sequences.
• Clustering Module: Cluster similar subsequences by an
appropriate clustering method.
• Profile Construction Module: Build a model for each cluster.
The important step here is the clustering of subsequences.
Note that the space of all possible subsequences of length l is
of size 20l, since there are 20 possible amino acids. Instead
of working in this very high dimensional space, we quantized
this space using the clusters of subsequences that are actually
existing in the positive training examples. One should note that,
as we clustered the subsequences, we were not actually look-
ing for underlying groupings. The aim here was to generate a
meaningful quantization of the subsequence space that espe-
cially represent groups of frequent and similar subsequences in
the positive training data. These subsequences might have been
conserved because of their importance for the function of that
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Fig. 1. SPMap flow diagram. (A) Subsequence profile map construction: subsequences of the proteins in positive training set are clustered to construct subsequence
profile map. (B) Classification: constructed profile map is utilized to find the feature space representation of the protein sequence to be classified.
class of proteins and we wanted our feature space to take them
into account. Clustering algorithm is given in Algorithm 1. It
is similar to the average link hierarchical clustering, however
it can be implemented very efficiently without calculating all
the pairwise distances. Initially the number of clusters is set
to 0. Each subsequence is compared against all of the existing
clusters and average similarity to the elements of each cluster
is calculated. A subsequence is assigned to the cluster, Cmax,
which gives the maximum average similarity value. If the simi-
larity to Cmax is less than a threshold, δ, a new cluster is created
and the subsequence is assigned to the new cluster. Similar-
ity between two subsequences x and y was calculated by the
formula
s(x, y) =
l∑
i=1
M(x(i), y(i)) (1)
where l is the length of the subsequences and M(x(i), y(i))
is the value in the similarity matrix for the ith elements of
x and y. For M, we used an amino acid similarity matrix,
since it allows us to incorporate evolutionary information in
finding and representing important conserved regions of a fam-
ily of proteins. The final number of clusters depend on the
threshold value δ. If it is set to a high value, clusters will be
smaller only allowing very similar subsequences and the total
number of clusters will be high. If it is set to a low value,
biologically unrelated subsequences might end up in the same
cluster.
Algorithm 1. Clustering Algorithm.
After the clustering step, we generated a probabilistic profile
for each cluster. A probabilistic profile PPk for cluster k, is an
l× 20 matrix, where l is the length of a subsequence. Entry
Pk(i, j) of this matrix represents the probability of amino acid j
to occur at the ith position of the subsequence. Given a cluster
Ck, the profile for this cluster is calculated by the following
equation:
PPk(i, j) = log φk(i, j) + κ|Ck| (2)
where φk(i, j) represents the count of the amino acid j at posi-
tion i of the subsequences in Ck. We added a pseudo-count κ for
amino acids at each position to avoid over-fitting and zero prob-
abilities. Actually, we took the log of the profiles and worked
with log-probabilities in the conversion step.
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2.2. Feature Vector Generation
Proteins were represented in the feature space as the distri-
bution of their subsequences over the generated subsequence
profile map. All the subsequences of a protein were extracted
to construct a feature vector. Each subsequence x was com-
pared with each probabilistic profile PPk and a probability was
calculated as
P(x|PPk) =
l∑
i=0
PPk(i, x(i)). (3)
The value for the kth dimension of the feature vector V is set
to
V (k) = maxxi ∈ SP(xi|PPk), (4)
the probability of highest scoring subsequence of protein S on
probabilistic profile PPk. This algorithm is similar to the vector
generation algorithm presented in Blekas et al. (2005) with the
difference that we set V (k) to 0 if the probability is very small.
2.3. Classification
Once the protein sequences are mapped onto the feature
space, any numerical machine learning tool can be employed.
Our choice was to use SVMs since they are experimentally
proven to be successful for various problems (Cristianini and
Shawe-Taylor, 2000). Radial basis function (RBF) was chosen
as the kernel for SVM. In all of the experiments, SVM param-
eter C and RBF kernel parameter γ were fixed to be 2 and
0.05, respectively. SVM-light software was used for learning
and classification steps (Joachims, 1999).
2.4. Experimental Setup
In all of the experiments, BLOSUM62 matrix was employed
to calculate the similarity between subsequences (Henikoff and
Henikoff, 1992) although it is possible to use different similarity
matrices depending on the sequence divergence or the taxo-
nomic distance between the proteins to be classified (Atalay and
Cetin-Atalay, 2005; Tomii and Kanehisa, 1996). BLOSUM62
is shown to be useful for a wide range of problems and is the
default selection for most of the alignment tools (Altschul et
al., 1990, 1997). Length of the subsequences was set to 5. Set-
ting the subsequence length to 5 did not mean that we sought
for motifs of 5 amino acid length. In SPMap, motifs were the
overall distribution of the subsequences over the profiles con-
structed from resulting 5 length subsequence clusters. Hence
subsequence length 5 allowed us to capture longer motifs as a
distribution over more than one profile. We tested the perfor-
mance of SPMap by changing the subsequence length in the
interval [5,12] on selected sample sets of data. We observed that
although there were differences in the performance with respect
to the change in the subsequence length, 5 was the optimal in the
sense of performance versus computational complexity. Thresh-
old similarity score δ in Algorithm 1 was fixed to 8 where
the expected similarity score of two random subsequences of
Table 1
Average ROC scores and standard deviations for subcellular localization
predictions
Localization Data size Mean ROC S.D.
ER targeted 3115 0.97 0.006
Cytoplasmic 1789 0.95 0.005
Mitochondrial 1148 0.96 0.006
Nuclear 2225 0.96 0.005
length 5 using BLOSUM62 matrix is −5.325. Compared to the
expected value, 8 is high enough to disallow random similari-
ties. Extensive tests with different threshold values showed that
8 performed better in most of the test cases and it was set as
default in all of the experiments.
3. Results
3.1. Subcellular Localization
The idea of subsequence distribution was first proposed in
P2SL (Atalay and Cetin-Atalay, 2005). However, we developed
more robust, reliable and efficient method for this idea. In order
to be able to show the improvement, we first performed tests on
the subcellular localization dataset on which P2SL was trained
and tested. Dataset was composed of four different classes,
namely ER targeted (ER), cytoplasmic (C), mitochondrial (M)
and nuclear (N) (Atalay and Cetin-Atalay, 2005). ER targeted
and mitochondrial proteins have signal peptides of length 25 and
35 amino acids, respectively, at the N-terminal of the proteins.
While extracting subsequences for feature map construction we
used first 30 amino acids for ER targeted proteins and first
40 amino acids for mitochondrial proteins. Two types of tests
were performed. First, in a one-versus-all setting, ROC scores
were calculated for each localization and results are given in
Table 1.
In the second test case, classifiers for each localization were
combined using the winner-take-all principle. Each test sam-
ple was assigned to the location whose classifier produced the
highest SVM score. The confusion matrix obtained by averag-
ing fourfold cross-validation tests and their comparison with
P2SL results are given in Table 2 (Atalay and Cetin-Atalay,
2005).
3.2. G-protein-Coupled Receptor Subfamily Classification
Tests are subsequently carried on G-protein-coupled receptor
(GPCR) subfamily classification problem that was extensively
studied in the literature. Consequently, GPCR subfamily clas-
sification constitutes a good benchmark dataset for comparing
with other methods. For GPCR subfamily classification, we
used the dataset presented in Karchin et al. (2002) to compare
with the results of various classifiers presented in Karchin et al.
(2002) and Cheng et al. (2005). Same train and test splits were
used for twofold cross validation for fairness of comparison.
SPMap was tested on level I and level II subfamily classification
of GPCR proteins. In level I subfamily classification, there
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Table 2
Confusion matrix representing average percentage results of fourfold prediction
tests compared with P2SL results
Actual Predicted label
N (%) C (%) M (%) ER (%)
N
SPMap 89.83 7.5 1.1 1.58
P2SL 75.34 19.94 3.29 1.43
C
SPMap 7.14 89.05 1.8 2.02
P2SL 14.66 79.33 3.65 2.36
M
SPMap 2.09 5.4 89.29 3.22
P2SL 3.31 7.23 83.80 5.66
ER
SPMap 2.07 2.5 1.41 94.03
P2SL 4.89 6.19 3.29 85.63
were 1269 sequences from 19 subfamilies within classes A
and C in addition to 149 non-GPCR sequences. In level II
subfamily classification, there were 1170 GPCR sequences
from 70 different level II subfamilies. Some of the sequences
in level I subfamily classification have no level II subfamily
classification and some of the level II subfamilies only have one
protein so they are grouped as other sequences with non-GPCR
sequences. Datasets and train and test splits are available at
http://www.soe.ucsc.edu/research/compbio/gpcr/subfamily seqs.
The comparison of accuracy of various classifiers and SPMap
is presented in Table 3. Fisher-SVM, BLAST, SAM-T2K HMM,
and kernNN methods were presented in Karchin et al. (2002)
and Decision Tree and Naı¨ve Bayes methods were presented in
Cheng et al. (2005).
3.3. Enzyme Class Classification
Finally we evaluated the performance of SPMap on enzyme
class classification. Enzymes play a central role in many of
the biological functions in a cell. They are indispensable for
understanding the molecular systems in a cell and are important
drug targets. Hence accurate classification is very important in
enzyme research.
Dataset for enzyme classification is extracted from BRENDA
database (Schomburg et al., 2002). International Union of
Biochemistry and Molecular Biology defines the numerical clas-
Table 3
Comparison of accuracy of various classifiers at GPCR levels I and II subfamily
classification
Classifier Level I accuracy Level II accuracy
BLAST 83.3 74.5
Decision Tree 77.3 70.8
Fisher-SVM 88.4 86.3
kernNN 64.0 51.0
Naı¨ve Bayes 93.0 92.4
SAM-T2K HMM 69.9 70.0
SPMap 95.4 93.8
Table 4
Comparison of success rates of various classifiers on six major enzyme classes
calculated with leave-one-out cross-validation
Classes Total Success (%)
Lu et al. Blast Psi-Blast SVM-Prot SPMap
Oxidoreductase 436 93.53 89.68 91.06 73.62 80.73
Transferase 832 93.63 88.46 87.98 82.45 66.23
Hydrolase 741 94.20 86.10 86.77 77.33 71.93
Lyase 170 75.29 75.29 70.59 68.82 94.12
Isomerase 114 74.56 73.68 73.68 68.42 96.49
Ligase 150 89.33 90.00 88.67 37.33 88.00
sification scheme for enzymes based on the chemical reactions
they catalyze. Each enzyme is described by a sequence of four
numbers (EC numbers) resulting from a four-level hierarchy
where first number specifies the most general class and the
last one specifies the most specific. At the highest level there
are six major classes of enzymes. Automated prediction meth-
ods are successfully applied to enzyme classification according
to the first (Lu et al., 2007) and second level of EC numbers
(Cai et al., 2003). We also performed tests according to the
first and second EC numbers. On the first level there are six
major classes of enzymes. Dataset used for this level is pre-
sented in Lu et al. (2007). Each class is filtered so that there
are no pair of proteins with more than 25% sequence iden-
tity. The success rates for various methods and SPMap for
six classes with leave-one-out cross-validation is presented in
Table 4.
We also classified proteins according to their first two EC
numbers, resulting in 56 classes. We omitted classes with very
few members. Sensitivity and specificity values calculated over
fourfold cross validation are presented in Table 5. This classi-
fier for 56 enzyme classes is available as an online service at
http://gen.ceng.metu.edu.tr/spmap/cgi-bin/enzyme.cgi.
4. Discussion
4.1. Computational Complexity
SPMap is composed of two main parts. First part is the sub-
sequence profile map construction. It is only performed once
for a new classifier to be trained. Hence, its efficiency does
not affect the performance during the classification of new
sequences. The most expensive part of the map construction is
the clustering of subsequences. Most of the standard clustering
algorithms require numerical vectors to work on. More specif-
ically, they require a metric to calculate the distance between
the cluster representations and data points and a method to
update these cluster representations throughout the course of
the algorithm. These methods usually perform O(nk) distance
calculations where n is the number of data points and k is the
number of clusters. They require the number of clusters k to
be given at the start. There are also clustering algorithms that
use only pairwise distances between data points. They do not
require the number of clusters k as a parameter but they have
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Table 5
Sensitivity (TP/(TP + FN)) and specificity (TN/(TN + FP)) values for 56 enzyme class classifiers calculated over fourfold cross validation
Enzyme class Data size Sensitivity Specificity
EC 1.1 Acting on the CH–OH group of donors 8878 95.33 85.05
EC 1.2 Acting on the aldehyde or oxo group of donors 4099 91.63 97.17
EC 1.3 Acting on the CH–CH group of donors 2455 85.75 98.09
EC 1.4 Acting on the CH–NH2 group of donors 1573 88.64 99.74
EC 1.5 Acting on the CH–NH group of donors 1244 81.35 99.72
EC 1.6 Acting on NADH or NADPH 5572 94.54 95.85
EC 1.7 Acting on other nitrogenous compounds as donors 802 83.67 99.93
EC 1.8 Acting on a sulfur group of donors 1699 89.94 99.82
EC 1.9 Acting on a heme group of donors 1620 93.99 98.51
EC 1.10 Acting on diphenols and related substances as donors 813 86.86 99.98
EC 1.11 Acting on a peroxide as acceptor 1267 91.56 99.97
EC 1.12 Acting on hydrogen as donor 243 68.89 99.97
EC 1.13 Acting on single donors/with incorporation of molecular oxygen (oxygenases) 1048 87.66 99.97
EC 1.14 Acting on paired donors, with incorporation/or reduction of molecular oxygen 1909 83.3 98.42
EC 1.15 Acting on superoxide radicals as acceptor 935 93.56 99.99
EC 1.16 Oxidising metal ions 142 65.71 99.96
EC 1.17 Acting on CH or CH2 groups 1063 90.31 99.92
EC 1.18 Acting on iron–sulfur proteins as donors 745 91.94 99.97
EC 1.20 Acting on phosphorus or arsenic in donors 66 66.67 99.99
EC 1.21Acting on X–H and Y–H to form an X–Y bond 60 88.89 100
EC 1.97 Other oxidoreductases 169 80.95 99.99
EC 2.1 Transferring one-carbon groups 6061 92.28 90.97
EC 2.2 Transferring aldehyde or ketonic groups 1058 94.32 99.94
EC 2.3 Acyltransferases 6149 92.52 91.55
EC 2.4 Glycosyltransferases 6004 92.65 89.54
EC 2.5 Transferring alkyl or aryl groups, other than methyl groups 5188 93.94 96.73
EC 2.6 Transferring nitrogenous groups 2011 95.22 99.85
EC 2.7 Transferring phosphorus-containing groups 23424 89.78 91.08
EC 2.8 Transferring sulfur-containing groups 982 87.35 99.91
EC 2.9 Transferring selenium-containing groups 72 88.89 100
EC 3.1 Acting on ester bonds 9879 74.79 96.05
EC 3.2 Glycosylases 4789 93.76 91.98
EC 3.3 Acting on peptide bonds (peptidases) 5945 93.4 87.48
EC 3.5 Acting on carbon–nitrogen bonds, other than peptide bonds 5942 90.28 88.25
EC 3.6 Acting on acid anhydrides 7430 96.23 88.22
EC 3.7 Acting on carbon–carbon bonds 66 81.25 100
EC 3.8 Acting on halide bonds 101 49.33 99.98
EC 4.1 Carbon–carbon lyases 7606 93.77 87.95
EC 4.2 Carbon–oxygen lyases 7211 93.23 87.46
EC 4.3 Carbon–nitrogen lyases 1264 91.14 99.89
EC 4.4 Carbon–sulfur lyases 626 82.91 99.8
EC 4.6 Phosphorus–oxygen lyases 614 91.28 99.9
EC 4.99 Other lyases 297 90.99 99.98
EC 5.1 Racemases and epimerases 2030 92.18 99.66
EC 5.2 cis–trans-Isomerases 1232 92.86 99.92
EC 5.3 Intramolecular isomerases 2910 90.65 99.18
EC 5.4 Intramolecular transferases (mutases) 2195 88.57 99.37
EC 5.5 Intramolecular lyases 135 71.72 99.98
EC 5.99 Other isomerases 1418 95.57 99.96
EC 6.1 Forming carbon–oxygen bonds 6285 97.05 98.39
EC 6.2 Forming carbon–sulfur bonds 1112 93.17 99.91
EC 6.3 Forming carbon–nitrogen bonds 6784 94.53 95.25
EC 6.4 Forming carbon–carbon bonds 785 94.9 99.87
EC 6.5 Forming phosphoric ester bonds 433 89.2 99.97
EC 6.6 Forming nitrogen-metal bonds 118 90.81 99.97
to perform O(n2) pairwise distance calculations and that might
be very inefficient in terms of time and memory for large n.
Note that n in this case is the total number of subsequences
extracted from all of the positive training examples, which is
roughly the number of amino acids in the positive training
examples. However, Algorithm 1 can be implemented in O(nk).
The critical step is the calculation of the average distance of
subsequence xi to the cluster u given in the following equa-
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tion:
su =
∑
xj ∈Cu
s(xi, xj)
|Cu| (5)
With this definition, Algorithm 1 requires n2 pairwise sub-
sequence similarity calculations. Combining Eqs. (1) and (5)
and rearranging the formula, su can be written as given in the
following equation:
su =
l∑
t=1
20∑
j=1
f tu(aj)M(xi(t), aj) (6)
where xi(t) denotes the amino acid appearing at the tth position
of the subsequence xi and M(xi(t), aj) is the entry of similarity
matrix for amino acids xi(t) and aj . f tu(aj) represents the fre-
quency of amino acid aj at the tth position of subsequences in
cluster u. The complexity of Algorithm 1 becomesO(nkl) where
l is the length of the subsequences, k is the number of clusters,
and n is the total length of all of the proteins in positive training
set. Since l, is an arbitrary but fixed parameter, it can be said that
it is O(nk) with respect to the size of the input sequences. k is
dependent on the threshold value δ given in Algorithm 1; but it
is around 1800 for the default δ value, 8. It is almost constant or
varying very slowly with the data size. The second part of the
presented method is construction of the feature vectors. Since
the probability of each subsequence of the protein against all
of the subsequence profiles must be calculated, it again can be
implemented in O(nk)time. In this case, n represents the length
of the given protein to be mapped and k is the number of subse-
quence profiles. SPMap is linear in the size of the input data. It
is very efficient and scalable to handle large datasets.
4.2. Performance Test Results
SPMap has a significant improvement over P2SL for sub-
cellular localization classification. The improvement is both in
terms of accuracy and computational efficiency. In order to dis-
cretize the subsequence space, P2SL uses self-organizing maps
(SOMs) which are hard to train because of the necessity of large
training data and convergence problems. As a result different
runs on SOM might result in different feature spaces. P2SL is
prone to missing some important subsequences since it does not
consider all possible subsequences. Since SOM requires numeri-
cal vectors, P2SL encodes amino acids as 20 dimensional vectors
which causes a 5 length subsequence to be represented as a
100 dimensional vector further complicating the SOM training.
SPMap uses clusters of all possible subsequences for discretiza-
tion of subsequence space instead of SOM in P2SL. Similarity
between subsequences are calculated using an amino acid simi-
larity matrix and standard string similarity calculation methods,
avoiding high dimensional encoding of subsequences. One of
the advantages of SPMap is that it works well on wide range of
different classification tasks with the default parameter values.
This makes it easier to use without expertise and optimization.
Furthermore, our feature space mapping algorithm have only one
parameter, the threshold value δ, which has a well performing
default value in general.
We also investigated the performance of SPMap on functional
classification tasks other than subcellular localization. In order
to assess and compare the capabilities of SPMap, we performed
tests on G-protein-coupled receptor subfamily level classifica-
tion. GPCRs are very important targets in drug design but known
to be hard to classify, because they have highly diverse family
at the sequence level (Moriyama and Kim, 2006). It can be seen
that SPMap outperformed other classifiers in both level I and
level II GPCR subfamily classification. To our knowledge, at
the time of writing this paper, Naı¨ve Bayes approach of Cheng
et al. (2005) was the best performing method on the benchmark
dataset presented in Karchin et al. (2002).
The application of SPMap on enzyme class classification
demonstrated that our method too generates comparable or better
results to those obtained by previous studies. The dataset used for
the test on 6 major enzyme classes was filtered so that there are
no pair of proteins with more than 25% sequence identity. This
makes the classification task more difficult especially for the
methods that only use sequence or subsequence similarity. Fur-
thermore, SPMap depends solely on the available training data
to generate the subsequence feature map, where the method pre-
sented in Lu et al. (2007) uses domains that are already available
in the databases. Nevertheless, results were interestingly com-
plementary. SPMap achieved very high accuracy when the other
methods performed poorly and vice versa. For the second level
of enzyme hierarchy SPMap achieved high sensitivity in most
of the classes. We used all the available data in fourfold cross
validation. As a result, a few classes with comparably large data
sizes were biased towards false positives, hence relatively low
specificity. Selecting a representative training subset for large
classes might enhance the specificity of the classifier.
4.3. Perspectives
Since supervised discriminative methods model the dif-
ferences between families of positive and negative examples
explicitly, they provide better solutions for most of the prob-
lems of function classification. Most widely used discriminative
method is the support vector machines (SVMs) combined with
an appropriate kernel or feature space mapping (Cristianini and
Shawe-Taylor, 2000). The main issue in classification of pro-
teins according to their primary sequences is to find a kernel
or a feature mapping that captures the information hidden in
the important discriminative regions of the given sequences.
Since, functionally important regions (catalytic sites, binding
sites, structural motifs) are conserved over much wider tax-
onomic distances than the sequences themselves, conserved
subsequences among different proteins are strong indicators of
functional or structural similarity. Hence, SPMap pursued a new
approach based on distribution of subsequences over a map
constructed using the actual protein sequences in the positive
training set.
The idea of constructing similarity graphs of subsequences
and extracting motifs from the clusters of these graphs was
already exploited for DNA sequences (Fratkin et al., 2006). In
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SPMap, we did not try to identify the motifs explicitly. We just
let the classification algorithm learn which subsequence distri-
butions are in fact discriminative. One advantage of SPMap is
that it allows further investigation of these constructed profiles
to identify motifs of positive training family. As a feature study,
constructed profiles can be investigated to see how similar or dif-
ferent they are, compared to the aligned regions resulting from
a multiple sequence alignment of that family of proteins.
One further step may be identifying disordered regions and
extracting subsequences from these regions. Most of the active
sites, catalytic sites, etc. lies along disordered regions (Dunker
et al., 2002; Wright and Dyson, 1999). This would reduce the
number of unrelated subsequences hence the noise during the
feature map construction.
One reason the discriminative methods do not receive as
much attention among the biologists compared to the standard
sequence alignment methods is the requirement of handling
large number of functional classes. It is almost prohibitive if one
wants to perform the classification in a one-versus-one scheme.
In this study we preferred to use one-versus-all classification. If
the number of classes is large, it would be infeasible to use all of
the proteins in the negative classes. One-class classifiers might
provide a good solution for this problem.
The use of discriminative classifiers is confined to selecting
the correct function among a small set of functional classes. In
order to develop a general annotation system with a discrimi-
native approach, one might define a hierarchical classification
system over a function ontology structure. Examples of two such
annotation systems are Gene Ontology (GO) and Mips Func-
tional Catalogue (FunCat) (Ashburner et al., 2000; Ruepp et al.,
2004). Although GO is an intensively used annotation system,
implementing such a discriminative framework over GO hier-
archy might pose (present) some problems. First, GO describes
gene products with fine granularity resulting in thousands of
terms. As a result many terms have none or very few gene prod-
ucts. One should carefully filter and generate relevant classes for
the classification system. Secondly, GO allows directed acyclic
graphs in its hierarchy, further complicating the selection of
terms to generate classes for the discriminative system. Being
a tree hierarchy with especially relevant terms, FunCat might
provide an easier framework to develop a general discriminative
annotation framework. Once such a framework is established,
each classifier might be extended to incorporate useful informa-
tion other than the primary sequence, such as structural motifs or
structural alignments (Can and Wang, 2004; Sacan et al., 2007).
5. Conclusion
We described a discriminative system for functional classifi-
cation of protein sequences. It uses a subsequence similarity
based feature space mapping, SPMap, to convert protein
sequences into vector representations. The main idea was to
consider the distribution of the subsequences of a given protein
over a set of subsequence profiles as its feature representa-
tion. SPMap outperformed P2SL tool in subcellular localization
and various well known methods in GPCR subfamily classifi-
cation. In enzyme class classification SPMap produced better
or at least comparable results to some of the existing meth-
ods.
Our results showed that using subsequence distributions over
a quantized space as a feature space for classification of proteins
is an effective method in wide range of different classification
problems. Furthermore, the proposed method is computationally
efficient and capable of handling large datasets.
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